<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioact Mater</journal-id><journal-id journal-id-type="iso-abbrev">Bioact Mater</journal-id><journal-id journal-id-type="pmc-domain-id">3413</journal-id><journal-id journal-id-type="pmc-domain">bioactmat</journal-id><journal-title-group><journal-title>Bioactive Materials</journal-title></journal-title-group><issn pub-type="epub">2452-199X</issn><publisher><publisher-name>KeAi Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12268350</article-id><article-id pub-id-type="pmcid-ver">PMC12268350.1</article-id><article-id pub-id-type="pmcaid">12268350</article-id><article-id pub-id-type="pmcaiid">12268350</article-id><article-id pub-id-type="pmid">40678264</article-id><article-id pub-id-type="doi">10.1016/j.bioactmat.2025.06.038</article-id><article-id pub-id-type="pii">S2452-199X(25)00274-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Biomaterials nanoplatform-based tumor vaccines for immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Li</surname><given-names initials="Z">Zhilin</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hongbin</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Gong</surname><given-names initials="Q">Qiyong</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Luo</surname><given-names initials="K">Kui</given-names></name><email>luokui@scu.edu.cn</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Key Laboratory of Research and Development for Natural Products, School of Pharmacy, Yunnan University, Kunming, 650500, China</aff><aff id="aff2"><label>b</label>Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China</aff><aff id="aff3"><label>c</label>Functional and Molecular Imaging Key Laboratory of Sichuan Province, NHC Key Laboratory of Transplant Engineering and Immunology, Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China</aff><aff id="aff4"><label>d</label>Xiamen Key Lab of Psychoradiology and Neuromodulation, Department of Radiology, West China Xiamen Hospital of Sichuan University, Xiamen, 361021, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. <email>luokui@scu.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>6</month><year>2025</year></pub-date><volume>51</volume><issue-id pub-id-type="pmc-issue-id">489677</issue-id><fpage>924</fpage><lpage>961</lpage><history><date date-type="received"><day>1</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-18 11:25:14.580"><day>18</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>With the increasing incidence of cancer, it has become one of the most significant diseases threatening global human health. Tumor vaccines effectively induce activation of antigen-specific anti-tumor immune responses by delivering tumor antigens and adjuvants to antigen presenting cells (APCs), significantly inhibiting tumor recurrence and metastasis. Consequently, tumor vaccines have emerged as one of promising modalities in the next generation tumor immunotherapy. Biomaterial-based nanoplatforms have exhibited remarkable potential in enhancing the efficacy of tumor vaccines through antigen stabilization, spatiotemporal co-delivery of antigens/adjuvants to APCs, augmented lymphatic targeting, and initiation of robust responses from Th1/or cytotoxic T lymphocytes with immunological memory. In this review, we analyzed the state-of-art development of tumor vaccines delivered by biomaterial-based nanoplatforms. We first elaborated tumor vaccine components, including tumor antigens and adjuvants, and their mechanisms of immune activation. We then dived into an array of biomaterial-based nanoplatforms explored for tumor vaccine delivery, including lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, biomimetic nanoparticles, and hydrogels. Furthermore, recent clinical trials of tumor vaccines were summarized, and future directions and key challenges in the development of tumor vaccines were discussed.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>Engineered biomaterial nanoplatforms (lipid/polymer/inorganic/biomimetic nanoparticles, hydrogels) serve as tumor vaccine delivery systems for immunotherapy. These systems enhance therapeutic efficacy by (1) protecting antigens from degradation, (2) enabling spatiotemporal co-delivery of antigens and adjuvants, (3) targeting lymphoid organs (lymph nodes or spleen), and (4) initiating robust antitumor immune responses.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">Tumor antigens and adjuvants are systematically elaborated.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Biomaterial-based nanoplatforms are examined as tumor vaccine delivery systems.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Innovations in nanoplatform design are emphasized.</p></list-item><list-item id="u0025"><label>&#8226;</label><p id="p0025">Recent clinical tumor vaccine trials are summarized, with key challenges and future directions discussed.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Biomaterial nanoplatforms</kwd><kwd>Tumor vaccines</kwd><kwd>Antigens</kwd><kwd>Adjuvants</kwd><kwd>Immunotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Cancer has posed a substantial threat to public health. Over the past decade, tumor immunotherapy by employing immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells, tumor vaccines, and cytokines has shifted the paradigm of tumor therapy from traditional chemotherapy and targeted therapy, and it has become one of most promising treatment modalities [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. ICIs targeting PD-1/PD-L1, CTLA-4, LAG-3, TIM-3, and/or TIGIT, cytokine-based therapeutics such as superagonists for interleukin-2 (IL-2), tumor necrosis factor-&#945; (TNF-&#945;) or IL-15/IL-18, and cytokine-antibody fusion proteins, have displayed clinical efficacy in restoring immune surveillance by enhancing tumor cell recognition and elimination. Notably, multiple therapeutic agents within these categories including Nivolumab, Pembrolizumab, Atezolizumab, and Ipilimumab have received Food and Drug Administration (FDA) approval for cancer immunotherapy [<xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>]. However, unsatisfactory response rates, immune-related adverse side effects, and acquired resistance diminish their benefits to patients [<xref rid="bib6" ref-type="bibr">6</xref>]. Among these immunotherapies, tumor vaccines deliver antigens and adjuvants to antigen presenting cells (APCs), such as dendritic cells (DCs), to induce tumor-specific immune responses to eradicate tumor cells, and they have shown promising anti-tumor therapeutic and preventive effects [<xref rid="bib7" ref-type="bibr">[7]</xref>, <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>].</p><p id="p0035">There are five critical steps for tumor vaccines to elicit potent, specific anti-tumor effects: (1) identification of tumor antigens; (2) development of immune-stimulating adjuvants, (3) incorporation of antigens and adjuvants into a drug delivery system; (4) efficient targeting of immune organs including lymph nodes or spleens; and (5) degradation of antigens in APCs and formation of complexes with major histocompatibility complex (MHC) class &#8544; or &#8545; molecules. The complexes are presented to T lymphocytes to activate cellular or humoral immune responses.</p><p id="p0040">Materials science and nanotechnology have played a crucial role in achieving potent immunotherapeutic effects of tumor vaccines [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>]. Nanoplatforms, such as lipid nanoparticles (LNPs), polymeric nanoparticles, inorganic nanoparticles, biomimetic nanoparticles, and hydrogels, have been extensively explored for tumor vaccine delivery. Herein, we summarized biomaterial/nanotechnology-based platforms for co-delivery of antigens and adjuvants for potent anti-tumor immune responses (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Tumor antigens and adjuvants that have been extensively studied and recently emerged were first elaborated. Subsequently, we surveyed the nanoplatforms developed for tumor vaccine delivery, encompassing (1) LNPs, (2) polymeric nanoparticles, (3) inorganic nanoparticles, (4) biomimetic nanoparticles, and (5) hydrogels. Furthermore, we summarized the status of clinical trials of tumor vaccines and provided perspectives and potential hurdles associated with clinical translation of biomaterials-based nanoplatforms for tumor vaccines.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Scheme of biomaterial nanoplatform-derived tumor vaccines for tumor immunotherapy. There are three vital components in tumor vaccines, including tumor antigens, adjuvants, and nanoplatforms.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2"><label>2</label><title>Development of antigens and adjuvants</title><sec id="sec2.1"><label>2.1</label><title>Tumor antigens</title><p id="p0045">The tumor antigen, in a format of an immunogenic protein, a peptide, an encoding mRNA, can elicit systemic immune responses. Tumor antigens are classified into tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs). TAAs are often abnormally or excessively expressed in tumor tissues, whereas their expression is at a low level in normal tissues [<xref rid="bib16" ref-type="bibr">16</xref>]. Well-recognized TAAs include prostate-specific antigen (PSA), glycoprotein 100 (gp100), human epidermal growth factor receptor-2 (HER2), mucin protein-1 (MUC-1), TTK protein kinase, and tyrosinase, and these TAAs have been widely used as model antigens [<xref rid="bib17" ref-type="bibr">17</xref>]. TSAs are heterogeneous tumor-antigens on the tumor surface or inside tumor cells, including neoantigens derived from somatic mutations, viral oncoproteins, and epigenetically reactivated cancer-testis antigens. Among these TSAs, neoantigens that arise from non-synonymous mutations or genomic rearrangements have emerged as prioritized targets for personalized cancer vaccines due to their high tumor specificity and low risks of central tolerance [<xref rid="bib18" ref-type="bibr">18</xref>]. For example, EGFRvIII is expressed in glioblastoma, non-small cell lung cancer, and ovarian cancer, while melanoma-associated antigen 3 (MAGE-A3) is predominantly expressed in melanoma, non-small cell lung cancer, and myeloma. Based on the characteristics of TAAs and TSAs, TSAs may avoid immune tolerance and mediate potent anti-tumor immune responses with high safety compared to TAAs [<xref rid="bib19" ref-type="bibr">19</xref>]. The advances of next-generation sequencing and whole-exome sequencing techniques, combined with bioinformatic tools such as NeoPredPipe, MuPeXI, Pvac-Seq, and CloudNeo, allow the prediction of TSAs and facilitate the exploration of their potential as therapeutic vaccine targets. As illustrated in <xref rid="fig2" ref-type="fig">Fig. 2</xref>, TAAs or TSAs can be presented through three distinct modalities: nucleic acids (DNA or mRNA), peptides, and cell-derived antigens.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Schematic presentation of different modalities of tumor antigens. DNA encoding antigens is delivered into host cells, where it is transcribed into mRNA and subsequently translated into the targeted antigens. mRNA encoding antigens can be translated to proteins in the cytoplasm. The peptide or protein-based antigens (including those from DNA or mRNA) could be processed to peptides, which bind to MHC class &#8544; or MHC class &#8545; molecules. T cell receptor (TCR) on T cells would recoginze the complexs of peptides-MHC class &#8544; or peptide-MHC class &#8545;. Simultaneously, the co-stimulatory signal of CD80/86 and cytokines activate T cells, resulting in anti-tumor immune responses.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0050">Nucleic acids for tumor antigens (DNA or RNA), which encode genetic information of tumor antigens, can be translated into proteins and processed into peptides. DNA vaccines, in particular, have displayed protective efficacy against diseases such as hepatitis B, HIV, and human papillomavirus [<xref rid="bib20" ref-type="bibr">20</xref>]. The DNA vaccine has a bacterial plasmid containing antigen-encoding gene, which can be first transcribed to RNA and then translated into proteins [<xref rid="bib21" ref-type="bibr">21</xref>]. It is important for DNA vaccines to penetrate through both cell membranes and nuclear membranes. RNA vaccines utilize messenger RNA (mRNA)-including conventional non-replicating mRNA or self-amplifying mRNA-or engineered circular RNA (circRNA), all of which are designed for cytoplasmic translation into antigenic proteins [<xref rid="bib22" ref-type="bibr">22</xref>]. The proteins translated from DNA or RNA undergo proteasomal degradation into peptides. The peptides are transported to the endoplasmic reticulum (ER) as intracellular antigens, and the resulting peptides are presented to MHC class I/ &#8545; molecules. Compared to DNA vaccines which require delivery of DNA into the cell nucleus, RNA vaccines can be directly translated in the cytoplasm, eliminating the risk of genomic integration [<xref rid="bib23" ref-type="bibr">23</xref>]. However, it is crucial to note that mRNA exhibits low stability, rendering it susceptible to degradation by various nucleases <italic toggle="yes">in vivo</italic>, and it often suffers from a suboptimal transfection efficiency [<xref rid="bib24" ref-type="bibr">24</xref>]. These factors must be carefully addressed in the design and development of tumor vaccines.</p><p id="p0055">Peptide-based antigens consist of polypeptides derived from well-known or predicted tumor antigen epitopes, which can be categorized into genetically engineered peptides and synthetic peptides including short peptides and synthetic long peptides (SLPs). Peptide-based vaccines are designed to be presented to T cells, thereby inducing epitope-specific T cell responses for protective immunity [<xref rid="bib25" ref-type="bibr">25</xref>]. Genetically engineered peptides are produced by integrating TAAs or TSAs genes into an appropriate expression platform, such as <italic toggle="yes">E. coli</italic> or mammalian cells, through genetic engineering, followed by large-scale culture and purification. SLPs, typically consisting of 20&#8211;50 amino acids, encompass multiple epitopes recognized by MHC class I or II molecules, thereby inducing comprehensive and well-balanced immune activation [<xref rid="bib26" ref-type="bibr">26</xref>]. The synthesis of SLPs is dictated by their amino acid sequence and the sequence directly influences key physicochemical properties of SLPs, including solubility, chemical stability, hydrophobicity, and propensity for aggregation. These factors can significantly impact the preparation time and failure rates during synthesis, thus the synthesis of SLPs faces significant challenges [<xref rid="bib27" ref-type="bibr">27</xref>]. Peptides-based antigens generally display low immunogenicity, and they can be administrated with adjuvants for efficient immune activation [<xref rid="bib28" ref-type="bibr">28</xref>].</p><p id="p0060">Cell-derived antigens could be derived from tumor cell lysates and immunogenically dying tumor cells, which collectively offer a comprehensive source of potential antigens [<xref rid="bib29" ref-type="bibr">29</xref>]. Tumor cell lysates, including both water-soluble and water-insoluble components, have demonstrated their remarkable potential in the prevention and treatment of triple-negative breast cancer, lung cancer, and melanoma in murine models [<xref rid="bib30" ref-type="bibr">30</xref>]. Immunogenically dying tumor cells are the tumor cells after treatment with chemotherapeutics (e.g., doxorubicin, mitoxantrone, paclitaxel, or oxaliplatin) [<xref rid="bib31" ref-type="bibr">31</xref>], photodynamic/photothermal therapy [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>], radiotherapy [<xref rid="bib36" ref-type="bibr">36</xref>], and chemodynamic therapy [<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>]. Immunogenic cell death (ICD) would be induced to release TAAs and TSAs from these tumor cells [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. The released TAAs and TSAs can be captured and presented by APCs to initiate the cancer-immunity cycle, acting as <italic toggle="yes">in situ</italic> vaccination [<xref rid="bib41" ref-type="bibr">41</xref>]. The development of cell-based tumor vaccines requires intensive extraction and <italic toggle="yes">ex vivo</italic> manipulation of patient-derived cells, which not only extends biomanufacturing timelines but also imposes substantial economic constraints. In addition, their scalability and clinical translatability remain to be addressed.</p><p id="p0065">After uptake of antigens by APCs, the antigens are proteolytically processed into small polypeptide fragments. These fragments subsequently bind to MHC molecules, forming peptide-MHC complexes. These complexes are then translocated to the APC surface, where they are presented for recognition by T cell receptors (TCRs) on T cells. This comprehensive process is referred to as antigen presentation [<xref rid="bib42" ref-type="bibr">42</xref>]. There are two primary pathways: the MHC class I pathway and the MHC class II pathway [<xref rid="bib43" ref-type="bibr">43</xref>]. For exogenous antigens, the process begins with their endocytosis into lysosomes, where they are degraded by acid-dependent enzymes, such as proteases and hydrolases, into long peptides (typically 15&#8211;25 amino acids in length). These peptides subsequently bind to the MHC class II molecules. The obtained antigen-MHC class II complexes are subsequently translocated to the APC membrane, where they are specifically recognized by CD4<sup>+</sup> T cells. Endogenous antigen peptides are degraded into short peptides (8&#8211;10 amino acids) by proteasomes in the cytoplasm. These peptides bind to the MHC class I molecules and the formed complexes are transferred to the cell surface for recognition by CD8<sup>+</sup> T cells [<xref rid="bib44" ref-type="bibr">44</xref>]. Additionally, exogenous antigens can be presented through the MHC class I pathway via antigen cross-presentation [<xref rid="bib45" ref-type="bibr">45</xref>]. Cytosolic and vacuolar pathways can mediate the antigen cross-presentation process [<xref rid="bib46" ref-type="bibr">46</xref>]. In the cytosolic pathway, internalized exogenous antigens are transported to the cytosol, where they are degraded into short peptides. These fragments are loaded onto the MHC class I molecules to form the peptide-MHC class I complexes. By contrast, in the vacuolar pathway, antigen processing and assembly with the MHC class I molecules occur within phagosomes. Since CD8<sup>+</sup> T cells play a critical role in mediating antitumor immunity [<xref rid="bib47" ref-type="bibr">47</xref>], exogenous antigens-based tumor vaccines could be directed into cytosolic and vacuolar pathways through rational design to effectively activate CD8<sup>+</sup> T cells via antigen cross-presentation. CD8<sup>+</sup> T cells are cytotoxic to tumor cells through two primary mechanisms: the perforin-granzyme pathway in which perforin facilitates membrane pore formation to enable granzyme-induced caspase-dependent apoptosis, and the death receptor pathway in which FasL-Fas binding triggers caspase-8-mediated apoptosis. CD4<sup>+</sup> T cells, polarized by cytokine cues (e.g., IL-12), can be differentiated into the Th1 subtype that secrete IFN-&#947; to enhance MHC class I expression, amplify the APC activity, and recruit macrophages and natural killer (NK) cells. Innate effector cells further augment these responses: NK cells exert antibody-dependent cellular cytotoxicity (ADCC) and execute direct killing via NKG2D recognition of stress ligands (e.g., MICA/MICB). Antitumor immune responses, initiated by antigen presentation, are coordinated through synergistic interplays between activated T cells and associated effector cells [<xref rid="bib48" ref-type="bibr">48</xref>].</p></sec><sec id="sec2.2"><label>2.2</label><title>Adjuvants</title><p id="p0070">Adjuvants (from adjuvare that means help) are the molecules that can potentiate the strength and longevity of immune responses [<xref rid="bib49" ref-type="bibr">49</xref>]. Aluminum adjuvants, the oldest adjuvant, has been used in the diphtheria vaccine since 1920s. They have a high safety profile and a low cost in preparation. Aluminum adjuvants, such as aluminum oxyhydroxide (AlO(OH)) that is known as commercial Alhydrogel&#174; (Alum), induce humoral immunity responses via the &#8220;depot effect&#8221; mechanism [<xref rid="bib50" ref-type="bibr">50</xref>]. Other FDA licensed adjuvants including MF59, AS01B, AS03, AS04, and CpG 1018, and they have been used in commercially available vaccines [<xref rid="bib51" ref-type="bibr">51</xref>]. Pathogen recognition receptors (PRRs) on innate immune cells are the guards that detect foreign substances to protect the host. The immune system in the host employs five major classes of PRRs, comprising Toll-like receptors (TLRs), retinoic acid-inducible gene-I-like receptors (RLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), C-type lectin receptors (CLRs), and cytosolic DNA sensors [<xref rid="bib52" ref-type="bibr">52</xref>]. These receptors can identify pathogen-associated molecular patterns (PAMPs) from microbial invaders and damage-associated molecular patterns (DAMPs) originating from cellular components [<xref rid="bib53" ref-type="bibr">53</xref>]. Among these PRRs sensors, TLRs and cytosolic DNA sensors have shown great potential in boosting immune responses. A summary of adjuvants including TLR agonists, cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) agonists, polyphosphazene, and ICD-based adjuvants are listed in <xref rid="tbl1" ref-type="table">Table 1</xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>A summary of adjuvants including TLR agonists, cGAS-STING agonists, polyphosphazene, and ICD-based adjuvants.</p></caption><alt-text id="alttext0075">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Types of adjuvants</th><th colspan="1" rowspan="1">Subsets</th><th colspan="1" rowspan="1">Representative agonists</th><th colspan="1" rowspan="1">Immune activation function</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td rowspan="6" align="left" colspan="1">TLR agonists<hr/></td><td align="left" colspan="1" rowspan="1">TLR2</td><td align="left" colspan="1" rowspan="1">Lipopeptides, lipoarabinomannans, lipoteichoic acids, zymosan, and peptidoglycan</td><td align="left" colspan="1" rowspan="1">Secreting proinflammatory cytokines (IL-6, TNF-&#945;) and chemokine, and enhancing DC maturation</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR3</td><td align="left" colspan="1" rowspan="1">Double-stranded RNA and Poly I:C</td><td align="left" colspan="1" rowspan="1">Secreting of type I interferons and inflammatory cytokines, promoting adaptive immunity through enhanced T cell priming.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR4</td><td align="left" colspan="1" rowspan="1">Lipopolysaccharide, monophosphoryl lipid A, and glucopyranosyl lipid A</td><td align="left" colspan="1" rowspan="1">Inducing robust cellular immune responses</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR5</td><td align="left" colspan="1" rowspan="1">Flagellin</td><td align="left" colspan="1" rowspan="1">Production of proinflammatory cytokines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR7/8</td><td align="left" colspan="1" rowspan="1">Guanyl- and uridine-rich ssRNA, short-chain dsRNA, oligonucleotides, and imidazoquinoline family (imiquimod, resiquimod)</td><td align="left" colspan="1" rowspan="1">Secretion of proinflammatory cytokines including IFN-&#945;, TNF-&#945;, and IL-12</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib63" ref-type="bibr">63</xref>,<xref rid="bib64" ref-type="bibr">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TLR9<hr/></td><td align="left" colspan="1" rowspan="1">CpG<hr/></td><td align="left" colspan="1" rowspan="1">Promoting T cells activation and infiltration into tumor sites<hr/></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib65" ref-type="bibr">65</xref>,<xref rid="bib66" ref-type="bibr">66</xref>]<hr/></td></tr><tr><td rowspan="6" align="left" colspan="1">STING agonists<hr/></td><td align="left" colspan="1" rowspan="1">CDN and CDN derivatives</td><td align="left" colspan="1" rowspan="1">cGAMP, ADU-S100</td><td rowspan="3" align="left" colspan="1">(1) Promoting antigen capture, processing, and presentation<break/>(2) Eliciting potent humoral immune responses<break/>(3) Secretion CXCL10 to recruit antigen specific CD8<sup>+</sup> T cells into inflammation and tumor sites</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib74" ref-type="bibr">[74]</xref>, <xref rid="bib75" ref-type="bibr">[75]</xref>, <xref rid="bib76" ref-type="bibr">[76]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-CDN small molecular agonists</td><td align="left" colspan="1" rowspan="1">DMXAA, 10-carboxymethyl-9-acridanone (CMA), diABZI, SR-717, and MSA-2</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib77" ref-type="bibr">[77]</xref>, <xref rid="bib78" ref-type="bibr">[78]</xref>, <xref rid="bib79" ref-type="bibr">[79]</xref>, <xref rid="bib80" ref-type="bibr">[80]</xref>, <xref rid="bib81" ref-type="bibr">[81]</xref>, <xref rid="bib82" ref-type="bibr">[82]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cytosolic dsDNA</td><td align="left" colspan="1" rowspan="1">Mitochondria-derived cytosolic dsDNA</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib83" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Metal ion</td><td align="left" colspan="1" rowspan="1">Manganese ions and zinc ions</td><td align="left" colspan="1" rowspan="1">Manganese ion activating cGAS in absence of dsDNA, and increasing the binding affinity between cGAMP and STING. Zn<sup>2+</sup> enhances cGAS phase separation/catalytic activity, inducing ROS-driven mitochondrial DNA (mtDNA) release to activate the cGAS-STING-pathway.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib84" ref-type="bibr">[84]</xref>, <xref rid="bib85" ref-type="bibr">[85]</xref>, <xref rid="bib86" ref-type="bibr">[86]</xref>, <xref rid="bib87" ref-type="bibr">[87]</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">Polymer<hr/></td><td align="left" colspan="1" rowspan="1">Chitosan</td><td align="left" colspan="1" rowspan="1">Inducing mitochondrial stress to release ROS and activating the cGAS-STING pathway by mtDNA, leading to type I IFN production</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib88" ref-type="bibr">88</xref>,<xref rid="bib89" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymers bearing cyclic or linear tertiary amines on the side chain, such as PC7A<hr/></td><td align="left" colspan="1" rowspan="1">Mediating potent antigen-specific CD8<sup>+</sup> T cells as well as Th1 and Th2 responses<hr/></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib90" ref-type="bibr">90</xref>,<xref rid="bib91" ref-type="bibr">91</xref>]<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">Polyphosphazene polyelectrolytes</td><td colspan="2" align="left" rowspan="1">Poly[di(carboxylatophenoxy) phosphazene] (PCPP), poly[di(carboxylatoethylphenoxy)phosphazene] (PCEP), and poly[di(carboxylatomethylphenoxy)phosphazene] (PCMP)</td><td align="left" colspan="1" rowspan="1">Enhancing and modulating the quality of immune responses while the mechanism for the adjuvant effect is not elucidated.</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib92" ref-type="bibr">92</xref>,<xref rid="bib93" ref-type="bibr">93</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">ICD-based adjuvants</td><td colspan="2" align="left" rowspan="1">CRT</td><td align="left" colspan="1" rowspan="1">Acting as &#8220;eat me&#8221; signal to promote the production of IL-6 and TNF-&#945; through CD91 on APCs</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib95" ref-type="bibr">95</xref>,<xref rid="bib96" ref-type="bibr">96</xref>]</td></tr><tr><td colspan="2" align="left" rowspan="1">HMGB1</td><td align="left" colspan="1" rowspan="1">Binding to the TLR4 receptor to facilitate the release of proinflammatory cytokines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib97" ref-type="bibr">97</xref>]</td></tr><tr><td colspan="2" align="left" rowspan="1">ATP</td><td align="left" colspan="1" rowspan="1">Acting as &#8220;find me&#8221; signal to promote immune cells recruitment to engulf dead tumor cells, and activation of the NLRP3 inflammasome</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib98" ref-type="bibr">98</xref>]</td></tr><tr><td colspan="2" align="left" rowspan="1">HSPs</td><td align="left" colspan="1" rowspan="1">Binding to CD91 receptors to promote antigen presentation and DC maturation</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib99" ref-type="bibr">99</xref>]</td></tr></tbody></table></table-wrap></p><sec id="sec2.2.1"><label>2.2.1</label><title>TLR agonists</title><p id="p0075">To date, the TLRs family has been profiled with 10 members in the human body (TLR1-TLR10), while mice possess 12 TLRs (TLR1-TLR9 and TLR11-TLR13). In the human TLRs family, TLR1, TLR2, TLR4, TLR5, and TLR6 are expressed on the plasma membrane, while TLR3, TLR7, TLR8, and TLR9 reside within intracellular compartments such as endosomes and lysosomes [<xref rid="bib54" ref-type="bibr">54</xref>]. In contrast, murine TLR11 and TLR12, which are absent of human orthologs, displaying species-specific adaptation in innate immune sensing mechanisms [<xref rid="bib55" ref-type="bibr">55</xref>] (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A). TLR signaling bifurcates into two cardinal pathways: the MyD88-dependent pathway and the TRIF-dependent pathway (MyD88-independent). The MyD88-dependent pathway, utilized by nearly all TLRs, initiates rapid activation of NF-&#954;B and Mitogen-activated protein kinases (MAPKs), driving pro-inflammatory cytokine/chemokine production. Conversely, the Toll/IL-1R domain-containing adaptor-inducing IFN-&#946; (TRIF)-dependent pathway, selectively engaged by TLR3 and TLR4, activates TANK-binding kinase 1 (TBK1) to phosphorylate interferon regulatory factor 3 (IRF3) and IRF7, culminating in type I interferon (IFN-&#945;/&#946;) induction and antiviral immunity [<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib57" ref-type="bibr">57</xref>].<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Adjuvants including TLR agonists (A), cGAS-STING agonists (B), polyphosphazene (C), and ICD-based immune stimulators (D) mediate downstream signaling pathways.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0080">TLRs engagement can promote antigen capture and presentation to stimulate inflammation and antigen-specific immune responses [<xref rid="bib58" ref-type="bibr">58</xref>]. TLR2 can form heterodimers with TLR1 and TLR6 (or TLR10 in humans), and the heterodimers can recognize a wide range of PAMPs including lipopeptides, lipoarabinomannans, lipoteichoic acids, zymosan and peptidoglycan [<xref rid="bib59" ref-type="bibr">59</xref>]. TLR3 recognizes viral double-stranded RNA (dsRNA), and it plays an important role in provoking adaptive immunity. Activation of TLR3 in DCs induces secretion of type I interferons (IFN-&#945;/&#946;) and inflammatory cytokines (e.g., IL-12, TNF-&#945;), thereby promoting adaptive immunity through enhanced T cell priming. Synthetic dsRNA analogs like Poly I:C serve as potent vaccine adjuvants for inactivated viral and recombinant protein vaccines [<xref rid="bib60" ref-type="bibr">60</xref>]. TLR4 specifically binds to lipopolysaccharides (LPS), a critical structural element of the outer membrane in Gram-negative bacteria, thereby initiating robust cellular immune responses. Synthetic compounds, such as monophosphoryl lipid A (MPLA) and glucopyranosyl lipid A, have shown a pronounced immune-potentiating power as TLR4 agonists [<xref rid="bib61" ref-type="bibr">61</xref>]. Flagellin, as a natural ligand of TLR5, activates NF-&#954;B via the MyD88 pathway, initiating inflammatory responses and innate immune responses, and it has shown great potential in boosting anti-cancer immune responses [<xref rid="bib62" ref-type="bibr">62</xref>]. TLR7/8 is another hot target in tumor immunotherapy, and it is expressed in immune cells such as DCs and monocytes. After interacting with its ligands, including single-stranded RNA (ssRNA), oligonucleotides, and synthetic agonists, TLR7/8 undergoes a conformational change to form a homodimer, which results in the activation of the IRF7 and NF-&#954;B signaling pathways via the downstream MyD88/IRAKs cascade, triggering the secretion of a series of inflammatory cytokines, including IFN-&#945; and TNF-&#945; [<xref rid="bib63" ref-type="bibr">63</xref>]. Synthetic imidazoquinoline family members including imiquimod (R837) and resiquimod (R848) are widely used as TLR7/8 agonists in immunotherapy and they exhibit potent adjuvant effects [<xref rid="bib64" ref-type="bibr">64</xref>]. TLR9 serves as a specific receptor for unmethylated cytosine-phosphate-guanine (CpG) motifs, which are PAMPs abundant in bacterial and viral DNA. Its activation induces innate immune signaling (e.g., IFN-&#945; or IL-6) in plasmacytoid DCs and B cells, indirectly promoting T cell priming and tumor infiltration [<xref rid="bib65" ref-type="bibr">65</xref>]. Synthetic 18-25-mer unmethylated CpG oligodeoxynucleotides (CpG ODNs) are well-established TLR9 agonists that drive Th1-polarized adaptive immunity and enhance B cell-mediated antibody responses [<xref rid="bib66" ref-type="bibr">66</xref>].</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>cGAS-STING agonists</title><p id="p0085">The cGAS-STING pathway, a cytosolic DNA sensing mechanism, has been demonstrated to be a highly promising therapeutic target within the immune system [<xref rid="bib67" ref-type="bibr">67</xref>] (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B). STING, which serves as a receptor for cyclic dinucleotides (CDNs) in their dimerized form, is primarily localized at the ER [<xref rid="bib68" ref-type="bibr">68</xref>]. As a cytosolic DNA sensor, cGAS undergoes allosteric activation through its interaction with double-stranded DNA (dsDNA). During this enzymatic process, the magnesium ion (Mg<sup>2+</sup>) is an essential catalytic cofactor to facilitate the production of 2&#8242;,3&#8242;-cyclic GMP-AMP (cGAMP) from precursor molecules including adenosine-5&#8242;-triphosphate (ATP) and guanosine-5&#8242;- triphosphate (GTP) [<xref rid="bib69" ref-type="bibr">69</xref>]. The resulting cGAMP, functioning as an endogenous CDN, exhibits high-affinity binding to a characteristic V-shaped cleft within the STING dimer complex. This molecular interaction initiates a cascade of structural rearrangements in the STING protein, ultimately promoting its intracellular trafficking from the ER to the Golgi apparatus. S-palmitoylation modification of STING within the Golgi compartment has been identified as a critical regulatory mechanism for orchestrating sequential recruitment of TBK1 and subsequent phosphorylation-dependent activation of IRF3 [<xref rid="bib70" ref-type="bibr">70</xref>]. This post-translational modification cascade ultimately initiates the transcriptional program responsible for IFN production and downstream IFN-inducible effector gene expression, and coordinates release of pro-inflammatory cytokines, which collectively enhance antigen presentation and drive DC maturation [<xref rid="bib71" ref-type="bibr">71</xref>]. Activation of this pathway also helps establishing a critical immunostimulatory microenvironment that bridges innate immune sensing with adaptive immunity potentiation [<xref rid="bib72" ref-type="bibr">72</xref>]. A great many of pre-clinical studies have confirmed that STING agonists may act as adjuvants in anti-cancer vaccines [<xref rid="bib73" ref-type="bibr">73</xref>].<list list-type="simple" id="olist0010"><list-item id="o0010"><label>(1)</label><p id="p0090">CDNs and CDN derivatives. cGAMP, a natural CDN, has been evaluated as a potential STING agonist, and it has shown excellent anti-tumor effects in both CT26 and B16-bearing mouse models [<xref rid="bib74" ref-type="bibr">74</xref>]. However, phosphodiester bonds in cGAMP are susceptible to degradation by phosphodiesterases and nucleases, resulting in a short half-life and a poor pharmacokinetic profile [<xref rid="bib75" ref-type="bibr">75</xref>]. Through structural modification, phosphothioate analogs, such as Rp, Rp-2&#8242;,3&#8242;-c-di-AMPSS (ADU-S100), can effectively activate the STING pathway, and they are undergoing evaluation in clinical trials [<xref rid="bib76" ref-type="bibr">76</xref>].</p></list-item><list-item id="o0015"><label>(2)</label><p id="p0095">Non-CDN small molecular agonists. The development of non-CDN small-molecular agonists has been motivated because of suboptimal pharmacokinetic properties of CDN-based agonists. DMXAA (5,6-dimethylxanthenone-4-acetic acid), a synthetic derivative of flavone-8-acetic acid, functions as a species-specific STING agonist with potent activity in the murine system, and it elicits robust IFN-&#946; secretion through selective engagement of the murine STING signaling axis [<xref rid="bib77" ref-type="bibr">77</xref>]. However, since it can not effectively activate the human STING, the development of DMXAA was discontinued during its Phase III clinical trial [<xref rid="bib78" ref-type="bibr">78</xref>]. diABZI is a human active small molecular STING agonist. After administration of diABZI via intravenous injection, a great breakthrough for immune-mediating cancer treatment in murine models has been achieved [<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib80" ref-type="bibr">80</xref>]. Chin et al. synthesized a non-nucleotide small-molecular STING agonist, SR717, which effectively promoted antigen cross-presentation, leading to an elevation in the number of CD8<sup>+</sup> T cells and NK cells in the spleen and lymph nodes [<xref rid="bib81" ref-type="bibr">81</xref>]. Pan et al. implemented an integrated high-throughput cellular phenotypic screening strategy to identify MSA-2 (benzothiophene oxobutanoic acid), which promoted STING activation through noncovalent dimer stabilization, thereby potentiating IFN-&#946; biosynthesis. This STING agonist can be orally administered; thus, it has great potential for clinical application due to its convenient and cost-effective delivery method [<xref rid="bib82" ref-type="bibr">82</xref>].</p></list-item><list-item id="o0020"><label>(3)</label><p id="p0100">Cytosolic dsDNA. Mitochondria-derived cytosolic dsDNA is an endogenous ligand for cGAS, and it triggers the STING-dependent signaling cascade activation. Radiotherapy and chemotherapy agents, including cisplatin, doxorubicin, camptothecin, and paclitaxel, induce DNA damage or interfere with DNA replication, leading to the activation of the cGAS-STING pathway [<xref rid="bib83" ref-type="bibr">83</xref>].</p></list-item><list-item id="o0025"><label>(4)</label><p id="p0105">Manganese ions. The pioneering investigation by the Jiang's team in 2018 suggested that manganese ions (Mn<sup>2+</sup>) could enhance the cGAS sensitivity as a biochemical sensor for dsDNA, concurrently promoting cGAMP-STING interfacial binding dynamics [<xref rid="bib84" ref-type="bibr">84</xref>,<xref rid="bib85" ref-type="bibr">85</xref>]. A subsequent mechanistic study in 2020 revealed that Mn<sup>2+</sup>-mediated cGAS activation drives cGAMP biosynthesis through a dsDNA-independent catalytic mechanism [<xref rid="bib86" ref-type="bibr">86</xref>]. Furthermore, zinc ions (Zn<sup>2+</sup>) promote cGAS phase separation, enhance catalytic activity, and induce reactive oxygen species (ROS)-mediated mitochondrial damage and mitochondrial DNA (mtDNA) release, activating the cGAS-STING pathway to trigger innate immune responses via type I interferons [<xref rid="bib87" ref-type="bibr">87</xref>].</p></list-item><list-item id="o0030"><label>(5)</label><p id="p0110">Natural polysaccharides and synthetic polymers. Chitosan, a cationic polysaccharide with excellent biocompatibility, can promote DC maturation and enhance Th1 cell responses, thus it has been attempted as an adjuvant [<xref rid="bib88" ref-type="bibr">88</xref>]. The mechanism of chitosan-mediated immune responses was revealed: chitosan may enhance mitochondrial ROS production and endogenous DNA release to activate the STING pathway [<xref rid="bib89" ref-type="bibr">89</xref>]. The Gao group engineered a series of pH-ultrasensitive nanoparticles, and they found that cyclic tertiary amine-containing copolymers, particularly those with seven-membered ring architectures (designated as PC7A), were efficient in cytosolic delivery of tumor antigens to lymph nodes and activation of type I interferon-stimulated genes, and these nanoparticles with great anti-tumor effects could be employed to construct a multifunctional nanovaccine system [<xref rid="bib90" ref-type="bibr">90</xref>]. The polymer length significantly influences the valency of interaction, thereby modulating the degree of STING activation. PC7A selectively targets an allosteric binding site on STING that is structurally distinct from the canonical cGAMP-binding domain, thereby inducing sustained amplification of pro-inflammatory cytokine secretion through non-competitive pathway modulation [<xref rid="bib91" ref-type="bibr">91</xref>].</p></list-item></list></p></sec><sec id="sec2.2.3"><label>2.2.3</label><title>Polyphosphazene</title><p id="p0115">Polyphosphazene, a water-soluble and biodegradable macromolecule, can be intrinsically assembled with tumor antigens to form a virion-mimetic nanostructure to achieve co-delivery of antigens and adjuvants [<xref rid="bib92" ref-type="bibr">92</xref>]. Emerging polyphosphazene-based adjuvants, particularly their structurally analogous derivatives including poly[di(carboxylatophenoxy)phosphazene] (PCPP), poly[di(carboxylatoethylphenoxy)phosphazene] (PCEP), and poly[di(carboxylatomethylphenoxy)phosphazene] (PCMP), have been explored (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C). These carboxylated polyphosphazene polyelectrolytes, which belong to a homologous polymer class, have demonstrated encouraging immunomodulatory potential in extensive preclinical evaluations and early-phase clinical trials, with evidence of enhanced antigen-specific immune responses [<xref rid="bib93" ref-type="bibr">93</xref>]. Despite their considerable promise as vaccine adjuvants, the mechanisms underlying their immune activation remain to be comprehensively unveiled.</p></sec><sec id="sec2.2.4"><label>2.2.4</label><title>ICD-based adjuvants</title><p id="p0120">Immune signaling pathways activated by ICD can be considered as an endogenous adjuvant (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D). Chemotherapy by agents such as anthraquinones and oxaliplatin, photodynamic therapy, photothermal therapy, and radiotherapy could effectively induce ICD [<xref rid="bib94" ref-type="bibr">94</xref>]. After ICD is successfully induced from tumor cells, calreticulin (CRT) can be transferred from the ER to the surface of cell membranes, acting as an &#8220;eat me&#8221; signal. CRT binds to the CD91 receptor on DCs to promote antigen engulfment and presentation [<xref rid="bib95" ref-type="bibr">95</xref>]. Over-expressed CRT on the cell membrane results in an increase in the mature ratio of bone marrow-derived dendritic cells (BMDCs) compared to that on the normal tumor cell membrane, suggesting that CRT could be a promising adjuvant for tumor vaccines [<xref rid="bib96" ref-type="bibr">96</xref>]. High mobility group box 1 (HMGB1), the most abundant nonhistone chromatin protein in the cellular nucleus, may be released to the cytoplasm in the process of apoptosis. Extracellular HMGB1 can bind to TLR4, and the formed complex could be a potent proinflammatory stimulus to facilitate secretion of TNF-&#945;, IL-1&#946;, and IL-8 [<xref rid="bib97" ref-type="bibr">97</xref>]. Dying tumor cells release ATP as a &#8220;find me&#8221; signal, and the signal is sensed by the P2Y7 receptor on monocytes to promote immune cells recruitment to engulf dead tumor cells and it can bind to the P2X7 receptor on DCs and macrophages to activate the NALP3 inflammasome pathway to secrete IL-1&#946; [<xref rid="bib98" ref-type="bibr">98</xref>]. The released heat-shock proteins (HSPs), including HSP70 and HSP90, can be recognized by the CD91 receptor to promote antigen presentation and DC maturation [<xref rid="bib99" ref-type="bibr">99</xref>].</p></sec></sec></sec><sec id="sec3"><label>3</label><title>Biomaterial-based nanoplatforms for efficient vaccine delivery</title><p id="p0125">Nano-sized delivery systems have been widely explored as carriers for the delivery of antigens and adjuvants to APCs. Biomaterials-based nanoplatforms exhibit desirable properties, such as biocompatibility, versatile surface modifications, accommodation for diverse molecules, stimuli-responsiveness, and high antigens/adjuvants-loading capacity [<xref rid="bib100" ref-type="bibr">[100]</xref>, <xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>, <xref rid="bib103" ref-type="bibr">[103]</xref>, <xref rid="bib104" ref-type="bibr">[104]</xref>, <xref rid="bib105" ref-type="bibr">[105]</xref>, <xref rid="bib106" ref-type="bibr">[106]</xref>, <xref rid="bib107" ref-type="bibr">[107]</xref>, <xref rid="bib108" ref-type="bibr">[108]</xref>, <xref rid="bib109" ref-type="bibr">[109]</xref>]. Tailored functionalities can be created for these nanoplatforms to optimize immune responses. The functionalities have been demonstrated including protecting antigens from degradation, spatiotemporally co-delivering antigens and adjuvants to APCs, facilitating APCs engulfment of tumor vaccines, improving accumulation of tumor vaccines in immune organs [<xref rid="bib110" ref-type="bibr">110</xref>], initiating potent anti-tumor Th1 or cytotoxic T lymphocytes (CTLs) responses, and establishing durable antigen-specific immunological memory. The physicochemical and functional characteristics of biomaterial-derived nanoplatforms, including LNPs, polymeric nanoparticles, inorganic nanoparticles, biomimetic nanoparticles, and hydrogels, are systematically summarized in <xref rid="tbl2" ref-type="table">Table 2</xref>.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Characteristics of biomaterials-based nanoplatform including LNPs, polymeric nanoparticles, inorganic nanoparticles, biomimetic nanoparticles, and hydrogels.</p></caption><alt-text id="alttext0080">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Nanocarrier types</th><th colspan="1" rowspan="1">Loaded drugs</th><th colspan="1" rowspan="1">Critical determinants of drug-loading capacity</th><th colspan="1" rowspan="1">Advantages</th><th colspan="1" rowspan="1">Limitations</th><th colspan="1" rowspan="1">Challenges in clinical translation</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LNPs</td><td align="left" colspan="1" rowspan="1">Nucleic acids, hydrophobic small molecules, and proteins</td><td align="left" colspan="1" rowspan="1">Payload-specific encapsulation mechanisms dictated by the physicochemical interplay between therapeutic agents and lipid architectures</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0030"><list-item id="o0075"><label>(1)</label><p id="p0465">Excellent biocompatibility and biodegradability;</p></list-item><list-item id="o0080"><label>(2)</label><p id="p0470">Efficient delivery of nucleic acid/lipophilic drug;</p></list-item><list-item id="o0085"><label>(3)</label><p id="p0475">Clinically validated (e.g., COVID-19 mRNA vaccines)</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0035"><list-item id="o0090"><label>(1)</label><p id="p0480">Poor storage stability (oxidation, aggregation);</p></list-item><list-item id="o0095"><label>(2)</label><p id="p0485">Complex large-scale manufacturing</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0040"><list-item id="o0100"><label>(1)</label><p id="p0490">Stability optimization (lyophilization requirements);</p></list-item><list-item id="o0105"><label>(2)</label><p id="p0495">Long-term safety and immunogenicity studies</p></list-item></list></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib111" ref-type="bibr">[111]</xref>, <xref rid="bib112" ref-type="bibr">[112]</xref>, <xref rid="bib113" ref-type="bibr">[113]</xref>, <xref rid="bib114" ref-type="bibr">[114]</xref>, <xref rid="bib115" ref-type="bibr">[115]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticles</td><td align="left" colspan="1" rowspan="1">Chemotherapeutics, proteins, and hydrophilic/hydrophobic drugs</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0045"><list-item id="o0110"><label>(1)</label><p id="p0500">Physical encapsulation via non-covalent interactions: polymer-drug compatibility influence drug-loading capacity;</p></list-item><list-item id="o0115"><label>(2)</label><p id="p0505">Covalent conjugation: functional group density, conjugation stoichiometry, and spacer arm flexibility govern drug-loading capacity</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0050"><list-item id="o0120"><label>(1)</label><p id="p0510">Tunable drug release kinetics;</p></list-item><list-item id="o0125"><label>(2)</label><p id="p0515">Surface functionalization for targeting or responsive release;</p></list-item><list-item id="o0130"><label>(3)</label><p id="p0520">Biodegradability</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0055"><list-item id="o0135"><label>(1)</label><p id="p0525">Potential cytotoxicity from byproducts after degradation;</p></list-item><list-item id="o0140"><label>(2)</label><p id="p0530">Batch-to-batch variability</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0060"><list-item id="o0145"><label>(1)</label><p id="p0535">Toxicological assessment of degradation products;</p></list-item><list-item id="o0150"><label>(2)</label><p id="p0540">Scalability and reproducibility in manufacture</p></list-item></list></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib126" ref-type="bibr">[126]</xref>, <xref rid="bib127" ref-type="bibr">[127]</xref>, <xref rid="bib128" ref-type="bibr">[128]</xref>, <xref rid="bib129" ref-type="bibr">[129]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Inorganic nanoparticles</td><td align="left" colspan="1" rowspan="1">Small molecules, and imaging agents (gold or iron oxide)</td><td align="left" colspan="1" rowspan="1">Exemplified by MSNs, leverage high surface area for small-molecule adsorption, while pore-size limitations restrict intrapore loading of biomacromolecules, surface functionalization, pore engineering, and hierarchical designs enable robust incorporation of proteins, nucleic acids, and other macromolecules</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0065"><list-item id="u0030"><p id="p0545">(1)High stability and unique physicochemical properties (e.g., magnetic, photothermal);</p></list-item><list-item id="o0155"><label>(2)</label><p id="p0550">High drug loading in mesoporous systems</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0070"><list-item id="o0160"><label>(1)</label><p id="p0555">Poor biodegradability (persistent accumulation);</p></list-item><list-item id="o0165"><label>(2)</label><p id="p0560">Risks of metal ion toxicity</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0075"><list-item id="o0170"><label>(1)</label><p id="p0565">Long-term biodistribution and clearance of inorganic nanoparticles;</p></list-item><list-item id="o0175"><label>(2)</label><p id="p0570">Safety concerns over metal/non-degradable materials</p></list-item></list></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib145" ref-type="bibr">[145]</xref>, <xref rid="bib146" ref-type="bibr">[146]</xref>, <xref rid="bib147" ref-type="bibr">[147]</xref>, <xref rid="bib148" ref-type="bibr">[148]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Biomimetic nanoparticles</td><td align="left" colspan="1" rowspan="1">Proteins, nucleic acids, and chemotherapeutics</td><td align="left" colspan="1" rowspan="1">Primarily determined by the core nanoparticle's physicochemical parameters</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0080"><list-item id="o0180"><label>(1)</label><p id="p0575">Enhanced immune evasion and biocompatibility;</p></list-item><list-item id="o0185"><label>(2)</label><p id="p0580">Intrinsic targeting via natural membrane motifs</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0085"><list-item id="o0190"><label>(1)</label><p id="p0585">Technically challenging fabrication (membrane isolation, fusion);</p></list-item><list-item id="o0195"><label>(2)</label><p id="p0590">Low yield and scalability)</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0090"><list-item id="o0200"><label>(1)</label><p id="p0595">Standardization of membrane sources;</p></list-item><list-item id="o0205"><label>(2)</label><p id="p0600">Reproducible large-scale manufacturing processes;</p></list-item><list-item id="o0210"><label>(3)</label><p id="p0605">Preclinical-to-clinical predictability gaps</p></list-item></list></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib167" ref-type="bibr">[167]</xref>, <xref rid="bib168" ref-type="bibr">[168]</xref>, <xref rid="bib169" ref-type="bibr">[169]</xref>, <xref rid="bib170" ref-type="bibr">[170]</xref>, <xref rid="bib171" ref-type="bibr">[171]</xref>, <xref rid="bib194" ref-type="bibr">[194]</xref>, <xref rid="bib207" ref-type="bibr">[207]</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Hydrogels</td><td align="left" colspan="1" rowspan="1">Proteins, growth factors, hydrophilic drugs, and cells</td><td align="left" colspan="1" rowspan="1">Crosslinking density, mesh size dynamics, polymer-drug affinity, swelling behavior, and payload molecular weight could influence drug-loading efficiency</td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0095"><list-item id="o0215"><label>(1)</label><p id="p0610">High water content and biocompatibility;</p></list-item><list-item id="o0220"><label>(2)</label><p id="p0615">Sustained release (days to weeks);</p></list-item><list-item id="o0225"><label>(3)</label><p id="p0620">Injectability and stimuli-responsive release</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0100"><list-item id="o0230"><label>(1)</label><p id="p0625">Weak mechanical strength;</p></list-item><list-item id="o0235"><label>(2)</label><p id="p0630">Preferable to hydrophilic drugs;</p></list-item><list-item id="o0240"><label>(3)</label><p id="p0635">Uncontrolled degradation</p></list-item></list></td><td align="left" colspan="1" rowspan="1"><list list-type="simple" id="olist0105"><list-item id="o0245"><label>(1)</label><p id="p0640">Balancing degradation rates and drug release profiles;</p></list-item><list-item id="o0250"><label>(2)</label><p id="p0645">Inflammatory responses to long-term implants</p></list-item></list></td><td align="left" colspan="1" rowspan="1">[<xref rid="bib218" ref-type="bibr">[218]</xref>, <xref rid="bib219" ref-type="bibr">[219]</xref>, <xref rid="bib220" ref-type="bibr">[220]</xref>, <xref rid="bib221" ref-type="bibr">[221]</xref>]</td></tr></tbody></table></table-wrap></p><sec id="sec3.1"><label>3.1</label><title>LNPs</title><p id="p0130">Lipid-based drug delivery platforms are broadly categorized into conventional liposomes and next-generation LNPs, and they are differentiated by their structures and functions. Liposomes, spherical phospholipid/cholesterol bilayers, facilitate compartmentalized drug loading. Hydrophilic agents are encapsulated in hydrophilic cores and lipophilic payloads are often embedded within membranes [<xref rid="bib111" ref-type="bibr">111</xref>,<xref rid="bib112" ref-type="bibr">112</xref>]. A clinic example for the liposomes-based drug delivery system is Doxil&#174; which delivers doxorubicin via the enhanced permeability and retention (EPR) effect, and this system remains pivotal for chemotherapeutic application. LNPs as a multifunctional delivery platform have been demonstrated to successfully encapsulate and transport a myriad of therapeutic payloads, including hydrophilic compounds, hydrophobic agents, and nucleic acid-based therapeutics [<xref rid="bib113" ref-type="bibr">113</xref>]. Ionizable lipids (e.g., DLin-MC3-DMA), PEG-lipids, and cholesterol are employed to form stable LNPs via microfluidic self-assembly [<xref rid="bib114" ref-type="bibr">114</xref>,<xref rid="bib115" ref-type="bibr">115</xref>]. Comirnaty&#174;, an FDA-approved COVID-19 mRNA vaccine formulated with LNPs, leverages pH-dependent endosomal membrane disruption to enable cytosolic mRNA release, and this mechanism is not achievable by traditional liposomes [<xref rid="bib116" ref-type="bibr">116</xref>].</p><sec id="sec3.1.1"><label>3.1.1</label><title>Cationic LNPs</title><p id="p0135">Cationic LNPs with a positive charge can efficiently encapsulate negatively charged mRNA via electrostatic interaction, and they can protect mRNA from degradation in the blood. Cationic LNPs can facilely fuse with cell membranes to promote cell endocytosis through electrostatic interactions. Cationic lipids have been explored including N, N, N-trimethyl-2,3-bis(octadec-9-en-1-yloxy) propan-1-aminium chloride (DOTMA), dioleoyl-3-trimethylammonium propane (DOTAP), 2,3-Dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), and dioleoylethylphosphatidylcholine (EDOPC). Chen et al. developed a core-shell LNP system for mRNA delivery, which was fabricated using a microfluidic technique (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A(a)). In this system, protamine sulfate and mRNA constituted the inner core, while the outer lipid shell was composed of EDOPC, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol. The formulated mRNA vaccine particles (MPVs) displayed an optimal mRNA encapsulation efficiency and excellent stability and retained their biological activity even after lyophilization or freeze-thaw cycles. After intradermal injection, MPVs promoted DC maturation and activated the STING-dependent pathway to evoke T cell responses, which inhibited growth of MC38-OVA colorectal cancer and B16-OVA melanoma (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A(b-c)). It is worth noting that EDOPC, a cationic lipid, played an essential role in activating the STING pathway when it was formulated into LNPs [<xref rid="bib117" ref-type="bibr">117</xref>]. Other cationic lipid-like materials have been reported to form LNPs for mRNA delivery, and the cationic lipid-like materials can be acted as a potent immune adjuvant. Zhang et al. synthesized cationic lipid-like compounds via ring opening of epoxides and they found that poly(-amidoamine) (PAMAM) dendrimers with a 12-carbon tail, termed as C1, could efficiently deliver mRNA to APCs. C1, DSPE-PEG 2000, and mRNA were formulated into LNPs as a C1-mRNA nanovaccine through self-assembly at a size of around 150&#160;nm, and the nanovaccine remained stable within 7 days. The C1-mRNA nanovaccine effectively induced immune activation of both STING and TLR4-dependent NF-&#954;B signaling pathways. The C1-mRNA nanovaccine could serve as a potent preventive and therapeutic vaccine for B16-OVA tumors with high biosafety [<xref rid="bib118" ref-type="bibr">118</xref>].<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>LNPs for tumor vaccines delivery. A. Cationic lipid-formulated mRNA vaccines. (a) Schematic diagram of preparing an mRNA vaccine via a microfluidic instrument. (b&#8211;c) A cationic lipid-based mRNA vaccine inhibited MC-38 and B16 tumor growth through eliciting STING-dependent antitumor immunity. Reproduced with permission [<xref rid="bib117" ref-type="bibr">117</xref>]. Copyright 2023, Elsevier. B. Ionizable lipids-based nanoparticles for mRNA delivery. (a) Schematic view of ionizable lipid structural components. (b) A combinatorial library of ionizable lipid-like materials. Candidates in the amine, isocyanides, and alkyl ketones groups are marked in a red rectangle. Reproduced with permission [<xref rid="bib121" ref-type="bibr">121</xref>]. Copyright 2019, Springer Nature. C. Endogenously targeting lymph nodes by LNPs without the modification of active targeting ligands. (a&#8211;b) Chemical structures of lipids. (c) Illustrative images of bioluminescence distribution after administration of 113-O12B/mLuc or ALC-0315/mLuc. Reproduced with permission [<xref rid="bib125" ref-type="bibr">125</xref>]. Copyright 2022, National Academy of Sciences.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec3.1.2"><label>3.1.2</label><title>Ionizable LNPs</title><p id="p0140">Ionizable lipids exhibit a neutral charge under a physiological condition, but the neutral charge can be tuned to a positive charge when the pH is in the acidic range [<xref rid="bib119" ref-type="bibr">119</xref>]. Therefore, ionizable lipids-based LNPs have been widely explored for mRNA vaccine delivery. Lee et al. reported C12-200 ionizable lipids-based LNPs to incorporate mRNA and tri-palmitoyl-S-glyceryl cysteine linked to a pentapeptide (Pam3) as an adjuvant. The LNPs were fabricated by formulating C12-200, DOPE, C16-polyethylene glycol2000 (PEG-lipid), Pam3, and mRNA in a citrate buffer solution (pH 3). Under such an acidic condition, C12-200 acquired a positive charge, resulting in electrostatic interaction with mRNA, and the remaining lipid components self-assembled to form the LNPs [<xref rid="bib120" ref-type="bibr">120</xref>]. Miao et al. designed a series of cationic heads, linkers, and alkyl chains to construct a library of ionizable lipids containing 1080 compounds (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B (a)). The lipid compounds in conjunction with two helper lipids of DOPE and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) self-assembled into LNPs to deliver an mRNA vaccine. They identified critical structural characteristics of ionizable lipids for effective mRNA delivery: (1) an unsaturated lipid tail; (2) a dihydroimidazole linker; and (3) a head group containing cyclic amine (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B(b)). Besides, the LNPs prepared from the top candidate of the lipid compounds activated the STING pathway, which was TLR independent to stimulate immune cells, leading to inhibition of tumor growth and prolonged survival of B16F10-OVA-bearing mice over 40 days [<xref rid="bib121" ref-type="bibr">121</xref>].</p></sec><sec id="sec3.1.3"><label>3.1.3</label><title>Actively targeted LNPs</title><p id="p0145">LNPs can target immune organs including spleens and lymph nodes through two pathways: (1) decoration of LNPs with targeted molecules for actively targeted delivery, and (2) tuning of lipid components in LNPs to improve accumulation in secondary lymphoid organs. It has been reported that stearic acid-modified LNPs could effectively target the spleen [<xref rid="bib122" ref-type="bibr">122</xref>]. Stearic acid was mixed with conventional lipids, such as Dlin-MC3-DMA, DSPC, 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000), and cholesterol, to fabricate stearic acid-doped lipid nanoparticles (sLNPs). These nanoparticles were used to encapsulate ovalbumin (OVA)-encoding mRNA and MPLA as a TLR4 agonist, resulting in a nanovaccine: sLNPs-OVA/MPLA. sLNPs-OVA/MPLA selectively delivered mRNA to the spleen after intravenous injection. The LNPs exhibited an encapsulation efficiency of 81.58&#160;&#177;&#160;3.74&#160;% and remarkable stability, and they retained their spleen-targeting ability even after storage at 4&#160;&#176;C for 7 days. sLNPs-OVA/MPLA was efficiently internalized into DCs in the spleen, and this formulation promoted mRNA transcription and enhanced the expression of co-stimulatory molecules including CD80 and CD86, which resulted in the highest proportion (39&#160;%) of SIINFEKL-specific CD8<sup>+</sup> T cells compared to other formulations tested in this study. Furthermore, immunization with sLNPs-OVA/MPLA induced the production of a potent IgG antibody in the blood to mediate adaptive immunity. sLNPs-OVA/MPLA displayed a strong and long-term immune protection ability. Tumor recurrence was effectively blocked in a 6/6&#160;EG.7-OVA tumor-bearing murine model upon secondary challenges with EG.7-OVA cells for 60 days post-treatment [<xref rid="bib122" ref-type="bibr">122</xref>]. LNPs were also engineered through the incorporation of phosphatidylserine (PS) to actively enhance immune cell uptake in the spleen and lymph nodes. These targeted LNPs, termed as PS-LNPs, were formulated by adding 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) to the LNP components, including DSPC, cholesterol, and DMG-PEG2000. PS-LNPs exhibited an mRNA delivery efficiency of approximately 90&#160;% to the spleen and 10&#160;% to the liver, whereas 58&#160;% of LNPs without PS modification were delivered to the spleen and 41&#160;% to the liver [<xref rid="bib123" ref-type="bibr">123</xref>].</p><p id="p0150">An alternative strategy is proposed to achieve targeted delivery to immune organs by modulating the chemical composition of LNPs. Elwakil et al. engineered ligand-free glycidylamine (GA)-incorporated LNPs through rational molecular design to achieve spleen-selective mRNA delivery. The LNPs exhibited a high targeted transfection efficiency in splenic immune cell populations following systemic administration. A novel class of cholesterol-conjugated glycidylamine (Chol-GA) lipid derivatives was systematically synthesized via the controlled organocatalyzed ring-opening polymerization methodology. Cholesterol moieties were employed as a catalytic initiator for precise molecular assembly of GA monomeric building blocks under an optimized stoichiometric condition. The Chol-GA lipid derivative with a degree of polymerization of 30 and a racemic configuration was identified to be a top-performing lipid. This derivative was subsequently formulated with DOPE and DMG-PEG2000 to prepare LNPs, termed as estriol-GA05-30 LNPs. Estriol-GA05-30 LNPs exhibited pronounced targeting and delivery efficiencies towards APCs and induced strong anti-tumor effects in the E.G7-OVA bearing mice [<xref rid="bib124" ref-type="bibr">124</xref>]. Endogenous lymph nodes-targeting LNPs without modification with active targeting moieties were explored for mRNA delivery. After screening a library of reduction-responsive lipids, Chen et al. systemically examined the impact of the head, the tail, and linkers of lipids on their targetability (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C(a)). They suggested a few crucial structural components including: (1) the methyl group of the amine head that may play a role in targeting since replacement of the methyl group with hydroxyl, ethyl, or N-(1,2-ethanediyl)acetamide groups resulted in a reduced delivery efficiency; (2) the lipid with a shorter tail which outperformed one with a long tail; (3) an ester linker could promote transfection in lymph nodes compared to the amide bond. By capturing these lipid structural characteristics, a lipid was selected and named as 113-O12B (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C(b)). A LNPs delivery system was prepared through molecular integration of 113-O12B with cholesterol as a structural component, dioleoyl phosphatidylcholine (DOPC) as a zwitterionic helper lipid, and DMG-PEG 2000 as a steric stabilizer. Quantitative biodistribution profiling of subcutaneously delivered LNP formulations revealed distinct organotropic patterns between 113-O12B and ALC-0315 (an FDA approved lipid in the COVID 19 mRNA vaccine). 113-O12B exhibited preferential lymph nodes retention, while ALC-0315 displayed pronounced hepatic sequestration (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C(c)). The lymph nodes-targeting 113-O12B formulation significantly enhanced APCs presentation and promoted antigen-specific CD8<sup>+</sup> T cells infiltration into the tumor tissue, resulting in potent protective and therapeutic effects in the established B16F10-OVA tumor-bearing mice [<xref rid="bib125" ref-type="bibr">125</xref>].</p></sec></sec><sec id="sec3.2"><label>3.2</label><title>Polymeric nanoparticles</title><p id="p0155">Polymeric nanoparticles have been widely used for diagnosis and treatment of various diseases [<xref rid="bib126" ref-type="bibr">[126]</xref>, <xref rid="bib127" ref-type="bibr">[127]</xref>, <xref rid="bib128" ref-type="bibr">[128]</xref>, <xref rid="bib129" ref-type="bibr">[129]</xref>]. In recent years, polymer-based nanovaccines have been developed for cancer immunotherapy. Polymeric nanoparticles as nanocarriers for tumor vaccines have the following advantages: (1) polymeric nanoparticles enable co-delivery of antigens and adjuvants through covalent binding or encapsulation, facilitating the presentation of antigenic information via MHC class I or MHC class II molecules and promoting the expression of co-stimulatory molecules including CD80 and CD86, which result in effective activation of T cell-mediated immune responses; (2) polymeric nanoparticles facilitate endosome escape of antigens for cross presentation; and (3) polymers can be functionalized through chemical decoration.</p><sec id="sec3.2.1"><label>3.2.1</label><title>Polymeric nanoparticles for co-delivery of antigens and adjuvants</title><p id="p0160">Polymeric nanoparticles can efficiently encapsulate antigens and adjuvants within their core, thereby protecting antigens from enzymatic degradation and realizing spatiotemporal co-delivery of both components to APCs for robust enhancement in their activation of CTLs.</p><p id="p0165">Poly (L-lactide-co-glycolide) (PLGA), a biodegradable and biocompatible polymer, has been approved by FDA as a pharmaceutical excipient for parenteral and mucosal administration [<xref rid="bib130" ref-type="bibr">130</xref>]. An investigation revealed that PLGA-based nanocarriers simultaneously encapsulated multiple immunomodulatory agents, including Poly I:C as a TLR3 ligand, resiquimod (R848) as a dual TLR7/8 agonist, and MIP3&#945; as a chemotactic cytokine, thereby showcasing their capacity for accommodating multiple payloads in a murine model bearing TC-1 tumors [<xref rid="bib131" ref-type="bibr">131</xref>]. Cationic polyethyleneimine (PEI) can complex with a negatively charged antigensand CpG adjuvant via electrostatic interaction. The positive charge characteristics of PEI facilitated efficient internalization of nanoparticles by DCs, promoted lysosome escape, and achieved antigen cross-presentation for effectively activating CD8<sup>+</sup> T cell responses. A PEI-based vaccine nanoplatform for co-delivery of a tumor antigen and an adjuvant was constructed from a three-step preparation process. First, Adpgk, an MC38 colon cancer antigen, was conjugated to PEI via a disulfide bond, and the antigen was efficiently released under a reductive intracellular environment; next, the Adpgk-conjugated PEI was modified with PEG to reduce the cytotoxicity of PEI; finally, anionic CpG was incubated with the PEGylation antigen-conjugated PEI to self-assemble into sub-50 nm nanoparticles. The PEI-based vaccine elicited a robust CD8<sup>+</sup> T cell response, and the duration of immunity extended beyond three weeks, suggesting that engineered PEI could serve as a promising delivery vehicle for co-delivery of antigens and adjuvants [<xref rid="bib132" ref-type="bibr">132</xref>].</p><p id="p0170">pH-responsive polymeric nanoparticles (CRS NPs) were developed to co-deliver two TLR agonists (R848 and CpG) along with an antigen. A proton-sensitive star-branched copolymer (S40) comprised three functionally distinct domains: (1) cationic poly(2-dimethylaminoethyl methacrylate) (PDMA) segments that facilitate charge-driven complexation with anionic CpG oligonucleotides; (2) PEG coronas that could promote steric stabilization and attenuate the surface charge for enhanced hemocompatibility; and (3) pH-labile poly(2-diisopropylaminoethyl methacrylate) (PDPA) blocks as a hydrophobic core that could encapsulate neoantigen cargos through solvophobic entrapment. To integrate R848, a thiol-functionalized derivative (R848-SH) was site-specifically conjugated to maleimide-activated PEG-PLA copolymers, followed by combination with S40 to form hybrid nanoparticles. The bi-adjuvant/antigen nanoparticles co-delivered antigens and adjuvants to APCs to strengthen immunity responses, significantly increasing the ratio of SIINFEKL-specific CD8<sup>+</sup> T cells from 5.08&#160;% in the free antigen and adjuvant group (free CRS) to 33.63&#160;% in the nanoparticles group (CRS NPs) [<xref rid="bib133" ref-type="bibr">133</xref>].</p><p id="p0175">In addition to delivering exogenous adjuvants, polymeric nanoparticles containing primary amines have been demonstrated to possess an intrinsic adjuvant property: they are capable of stimulating DC maturation. Building on this discovery, a dual immunofunctional polymeric nanoplatform (DIPNP) has been developed through strategic integration of two complementary mechanisms (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A(a)). A triblock copolymer, PEG-PBAEMA-P18C6MA, was synthesized through a sequential reversible addition-fragmentation chain transfer polymerization strategy. During the initial synthesis step, a diblock precursor PEG-PBAEMA was constructed from a PEG-functionalized chain transfer agent (PEG-CPPA). Controlled polymerization of 18-crown-6-yl methacrylate (18C6MA) monomers and the diblock precursor was utilized to achieve a precise triblock architecture. Post-polymerization modification through acidolytic removal of NH-Boc protecting groups led to spontaneous self-assembly into a nanovaccine, DIPNV. Mechanistically, the p18C6MA block orchestrated the activation of the STING pathway via potassium ion (K<sup>+</sup>) flux-mediated ER stress, inducing conformational changes of STING proteins to initiate their trafficking through ER-Golgi-autophagosome networks (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A(b)). This cascade resulted in TBK1-dependent phosphorylation of IRF3, driving the secretion of IFN-&#946; (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A(c)). Concomitantly, the primary amine moieties on the PBAEMA segment were engaged in TLR4 signaling, which potentiated <funding-source id="gs5">DC</funding-source> maturation through inflammasome activation and antigen cross-presentation after lysosomal escape (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A(d)). <italic toggle="yes">In vitro</italic> validation studies revealed a synergistic enhancement in <funding-source id="gs6">DC</funding-source> activation, and assessments in B16-OVA and EG7-OVA murine tumor models supported that DIPNV had a profound antitumor efficacy, and it could induce durable immunological memory formation. The molecularly engineered triblock architecture also allowed concurrent antigen (OVA) encapsulation via charge-mediated complexation and spatiotemporal regulation of dual immune activation pathways. The multimodal functionalities shifted from carrier-only to carrier/adjuvant dual-functionality, thus a robust platform derived from this copolymer scaffold could be established for developing next generation nanovaccines with programmable immunopharmacological profiles [<xref rid="bib134" ref-type="bibr">134</xref>].<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Polymeric nanoparticles for co-delivery of antigens and adjuvants. A. A dual immunofunctional polymeric nanoplatform (DIPNP) to serve as a self-adjuvant and a carrier for a model antigen OVA. (a) Structural architecture of a triblock copolymer, PEG-PBAEMA-P18C6MA, and functional roles of constituent blocks in this copolymer. (b) Schematic diagram of DIPNP activation of the STING pathway. (c) Quantitative analysis of IFN-&#946; secretion in DCs after different treatments. (d) Schematic illustration of DIPNP activation of TLR4 signaling, and promotion of antigen cross-presentation facilitated by lysosomal escape. Reproduced with permission [<xref rid="bib134" ref-type="bibr">134</xref>], Copyright 2025, ACS. B. A polymeric nanovaccine equipped with a pH-sensitive property displayed efficient cytosolic delivery through controlled vaccine release and promoted endosomal escape mechanisms. (a) Star-shaped polymers underwent self-assembly into pH-responsive nanoparticles, resulting in co-encapsulation and co-delivery of neoantigens and cGAMP. (b) Destabilization of pH-dependent erythrocyte membranes via the erythrocyte hemolysis assay. (c) Representative confocal microscopy images for promotion of endosomal escape by nanoparticles. Reproduced with permission [<xref rid="bib136" ref-type="bibr">136</xref>]. Copyright 2022, Wiley-VCH. C. Mannan-decorated pathogen-like polymeric nanovaccine (MPVax) for targeted delivery of an antigen and an adjuvant into lymph nodes. (a) The nanovaccine with a core-shell architecture comprised a mannose-functionalized outer shell and a PLA-PEI composite core for encapsulating both the antigen and the CpG adjuvant. (b) Representative fluorescence images of isolated lymph nodes at 24&#160;h post administration of the mannose-functionalized polymeric nanoparticles. (c) Tumor growth curves in B16-OVA bearing mice with different treatments. (d) Individual B16-OVA tumor growth profiles. The complete response criteria were 100&#160;% of tumor regression at the experimental endpoint (Day 21). Reproduced with permission [<xref rid="bib141" ref-type="bibr">141</xref>]. Copyright 2022, Elsevier.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Polymeric nanoparticles promote endosomal escape</title><p id="p0180">Polymers engineered with specific chemical structures or functional groups can facilitate endosomal escape, and the encapsulated antigens in the polymers can be released into the cytoplasm. Antigens released in this approach could promote their cross-presentation via the MHC class I pathway, thereby enhancing CD8<sup>+</sup> T cell activation. There are different engineering approaches for polymers to achieve their endosomal escape. First, polymers can destroy endosomal membranes to promote their endosomal escape. Poly (propylacrylic acid) (pPAA) with a PKa of 6.7 contains carboxyl groups, which can mediate membrane-destabilization in an acidic environment. Polyanionic pPAA was combined with antigen peptides modified with a cationic oligolysine tail to form polyplex nanoparticles, and efficient cytosolic delivery of antigens from the polyplex nanoparticles was achieved with enhanced cross-presentation with MHC class I molecules [<xref rid="bib135" ref-type="bibr">135</xref>]. The &#8220;proton sponge&#8221; effect is another approach to rupturing endosomes to promote endosome escape of polymeric nanoparticles containing antigens. A pH-sensitive polymer, PDPA, was synthesized via atom transfer radical polymerization. This polymer self-assembled into a multivesicular nanovaccine upon mixing of PDPA with an antigen and a STING agonist (cGAMP) (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B(a)). The erythrocyte hemolysis assay was employed to assess the endo-osmotic activity of drug vesicles. The result revealed that the PDPA nanoparticles induced distinct hemolysis at a pH of 6.2, while negligible hemolysis at a pH of 7.4 (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B(b)). The nanocarriers with high pH sensitivity were confirmed to remain stable under a physiological condition but facilitate endosome escape in an acidic environment to release cGAMP and the antigen into cytosol (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B(c)). The nanovaccine induced a pronounced increase in the number of antigen-specific CD8<sup>+</sup> T cells, which was 8-fold higher than that in the PBS group. More encouragingly, the treatment with the nanovaccine led to an elevation of the proportion of memory T-cells including central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>) cells [<xref rid="bib136" ref-type="bibr">136</xref>]. Similarly, poly (&#946;-amino ester) would self-degrade into small fragments in response to a change in pH after poly (&#946;-amino ester) entered the endosome. After successful endosome escape, the antigen and cGAMP released from poly (&#946;-amino ester) promoted cross presentation to MHC class &#8544; molecules and release of IFN-&#947; [<xref rid="bib137" ref-type="bibr">137</xref>].</p><p id="p0185">The third approach is to introduce functional groups into polymers to reduce/mitigate their entrance into endosomes and enhance the cytosolic delivery efficiency. For example, polyethyleneimine derivatives functionalized with fluoroalkane moieties could enter cytosolic compartments directly, which may be attributed to a low surface energy and lipophobic characteristics of fluoroalkyl side chains. Xu et al. constructed a fluoroalkane-grafted polyethyleneimine nanovaccine, which delivered the antigen to the cytoplasm for cross presentation and induced robust immune responses <italic toggle="yes">in vivo</italic> [<xref rid="bib138" ref-type="bibr">138</xref>]. Fluoroalkane-grafted polyethyleneimines were demonstrated to efficiently deliver OVA-encoding mRNA intracellularly and activate the TLR4 signal pathway, which promoted DC maturation and induced OVA-specific T cell responses [<xref rid="bib139" ref-type="bibr">139</xref>].</p><p id="p0190">Besides the above approaches to facilitating endosome escape, polymeric nanoparticles could be transformed to mechanically disrupt the endosomal membrane for cytoplasm delivery. For instance, Gong et al. constructed a proton-actuated nanotransformer-based vaccine (NTV), which could be transformed from a nano-size to a micro-size to burst the endosomal membrane [<xref rid="bib140" ref-type="bibr">140</xref>]. The NTV consisted of a polymer and a peptide conjugate via an acetal bond. It had a monodispersed spherical nanostructure with a mean hydrodynamic diameter of 100&#160;nm. After internalization, the pyrene-conjugated d-peptide (PDP) in the NTV was degraded in an acidic endosomal environment (pH 6.5), and the polymer/peptide re-assembled into 5&#8211;8&#160;&#956;m nanosheets with a Young's modulus of 491.1&#160;MPa. The nanosheets disrupted the endosomal membrane and the peptide antigen was released into the cytoplasm for cross-presentation. The antigen presentation process was enhanced as the NTV effectively activated the NLRP3-inflammasome pathway. NTV vaccination indued potent CD8<sup>+</sup> T cell-mediated anti-tumor immune responses and long-term immune memory, resulting in a survival rate of 37.5&#160;% for the B16F10-OVA bearing-mice on day 62 and the same survival rate for the TC-1 bearing mice on day 83 after tumor inoculation [<xref rid="bib140" ref-type="bibr">140</xref>].</p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>Polymeric nanoparticles for targeted delivery</title><p id="p0195">Polymers can be decorated with a specific ligand or an antibody for targeted delivery. Mannose, which binds to mannose receptors, a subset of C-type lectins expressed on APCs such as macrophages and DCs, has been utilized for targeted delivery of antigens to APCs [<xref rid="bib142" ref-type="bibr">142</xref>]. Therefore, mannose-modified polymers or mannosylated compounds have been demonstrated to have great potential in the development of tumor vaccine platforms. A mannan-decorated pathogen-like polymeric nanovaccine (MPVax) was reported by Xu et al. The nanovaccine had a core-shell architecture with a mannose-functionalized outer shell and a polylactic acid-polyethylenimine (PLA-PEI) composite core, and the antigen and CpG were encapsulated within the core (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C(a)). Mannose decoration effectively promoted nanovaccine accumulation in lymph nodes, and the fluorescence intensity was 18.3-fold higher than that in the free antigen group (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C(b)). After vaccination three times, the nanovaccine induced antigen-specific T cell responses at a tumor inhibition rate of 94&#160;% (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C(c)) and a cure rate of 50&#160;% (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C(d)) in a B16-OVA tumor model [<xref rid="bib141" ref-type="bibr">141</xref>]. Zhou et al. developed a mannose-modified acid-responsive nanovaccine to target DCs and effectively deliver an antigen and a STING agonist (DMXXA) into the cytoplasm [<xref rid="bib143" ref-type="bibr">143</xref>]. The nanovaccine was constructed from poly (ethylene glycol)-block-poly (2-(diisopropanol amino) ethyl methacrylate) (PEG-b-PDPA) and a cationic polymer 1,2-epoxytetradecane alkylated oligoethylenimine 800 (OEI-C14). DMXAA and mannose were conjugated to PEG-b-PDPA via ester bonds. After OVA was loaded at an encapsulation efficiency of &#8764;70&#160;%, the nanovaccine at a size of about 50&#160;nm could efficiently accumulate in lymph nodes. The uptake efficiency of the mannose-modified nanovaccine was 2.8-fold higher compared to the formulation without mannose modification. OEI-C14-mediated endosome escape promoted OVA and DMXAA release into the cytosol for MHC class &#8544; presentation and activation of the STING pathway. The versatile nanovaccine promoted DC maturation, resulting in an increase in the ratio of CD8<sup>+</sup> T cells/regulatory T cells (Treg) and an enhancement in antigen-specific CD8<sup>+</sup> T cell infiltration in the tumor site, which dramatically prevented progression of B16-OVA melanoma and 4T1 triple-negative breast tumors [<xref rid="bib143" ref-type="bibr">143</xref>].</p><p id="p0200">A mannose-functionalized copolymer was synthesized via addition-fragmentation chain transfer-mediated polymerization, and the spontaneously formed 100&#160;nm micellar nanostructure was capable of encapsulation and delivery of tumor antigens [<xref rid="bib144" ref-type="bibr">144</xref>]. Mannose methacrylate (MMA) was polymerized to form a mannose block, 2-diisopropylaminoethyl methacrylate (DIPAMA) was incorporated into the block to confer pH sensitivity, and pyridyl disulfide ethyl methacrylate (PDSEMA) was copolymerized to facilitate conjugation with thiolated peptide antigens through disulfide-thiol exchange chemistry, resulting in a mannosylated polymer. The amount of the tumor antigen in the mannosylated micelle internalized by DCs in lymph nodes was increased by 79-fold compared to the naked antigen group. Mannosylated micelles loaded with MHC class I and II OVA epitopes with a loading efficiency of 67&#160;% and 50&#160;%, respectively, significantly increased the proportion of mature DCs (CD86<sup>+</sup>MHCII<sup>+</sup>) and subsequently activated antigen-specific CD8<sup>+</sup> T cells <italic toggle="yes">in vivo</italic>. This approach markedly delayed the growth rate of B16F10-OVA tumors and extended the survival rate when the vaccine was combined with an anti-PD-1 antibody therapy [<xref rid="bib144" ref-type="bibr">144</xref>].</p></sec></sec><sec id="sec3.3"><label>3.3</label><title>Inorganic nanoparticles</title><p id="p0205">Inorganic materials, such as silica, carbon, and metals, represent another major category of materials for the construction of nanoplatforms [<xref rid="bib145" ref-type="bibr">145</xref>]. Inorganic nanoparticles have a high surface-to-volume ratio, and they often display a remarkable loading capacity for therapeutic agents. Their synthetic process is facile compared to a sophisticated synthetic process for polymers [<xref rid="bib146" ref-type="bibr">146</xref>]. Beyond the conventional size-dependent EPR effect for inorganic nanoparticles, tumor-specific targeting can be achieved through rational surface engineering strategies [<xref rid="bib147" ref-type="bibr">147</xref>]. Recently, inorganic nanocarriers have been applied to co-deliver antigens and adjuvants for tumor immunotherapy.</p><sec id="sec3.3.1"><label>3.3.1</label><title>Mesoporous silica nanoparticles (MSNs)</title><p id="p0210">Mesoporous silica is a typical inorganic material, and it has been applied in drug delivery owing to a porous structure, facile surface modification, and a controllable size [<xref rid="bib148" ref-type="bibr">148</xref>]. MSNs display pore size-dependent immune activation when they are used as a vaccine delivery platform. MSNs at a particle size of around 80&#160;nm with a large pore size (12.9&#160;nm, MSN-L), a medium pore size (10.3&#160;nm, MSN-M), and a small pore size (7.8&#160;nm, MSN-S) were prepared through adjustment of the concentration of tetraethyl orthosilicate in cyclohexane [<xref rid="bib149" ref-type="bibr">149</xref>]. The encapsulation efficiency was positively correlated with the pore size: MSN-L showed the highest OVA encapsulation efficiency (89.6&#160;%), while the encapsulation efficiency was 73.2&#160;% for MSN-M and 51.5&#160;% for MSN-S. The MSNs exhibited sustained OVA release kinetics, and the release rate was 33&#160;% for MSN-L, 24&#160;% for MSN-M, and 20&#160;% for MSN-S. All these MSNs were transported to lymph nodes and effectively internalized by DCs. After their internalization, they escaped from endosomes and the released antigens were processed for cross presentation. MSN-L was found to be the most effective in the production of cytokines including IL-4, IFN-&#947;, and TNF-&#945;, thus significantly prolonging the survival of B16F10-OVA-bearing mice compared to MSN-S and MSN-M. Potent anti-tumor efficacy induced by MSN-L could be ascribed to its critical attributes: (1) MSN-L efficiently facilitated antigen cross-presentation; and (2) MSN-L had a faster degradation rate than MSN-S and MSN-M to promote the release of adequate OVA in lymph nodes to activate T cells [<xref rid="bib149" ref-type="bibr">149</xref>]. Beyond the immunomodulatory effect exerted by manipulating the MSNs size, architectural structures in MSN chemical frameworks significantly impact immune activation efficacy. To systematically investigate the structure-immunogenicity relationship of MSNs, three distinct architectural variants were engineered: tetrasulfide-incorporated MSNs (TMSNs), ethoxy-functionalized MSNs (EMSNs), and pristine Si-O-Si framework MSNs (MSNs) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A(a)). Encapsulation of the OVA antigen into these MSNs yielded OTMSNs, OEMSNs, OMSNs, respectively. Comprehensive analysis revealed TMSNs displayed superior performance based on multiple immunological parameters. Mechanistically, OTMSNs were found to enhance antigen loading, cellular internalization, ROS generation, lymph node targeting, immune activation, eventually improving the anti-tumor effect. The superior performance of TMSNs was stemmed from tetrasulfide-mediated dual-pathway cellular internalization: dynamin-dependent endocytosis in synergy with thiol-mediated transcytosis. Concurrently, intracellular glutathione scavenging by disulfide bonds in TMSNs induced redox dyshomeostasis, elevating ROS to polarize macrophages from an M2 phenotype to an M1 one (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A(b)). The structure-guided immune potentiation mechanism could lay a conceptual foundation for clinical translation of programmable nanovaccines for precision oncology interventions [<xref rid="bib150" ref-type="bibr">150</xref>].<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Inorganic nanoparticles for tumor vaccines delivery. A. Impact of MSNs with architectural variations in their chemical frameworks on their immune activation efficacy. (a) Illustration of MSNs with different skeletons: tetrasulfide-incorporated (TMSNs), ethoxy-functionalized (EMSNs), and pristine Si-O-Si framework (MSNs). (b) Immune activation and regulation of the immune microenvironment by the three MSNs. Reproduced with permission [<xref rid="bib150" ref-type="bibr">150</xref>]. Copyright 2024, Wiley-VCH. B. ZIF-8-based tumor vaccines. (a) Schematic for the synthesis of ZIF-8 nanoparticles and encapsulation of the model antigen OVA. (b) ZIF-8 nanoparticles exhibited pH-dependent release of OVA. Reproduced with permission [<xref rid="bib160" ref-type="bibr">160</xref>]. Copyright 2023, Wiley-VCH. C. PEGylated reduced graphene oxide nanosheets (RGO) conjugated with a neoantigen and loaded with CpG via &#960;&#8722;&#960; stacking interaction exhibited effective accumulation at lymph nodes after subcutaneous injection into the tail base. Reproduced with permission [<xref rid="bib163" ref-type="bibr">163</xref>]. Copyright 2020, American Chemical Society (ACS). D. A pH-sensitive nanocalcium carbonate (CaCO<sub>3</sub>) carrier was developed to co-deliver tumor cell lysates (TCL) and CpG and the vaccine was termed as CaCO<sub>3</sub>@TCL/CpG. (a) Preparation process of CaCO<sub>3</sub> nanoparticles. (b) Schematic diagram of lactate consumption in the tumor environment by CaCO<sub>3</sub> to increase the M1/M2 polarization ratio. (c) The lactate content in the supernatant of 4T1 cells treated with CaCO<sub>3</sub>@TCL/CpG. (d) The percentage of M2-like macrophages after administration of CaCO<sub>3</sub>@TCL/CpG. Reproduced with permission [<xref rid="bib164" ref-type="bibr">164</xref>]. Copyright 2023, Wiley-VCH.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0215">The elasticity of MSNs may influence the vaccine delivery efficiency. It was reported that soft MSNs could be a better vaccine delivery platform than stiff MSNs[151]. Mesoporous organosilica nanoparticles (MONs) at different elasticities were constructed. Stiff MONs were synthesized via a cetyltrimethylammonium bromide (CTAB)-directed sol-gel process, and soft MONs were prepared by dispersing stiff MONs in NaOH to etch inorganic silica species in the shell. Stiff and soft MONs were dispersed in a PEI solution for PEI modification, and the prepared nanoparticles were termed as MONP and SMONP, respectively. The elastic Young's modulus of MONP and SMONP was 144.4&#160;&#177;&#160;41.9&#160;MPa and 97.5&#160;&#177;&#160;27.9&#160;MPa, respectively, indicating successful construction of MONs at different elasticities. OVA, a model antigen, was encapsulated into MONP and SMONP as nanovaccines. The SMONP-derived nanovaccine displayed a higher DC uptake level, a higher cytoplasmic antigen delivery efficiency, and a greater degree of T cell activation compared to the MONP-derived nanovaccine. <italic toggle="yes">In vivo</italic> anti-tumor results revealed that the SMONP-derived nanovaccine treatment led to an increase in the proportion of CD8<sup>+</sup> T cells and a decrease in the Treg ratio in tumor tissues. More importantly, memory T cells were increased for long-term protection, thus inhibiting tumor growth in the E.G7-OVA tumor-bearing mice [<xref rid="bib151" ref-type="bibr">151</xref>].</p><p id="p0220">The structural configuration of MSNs can have an impact on the efficacy of antigens and adjuvants encapsulated in MSNs. Mesoporous silica rods (MSRs) were reported as an immunomodulatory scaffold to recruit APCs [<xref rid="bib152" ref-type="bibr">152</xref>]. A dual-scale mesoporous silica vaccine containing MSNs and MSRs was developed. The amine-modified MSNs were functionalized via silane coupling chemistry, and OVA and CpG were encapsulated in MSNs through electrostatic interaction. Meanwhile, granulocyte-macrophage colony-stimulating factor (GM-CSF), a DC-recruiting chemokine, was encapsulated in MSRs to produce GM-CSF-loaded MSRs. After incubation of MSNs with MSRs, MSNs at a particle size of 150&#160;nm were spontaneously assembled onto the MSR surfaces through synergistic van der Waals forces and hydrogen bonding interactions, resulting in the formation of a hierarchical MSN-MSR hybrid vaccine delivery system. After injection of the MSR-MSN-delivered vaccine into nodules, the number of DCs in the interparticle macropores of MSRs was increased from 2.5&#160;&#215;&#160;10<sup>4</sup> on day 1 &#8211; 5.8&#160;&#215;&#160;10<sup>5</sup> on day 7, demonstrating that the hybrid MSR-MSN system could effectively recruit DCs. The recruited DCs engulfed MSNs to process the released antigen from MSNs and their maturation was promoted, which activated OVA-specific CD8<sup>+</sup> T cells to kill tumor cells [<xref rid="bib153" ref-type="bibr">153</xref>].</p><p id="p0225">MSNs with extra-large mesopores, approximately 20&#8211;30&#160;nm, are termed as hollow MSNs (HMSNs). The HMSNs can accommodate multiple cargos with a high loading capacity, thus they have exhibited great promise in vaccine delivery [<xref rid="bib154" ref-type="bibr">154</xref>]. Lee et al<italic toggle="yes">.</italic> reported a HMSNs-based tumor vaccine. The HMSNs were prepared through two steps: MSNs with a spherical assembly were constructed from multicore iron oxide nanoparticles; and the HMSNs with extra-large mesopores (20&#8211;30&#160;nm) were obtained after extraction of MSNs in an acidic solution to remove iron oxide nanoparticles. To improve the immunomodulatory effect of HMSNs, PEI was modified on HMSNs to yield P-HMSNs. OVA as a model antigen was effectively loaded in P-HMSNs, and the prepared vaccine prolonged survival of the B16-OVA-based melanoma-bearing mice [<xref rid="bib155" ref-type="bibr">155</xref>].</p><p id="p0230">MSNs can be modified to realize responsive and controlled release of the loaded antigen. A pH/reduction dual sensitive MSN-based nanovaccine was constructed. PEI-modified MSNs with encapsulated OVA via electrostatic interaction acted as a core and disulfide bond-containing metal-phenolic networks (MPNs) were employed as the outer protective corona. 70&#160;% of OVA was released in pH 7.4 PBS supplemented with reductive glutathione within 8&#160;h, whereas only 23.9&#160;% of OVA was released in PBS alone over 35&#160;h. This difference was attributed to the thiol-disulfide exchange reaction in MPNs, leading to the removal of the corona for effective release of OVA in MSNs. In contrast, under a weakly acidic condition (pH 5.0 PBS), a cumulative OVA release of 80.5&#160;% was achieved within 10&#160;h, attributable to the pH-dependent dissociation of phenolic hydroxyl-ferric ion coordination bonds within the MPN structure. After subcutaneous immunization of the nanovaccine, cellular immunity was activated to inhibit tumor growth and memory immune responses were demonstrated after tumor rechallenge [<xref rid="bib156" ref-type="bibr">156</xref>].</p></sec><sec id="sec3.3.2"><label>3.3.2</label><title>Metal-organic frameworks</title><p id="p0235">Metal-organic frameworks (MOFs), as a class of organic-inorganic hybrid nanomaterial, are highly porous and structurally versatile, and they are composed of metal ions or metal clusters interconnected with organic ligands. They have an excellent loading capacity and become an emerging delivery system [<xref rid="bib157" ref-type="bibr">157</xref>]. Zeolitic imidazolate frameworks (ZIFs) are a crucial subfamily of MOFs with high stability and a pH-stimulation response, and ZIFs have been widely applied as nanocarriers for tumor immunotherapy [<xref rid="bib158" ref-type="bibr">158</xref>]. ZIF-8 nanoparticles could effectively co-deliver both antigens and adjuvants. For example, Zhang et al. prepared ZIF-8 nanoparticles at a size of around 200&#160;nm, and OVA and CpG were encapsulated in ZIF-8 via electrostatic interaction to serve as a tumor vaccine [<xref rid="bib159" ref-type="bibr">159</xref>]. ZIF-8 may be used as a nanocarrier to load cargos, and they could serve as an immunomodulator via Zn<sup>2+</sup>. Ding et al. revealed Zn<sup>2+</sup> promoted secretion of IFN-&#945; and IFN-&#946; from DCs through activation of the STING pathway, up-regulated the MMP-2 activity to facilitate tumor extracellular matrix degradation and induced tumor cell apoptosis at a concentration of 1000&#160;&#956;M [160]. They prepared ZPM@OVA-CpG by mixing Zn<sup>2+</sup>, PEI, and 2-methylimidazole in an aqueous solution, loaded OVA and CpG in the core, and coated the outer layer by D-mannose (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B(a)). Zn<sup>2+</sup> and OVA were released from ZPM@OVA-CpG in a pH-responsive manner (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B(b)), promoting antigen presentation and DC maturation. By activating immune responses and degrading ECM to reverse the immunosuppressive microenvironment, ZPM@OVA-CpG effectively inhibited melanoma growth, prevented tumor recurrence, and suppressed metastasis [<xref rid="bib160" ref-type="bibr">160</xref>].</p></sec><sec id="sec3.3.3"><label>3.3.3</label><title>Graphene-based nanoparticles</title><p id="p0240">Graphene and its derivatives including graphene oxide (GO) and reduced graphene oxide nanosheets (RGO) have become popular in recent years, and they have been explored for vaccine delivery [<xref rid="bib161" ref-type="bibr">161</xref>]. A GO-based therapeutic nanovaccine was reported by Zhang et al., OVA and CpG were loaded into a PEI-modified GO nanosheet, and PEG was conjugated to the nanosheet to prevent material aggregation and improve its biocompatibility [<xref rid="bib162" ref-type="bibr">162</xref>]. RGO as a delivery system has been demonstrated to display excellent lymph node-targeting ability. RGO was synthesized via thermal reduction of GO, and PEGylation of its surface yielded RGO-PEG at a size of 20&#8211;30&#160;nm and a thickness of 1.2&#160;nm. Adpgk, a neoantigen, was conjugated to PEG-RGO by reaction with maleimide groups on PEG, while CpG was loaded through &#960;&#8722;&#960; stacking interactions. The preparation process of the RGO-PEG system loaded with the antigen and adjuvant was finished in about 2&#160;h, which may offer a convenient platform to deliver a vaccine. The delivery system displayed over 100-fold greater accumulation in inguinal and axillary lymph nodes compared to free soluble antigens (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C). Strikingly, treatment with RGO-PEG led to an increase in the ROS content in DCs to induce alkalization of endo-lysosomes for effective antigen presentation to T cells. MC38-bearing mice with a single immunization of RGO-PEG-derived nanovaccine induced strong and long-term antigen-specific T cell responses to eradicate the MC38 tumors [<xref rid="bib163" ref-type="bibr">163</xref>].</p></sec><sec id="sec3.3.4"><label>3.3.4</label><title>Calcium carbonate nanoparticles</title><p id="p0245">Calcium carbonate (CaCO<sub>3</sub>) with advantages including pH-sensitivity, facile preparation and a low cost has shown the promise in drug delivery [<xref rid="bib165" ref-type="bibr">165</xref>]. Coprecipitation of Na<sub>2</sub>CO<sub>3</sub> and NaCl<sub>2</sub> is often used to prepare CaCO<sub>3</sub> microparticles. OVA and the TLR7/8 agonist were adsorbed onto the surface of CaCO<sub>3</sub> microparticles with a high incorporation efficiency, thus CaCO<sub>3</sub> microparticles could be prepared for co-delivery of antigens and adjuvants [<xref rid="bib166" ref-type="bibr">166</xref>]. A pH-responsive calcium carbonate-based nanoplatform was also synthesized through a precipitation-based fabrication strategy, and the tumor cell lysate (TCL) as an antigen library and CpG as an adjuvant were loaded onto the nanocarrier via electrostatic interaction. To improve the stability of the vaccine during blood circulation, PEG was coated as an outer shell (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D (a)). The CaCO<sub>3</sub>-based vaccine, CaCO<sub>3</sub>@TCL/CpG, exhibited pH-responsive release of TCL, and the TCL release percentage in pH 6.5 was 2.4 folds of that in pH 7.4 (67.83&#160;%&#160;&#177;&#160;6.37&#160;% <italic toggle="yes">vs</italic> 27.13&#160;%&#160;&#177;&#160;2.55&#160;%). CaCO<sub>3</sub>@TCL/CpG down-regulated the lactate content in the tumor microenvironment (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D (b-c)), effectively polarizing M2 macrophages to M1 macrophages (<xref rid="fig6" ref-type="fig">Fig. 6</xref>D (d)) and enhancing effector T cell infiltration into the tumor site to curb tumor growth [<xref rid="bib164" ref-type="bibr">164</xref>].</p></sec></sec><sec id="sec3.4"><label>3.4</label><title>Biomimetic nanoparticles</title><p id="p0250">Biomimetic nanoparticles that are inspired from nature with multi-functionalities have reshaped the development of nanoplatforms for drug delivery [<xref rid="bib167" ref-type="bibr">167</xref>]. Biomimetic nanoparticles are often constructed by coating inner nanoparticles with biomimetic membranes as an outer layer, which integrates the characteristics of nanoparticles and membranes to improve the functions of nanoplatforms [<xref rid="bib168" ref-type="bibr">168</xref>]. The most widely explored biomimetic membranes include tumor cell membranes, immune cell membranes, exosomes, and bacterial outer membranes (OMVs) (<xref rid="fig7" ref-type="fig">Fig. 7</xref>). Biomimetic nanoparticles-based tumor vaccines could revolutionize tumor immunotherapy.<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Scheme of biomimetic nanoplatforms derived from cell membranes, exosomes, and OMVs. Core nanoparticles are coated with these biomimetic membranes to obtain biomimetic nanoparticles. Cell membranes could be sourced from blood cells, immune cells, and tumor cells, and they have source-specific functions. Cell membranes can be functionalized via gentle chemical reaction, lipid insertion, genetic engineering, and membrane fusion. Exosomes are phospholipid bilayer-enclosed vesicles secreted from cells or shed from plasma membranes. Rab GTPase, ESCRT proteins, CD9, CD81, CD63, flotillin, TAG101, ceramide, and Alix are major biomarkers of exosomes. Exosomes from DCs, macrophages, and tumor cells are promising delivery vesicles for tumor vaccines. OMVs are constitutively released through membranes blebbing from the outer membrane of Gram-negative bacteria. OMVs for delivery of tumor vaccines have the following features: (1) OMVs can be effectively engulfed by DCs due to their nano-size; (2) myeloid cells can recognize the PAMPs on OMVs to mediate innate immune pathways; and (3) OMVs can be functionalized via chemical modification and genetic engineering to display antigens/epitopes for personalized vaccination.</p></caption><alt-text id="alttext0045">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><sec id="sec3.4.1"><label>3.4.1</label><title>Cell membrane-derived biomimetic nanoparticles</title><p id="p0255">The cell is a fundamental unit of biology, and it can independently collaborate with other cells to carry out various activities of the organism. Cell membranes as the outermost layer of cells consist of lipids, proteins, and polysaccharides, and they facilitate information exchange with different cells and substance exchange with its external environment. The cell membrane-coating nanotechnology is a top-bottom method. The collected cell membranes are coated onto nanoparticles as their outmost layer via sonication, extrusion, or microfluidic mixing [<xref rid="bib169" ref-type="bibr">169</xref>]. The cell membrane coating nanotechnology provides a facile approach to recapitulating unique bio-interfacing properties of cells, but these properties can not be easily imparted onto nanoparticles via traditional chemical synthesis methods. Zhang et al., in 2011 first reported an erythrocyte-coated PLGA nanoparticle, and the blood circulation time of the nanoparticle was extended up to 72&#160;h, which opened an avenue to developing cell membrane-derived biomimetic nanoparticles [<xref rid="bib170" ref-type="bibr">170</xref>]. It has been reported that a great many of cells have been employed to develop cell membrane-camouflaged nanoplatforms. Cell membrane-based biomimetic nanoparticles are commonly classified according to the source of cell membranes: blood cells (red blood cells, leukocyte, and platelets), immune cells (DCs, macrophages, neutrophils, and NK cells) [<xref rid="bib171" ref-type="bibr">171</xref>], and tumor cells.</p><p id="p0260">Cell membranes from different types of cells inherit some intrinsic properties of their source cells. Immune cell membranes endow these membrane-coated nanoparticles with invisibility to immune surveillance and these membrane-coated nanoparticles preferably home to an inflammatory site. DC membrane-derived nanovaccines exhibit lymph node-specific tropism and enhanced intranodal retention through CCR7-mediated chemotactic trafficking [<xref rid="bib172" ref-type="bibr">172</xref>]. In addition, co-stimulatory signaling molecules on the DC membrane, such as CD80 and CD86, can enhance the activation of T cells [<xref rid="bib173" ref-type="bibr">173</xref>]. For example, DC membrane-coated nanoparticles were developed from histidine-modified stearic acid-grafted chitosan as the core, and the model antigen OVA was encapsulated within the chitosan nanoparticles. These core nanoparticles mediated lysosome escape to present the antigen to CD8<sup>+</sup> T cells and promote DC maturation both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. After subcutaneous injection, remarkable accumulation of the nanovaccine in lymph nodes was observed and the retention time was about 168&#160;h, confirming the homing effect of DC membranes to lymph nodes. This nanovaccine effectively inhibited B16-OVA tumor growth through activation of CD8<sup>+</sup> T cell-mediated specific anti-tumor immune responses and production of antitumor cytokines, such as IFN-&#947;, TNF-&#945;, IL-6, and IL-12 [<xref rid="bib174" ref-type="bibr">174</xref>]. Macrophage membranes, an alternative antigen-presenting cell derivative in addition to DCs, display intrinsic inflammatory tropism through surface adhesion molecules (CCR2, VCAM-1, and ICAM-1), which promote homing to the inflammatory site. PEI-modified macrophage membranes were utilized to construct a vaccine delivery system. In this system, dendrobium devonianum polysaccharides served as an adjuvant and OVA as an antigen. The antigen and the adjuvant were co-encapsulated within the core of PLGA nanoparticles. The macrophage membrane coating promoted uptake of the vaccine by APCs and effectively activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells [<xref rid="bib175" ref-type="bibr">175</xref>].</p><p id="p0265">Tumor cell membrane-camouflaged nanoplatforms can often achieve dual functionalities by leveraging homotypic targeting mechanisms to enhance tumor-specific recognition specifically through EpCAM/E-cadherin adhesion and Thomsen-Friedenreich (TF) antigen/Galectin-3 interactions, as well as concurrently exploiting CD47/SIRP&#945;-mediated immune evasion. These biomimetic systems not only exhibit a superior homologous targeting efficiency for tumor accumulation but also serve as antigen reservoirs to prime DCs and amplify adaptive immune responses. The synergistic integration of homophilic adhesion and antigenic mimicry helps establishing a paradigm for precision theranostics [<xref rid="bib176" ref-type="bibr">176</xref>]. CRT over-expressed on tumor cell membranes not only provides an entire spectrum of tumor cell membrane antigens but also promotes DC uptake due to the interaction between CRT and the CD91 receptor on DCs. Xiong et al. reported a CRT-overexpressed 4T1 cell membrane-coated PLGA nanoparticle delivery system, and R837, a TLR7 agonist, was encapsulated as an adjuvant in the delivery system to improve immune responses (<xref rid="fig8" ref-type="fig">Fig. 8</xref>A). 4T1 cells were pre-treated with 10&#160;&#956;g/mL of doxorubicin to undergo ICD, and the ratio of CRT-positive cells was 64.9&#160;%. Compared with the normal tumor cell membrane-coated nanovaccine, the CRT-overexpressed cell membrane-coated nanovaccine effectively facilitated active uptake of the nanovaccine by DCs. This nanovaccine displayed an inhibition rate of 67.8&#160;% in 4T1-bearing mice and 70.85&#160;% in an immunoprophylaxis assay model, and it could have great potential in personalized vaccine immunotherapy [<xref rid="bib177" ref-type="bibr">177</xref>].<fig id="fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Cell membrane-coated nanoplatforms for tumor vaccine delivery. A. CRT-overexpressed tumor cell membranes were used to coat PLGA nanoparticles, and R848 as an adjuvant was encapsulated in the core of PLGA nanoparticles. The CRT-exposed nanovaccine could be effectively uptaken by DCs to mediate anti-tumor immune responses. Reproduced with permission [<xref rid="bib177" ref-type="bibr">177</xref>]. Copyright 2021, ACS. B. Cell membranes were functionalized via click reaction between azid and DBCO. (a) Immature DCs were pre-treated with Ac<sub>4</sub>ManNAz and tumor antigens. They were stimulated by IFN-&#947; and LPS to promote their maturation. The collected DC membranes were coated onto PLGA nanoparticles, and imiquimod was encapsulated in the core. The addition of the DBCO-modified &#945;CD3&#949; antibody triggered the click reaction between DBCO and azid on DC membranes, and nanoscale aAPCs, M<sup>[&#945;CD3&#949;/Ag]</sup>-NP-Imq, were obtained. (b) TEM image of M<sup>[&#945;CD3&#949;/Ag]</sup>-NP-Imq, scale bar&#160;=&#160;200&#160;nm. (c) Proliferation of CD8<sup>+</sup> T cells examined via the carboxyfluorescein succinimidyl ester (CFSE) labeled method. Reproduced with permission [<xref rid="bib180" ref-type="bibr">180</xref>]. Copyright 2021, ACS. C. Cell membranes were functionalized via lipid insertion. Cancer cell membranes were co-cultured with cholesterol (Cho)-CpG and Cho-aptamer at 4&#160;&#176;C for 1&#160;h to obtain CpG/aptamer-modified membranes. Reproduced with permission [<xref rid="bib183" ref-type="bibr">183</xref>]. Copyright 2021, ACS. D. An antibody-anchored membrane nanovaccine (Nano-AAM) was constructed. An anti-CD40 single chain variable fragment (scFv) was anchored into tumor cell membranes via genetic engineering. Reproduced with permission [<xref rid="bib186" ref-type="bibr">186</xref>]. Copyright 2023, Wiley-VCH.</p></caption><alt-text id="alttext0050">Fig. 8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p><p id="p0270">The function of the cell membranes can be improved due to its modifiable characteristics. Cell membrane modification techniques have been extensively developed to achieve functionalized cell membranes.<list list-type="simple" id="olist0015"><list-item id="o0035"><label>(1)</label><p id="p0275">Gentle chemical reaction, such as the click reaction between azid and dibenzocyclooctyne (DBCO) [<xref rid="bib178" ref-type="bibr">178</xref>]. This reaction can be conducted in an aqueous solution with high selectivity and excellent biocompatibility. It has been widely applied to incorporate an antibody onto a cell membrane. Azid is commonly decorated on the cell membranes, and the candidate antibody is modified with NHS-PEG<sub>4</sub>-DBCO. The modified cell membranes and the target antibody are mixed for click reaction. There are two common methods to obtain azid-decorated cell membranes: direct incubation of cell membranes with 0.1&#160;mM azid-choline for 24&#160;h or indirect metabolic engineering to label a chemical tag on living cell membranes [<xref rid="bib179" ref-type="bibr">179</xref>]. N-azidoacetyl mannosamine-tetraacylated (Ac<sub>4</sub>ManNAz) is the most widely used reagent in metabolic engineering. After cells are co-cultured with Ac<sub>4</sub>ManNAz for 72&#160;h, Ac<sub>4</sub>ManNAz can be metabolized into N-azidoacetyl neuraminic acid and incorporated into glycans on the membrane. Considering the issue associated with the reliance of the immune activation efficacy on the labeled MHC class I molecules and CD28 antibodies, a mature DC membrane-based artificial APCs (aAPCs) system was developed [180]. DCs from the bone marrow were first pre-treated with Ac<sub>4</sub>ManNAz, tumor antigens, IFN-&#947;, and LPS, and the azid-labeled cell membranes with MHC class I molecules and CD28 co-stimulators were obtained. PLGA nanoparticles were functionalized by coating the collected cell membranes, and imiquimod was encapsulated in the core of PLGA nanoparticles through sonication. To improve the immune activation capacity, an &#945;CD3&#949; antibody which can interact with the CD3 receptor on T cells to mediate transduction and cellular activation was conjugated to cell membranes after incubation of the above nanoparticles with the DBCO-&#945;CD3&#949; antibody (<xref rid="fig8" ref-type="fig">Fig. 8</xref>B(a)). The constructed spherical polyclonal aAPCs, termed as M<sup>[&#945;CD3&#949;/Ag]</sup>-NP-Imq, was illustrated in <xref rid="fig8" ref-type="fig">Fig. 8</xref>B(b). M<sup>[&#945;CD3&#949;/Ag]</sup>-NP-Imq exhibited an enhanced lymphatic targeting efficiency and prolonged its retention in lymph nodes. They enhanced the proportion of mature DCs, polarized macrophages toward their M1 phenotype, and activated CD8<sup>+</sup> T cells (<xref rid="fig8" ref-type="fig">Fig. 8</xref>B(c)). In synergy with an anti-PD-1 antibody, M<sup>[&#945;CD3&#949;/Ag]</sup>-NP-Imq elicited a pronounced prophylactic effect in melanoma tumors and a marked therapeutic effect in colorectal tumors [<xref rid="bib180" ref-type="bibr">180</xref>].</p></list-item><list-item id="o0040"><label>(2)</label><p id="p0280">The lipid insertion method. This method is based on the finding that lipids can be automatically inserted into cell membranes through hydrophobic interaction [<xref rid="bib181" ref-type="bibr">181</xref>]. Mannose, a mannose receptor overexpressed on APCs including DCs and macrophages, has been widely employed as a modified ligand in nanoplatforms for targeted delivery of vaccines to DCs. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol-mannose (DSPE-PEG-Man) could be inserted into cell membranes after incubation of DSPE-PEG-Man with cell membranes under stirring. Erythrocyte membranes with inserted DSPE-PEG-Man could actively target APCs in lymph nodes. For instance, an antigenic peptide, hgp100<sub>25-33</sub>, and MPLA as an adjuvant were loaded into PLGA nanoparticles, which were coated with mannose-modified erythrocyte membranes, resulting in a nanovaccine, Man-RBC-NP [<xref rid="bib182" ref-type="bibr">182</xref>]. An increase in the efficiency of internalizing the nanovaccine was seen in DC2.4&#160;cells (<italic toggle="yes">in vitro</italic>) and CD11b<sup>+</sup>CD11c<sup>+</sup> DCs (<italic toggle="yes">in vivo</italic>, 31.4&#160;% in the Man-RBC-NP group <italic toggle="yes">vs</italic> 22.4&#160;% in the RBC-NP group). Meanwhile, a longer retention time of Man-RBC-NP was found in lymph nodes compared to RBC-NP. After internalization into DCs, the nanovaccine effectively up-regulated the ratio of mature DCs from 33.1&#160;% in the PBS group to 81.6&#160;% in the Man-RBC-NP group and promoted the secretion of cytokines including TNF-&#945;, IL-12P70, and IFN-&#947;. The Man-RBC-NP nanovaccine exhibited a distinct preventive effect, significantly suppressing tumor growth with a potent anti-metastatic efficacy in a subcutaneously xenograft B16F10 melanoma mice model [<xref rid="bib182" ref-type="bibr">182</xref>]. To realize targeted delivery of tumor vaccines to DCs, a DC-targeting nanovaccine was developed including critical components such as tumor cell membranes, a TLR9 agonist (CpG), and an aptamer targeting DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN). The tumor cell membrane vesicle was functionalized using the lipid insertion method: cell membranes were incubated with cholesterol-conjugated CpG and the cholesterol-conjugated DC-SIGN aptamer at 4&#160;&#176;C for 1&#160;h (<xref rid="fig8" ref-type="fig">Fig. 8</xref>C). The aptamer anchored on the membrane facilitated DCs uptake of the nanovaccine and improved the delivery efficiency into lymph nodes. Treatment with this nanovaccine in conjunction with an anti-PD-1 antibody effectively delayed the growth of established tumors and prevented tumor recurrence due to induced immune memory [<xref rid="bib183" ref-type="bibr">183</xref>].</p></list-item><list-item id="o0045"><label>(3)</label><p id="p0285">Genetic engineering. Genetic engineering as another robust strategy can be harnessed to tailor specific components on cell membranes. The plasmid transfection method is often employed to generate overexpressed specific proteins on cell membranes [<xref rid="bib184" ref-type="bibr">184</xref>]. With the aid of gene editing technology, OVA, a model antigen, and a co-stimulatory marker, CD80, were overexpressed on B16F10&#160;cell membranes. The produced B16F10&#160;cell membranes directly presented antigens to activate T cells to mediate specific immune responses against tumors [<xref rid="bib185" ref-type="bibr">185</xref>]. Genetic engineering via lentivirus plasmid transfection was used to construct anti-CD40 single chain variable fragment (scFv)-overexpressed tumor cell membranes [<xref rid="bib186" ref-type="bibr">186</xref>]. The PLGA nanoparticles were coated with the antibody-anchored membrane (AAM) to form a nanovaccine, Nano-AAM/CD40. The Anti-CD40 scFv, a co-stimulatory immune checkpoint, retained its biological functionality through genetic engineering on the cell membrane surface (<xref rid="fig8" ref-type="fig">Fig. 8</xref>D). Nano-AAM/CD40 induced potent immune responses in both &#8220;hot&#8221; and &#8220;cold&#8221; tumors to inhibit MC38 and Panc02 tumor growth, which may be ascribed to targeted delivery to lymph nodes, promoted maturation of DCs, and the released IL-12 cytokine [<xref rid="bib186" ref-type="bibr">186</xref>].</p></list-item></list><list list-type="simple" id="olist0020"><list-item id="o0050"><label>(4)</label><p id="p0290">Membrane fusion. Membrane fusion is another promising approach for producing biomimetic nanoparticles. Two or more kinds of cell membranes are fused to form hybrid cellular membranes, which may integrate unique biological functions from each cell membrane [<xref rid="bib187" ref-type="bibr">187</xref>]. Hybrid membranes from erythrocyte membranes and cancer cell membranes displayed prolonged systemic circulation, effective immune evasion, and homotypic tumor-targetability [<xref rid="bib188" ref-type="bibr">188</xref>]. DC membranes and tumor cell membranes are complementary to produce cell membrane-based tumor vaccines: tumor cell membranes provide the immunogenicity from antigens on tumor cell membranes, and DC membranes enhance antigen presentation and provide co-stimulation signals [<xref rid="bib189" ref-type="bibr">189</xref>]. Zhang et al. developed a fusion cell membrane-based nanovaccine. The hybrid membranes were prepared from DC membranes and ovarian cancer cell membranes. PLGA nanoparticles loaded with CpG as an adjuvant were enveloped into the hybrid membranes. The nanovaccine was found to display effective antigen presentation, promote CTLs proliferation, and stimulate cytokines secretion to prevent tumor growth and metastasis [<xref rid="bib190" ref-type="bibr">190</xref>].</p></list-item></list></p></sec><sec id="sec3.4.2"><label>3.4.2</label><title>Exosome-derived biomimetic nanoparticles</title><p id="p0295">Extracellular vesicles (EVs) are phospholipid bilayer-enclosed vesicles secreted from cells or shed from plasma membranes. EVs allow the exchange of proteins, lipids, and nucleic acids between two cells, acting as a bridge for cell-to-cell communication [<xref rid="bib191" ref-type="bibr">191</xref>]. Based on the size of vesicles, EVs are commonly divided into exosomes (50&#8211;150&#160;nm) and microvesicles (50&#8211;500&#160;nm, up to 1&#160;&#956;m) [<xref rid="bib192" ref-type="bibr">192</xref>,<xref rid="bib193" ref-type="bibr">193</xref>]. Both exosomes and microvesicles can retain the characteristics of the original cell source, and they contain nucleic acids, proteins, lipids, and metabolites generated from their original cells. Exosomes can be used as a nanocarrier for tumor vaccines, and they have shown great potential in carrying chemotherapeutics and mRNA. Exosome-based delivery systems are garnering increasing attention for tumor treatment and diagnosis due to their excellent biocompatibility and targeted delivery [<xref rid="bib194" ref-type="bibr">194</xref>].</p><p id="p0300">Exosomes from DCs, termed as dexosomes, have enriched MHC class &#8544;/&#8545; molecules and costimulatory molecules including CD86, and they can effectively induce CD8<sup>+</sup>/CD4<sup>+</sup> T cells-mediated immune responses [<xref rid="bib195" ref-type="bibr">195</xref>]. Therefore, dexosomes have been widely applied to prepare tumor vaccines in preclinical and clinical studies [<xref rid="bib196" ref-type="bibr">196</xref>]. In one study, BMDCs were incubated with OVA and Poly I:C as a TLR-3 agonist to obtain the dexosomes loaded with OVA and Poly I:C, shortened as Dexo (OVA&#160;+&#160;PLC), through ultra-centrifugation. The B16F10 melanoma cell lysate containing tumor antigens was effectively encapsulated in dexosomes to prepare a tumor vaccine, which markedly recruited melanoma-specific CD8<sup>+</sup> T cells and NK cells into the tumor site to inhibit tumor growth and prolonged the survival of the B16F10-bearing mice [<xref rid="bib197" ref-type="bibr">197</xref>]. DC-derived exosomes were engineered as a biomimetic nanocarrier platform (Exo) for delivering tumor-specific neoantigens, including Adpgk (associated with MC38 colorectal cancer) and M27/M30 (B16F10 melanoma-associated epitopes). With lymph node migration capability, the Exo vaccine induced potent CD4<sup>+</sup>/CD8<sup>+</sup> T cell immune responses to retard tumor progression. In B16F10 rechallenge models, the M27/M30-loaded Exo vaccine elicited durable antigen-specific memory, characterized by CD3<sup>+</sup>CD44<sup>+</sup>CD62L<sup>+</sup> central memory T cells (82.6&#160;%) and CD3<sup>+</sup>CD44<sup>+</sup>CD62L<sup>&#8722;</sup> effector memory T cells (16&#160;%), conferring 100&#160;% survival for up to 180 days post-rechallenge [<xref rid="bib198" ref-type="bibr">198</xref>]. These results demonstrated that dexosomes-based nanovaccines could be developed for personalized immunotherapy.</p><p id="p0305">Exosomes from M1 macrophages have been reported to polarize M2 macrophages to their M1 phenotype, reversing an immunosuppressive microenvironment into an immunoactive one [<xref rid="bib199" ref-type="bibr">199</xref>]. Primary macrophages were cultured with LPS that could induce an elevation in the expression of CD80 and a decline in the expression of CD206 to stimulate them into M1 macrophages. M1<sub>OVA</sub>-Exo was isolated from the culture supernatant of M1 macrophages containing OVA (<xref rid="fig9" ref-type="fig">Fig. 9</xref>A(a)). After macrophages were incubated with M1<sub>OVA</sub>-Exo, they were remarkably polarized into their M1 phenotype via downregulation of the Wnt signaling pathway (<xref rid="fig9" ref-type="fig">Fig. 9</xref>A(b)). M1<sub>OVA</sub>-Exo treatment of B16-OVA melanoma resulted in an enhancement in the infiltration of CD4<sup>+</sup>/CD8<sup>+</sup> T cells into the tumor site, promotion of M2 macrophage polarization to M1, and secretion of cytokines to create a &#8220;hot&#8221; immune microenvironment [<xref rid="bib200" ref-type="bibr">200</xref>].<fig id="fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Exosome-derived biomimetic nanoparticles as tumor vaccine delivery carriers. A. Exosomes from M1 macrophages loaded with OVA to enhance tumor immunotherapy by remodeling the tumor microenvironment. (a) Schematic illustration of the preparation of an M1 macrophages-derived exosome nanovaccine (M1<sub>OVA</sub>-Exos). (b) M1<sub>OVA</sub>-Exos polarized macrophages toward their M1 phenotype by inhibiting the Wnt signaling pathway. Reproduced with permission [<xref rid="bib200" ref-type="bibr">200</xref>]. Copyright 2022, Elsevier. B. Biologically self-assembled tumor cell exosomes-derived cancer nanovaccines. (a) B16F10-OVA tumor cells internalized PLGA nanoparticles loaded with &#945;-mangostin (&#945;M-NPs), an ER stress inducer. &#945;M sustainedly released from PLGA nanoparticles triggered PERK-dependent ER stress, upregulating Hsp70s (70&#160;kDa). The biologically self-assembled tumor cell exosomes-derived nanovaccine (&#945;M-Exos) was harvested via centrifugation. (b) Immune activation by &#945;M-Exos after targeting lymph nodes [<xref rid="bib203" ref-type="bibr">203</xref>]. Copyright 2024, ACS. C. A chimeric exosome-based tumor vaccine engineered through the fusion of macrophage membranes and tumor cell membranes. (a) The nuclei isolated from 4T1 cells or B16&#160;cells were introduced into macrophages to obtain chimeric exosomes (aMT-Exos). (b&#8211;c) Chimeric exosomes contained tumor proteins (EpCAM expressed on 4T1 cell membranes and TRP1 expressed on B16&#160;cell membranes) and macrophage proteins (CD86, MHC &#8544;, and MHC &#8545;). (d) aMT-Exos activated immune cells inside lymph nodes (Top) and schematic illustration of the T cell activation routes (Bottom). Reproduced with permission [<xref rid="bib204" ref-type="bibr">204</xref>]. Copyright 2021, AAAS.</p></caption><alt-text id="alttext0055">Fig. 9</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr9.jpg"/></fig></p><p id="p0310">Tumor-derived exosomes (TEXs) exhibit a propensity for tumor-targeted delivery because of their intrinsic homotypic binding properties [<xref rid="bib201" ref-type="bibr">201</xref>]. Huang et al. constructed an <italic toggle="yes">in-situ</italic> DC vaccine derived from breast cancer exosomes. An overexpressed immunodominant protein on breast cancer, &#945;-Lactalbumin (&#945;-LA), was genetically engineered in MDA-MB-231&#160;cells, and &#945;-LA-expressed exosomes were obtained with improved DC-targetability and immunogenicity. A TLR3 agonist, hiltonol, and an ICD inducer, human neutrophil elastase (ELANE), were encapsulated into the exosomes to produce a nanovaccine, HELA-Exo. HELA-Exo displayed a potent anti-tumor effect in a mouse model and human organoids of breast cancer. The nanovaccine activated DCs at the tumor site for antigen cross-presentation and increased the ratio of CD8<sup>+</sup> T cells to kill tumor cells [<xref rid="bib202" ref-type="bibr">202</xref>]. Furthermore, Liang et al. engineered a bioinspired nanovaccine platform through programmable integration of ER stress induction and TEXs biogenesis. PLGA nanoparticles loaded with &#945;-mangostin (&#945;M-NPs), an ER stress inducer, were selectively internalized by B16F10-OVA tumor cells. Sustained release of &#945;M exerted PERK-dependent ER stress, upregulating Hsp70s (70&#160;kDa) (<xref rid="fig9" ref-type="fig">Fig. 9</xref>B). This cellular reprogramming orchestrated self-assembly of the TEXs-mimicking nanovaccine (&#945;M-Exos). In this &#945;M-Exos nanovaccine, (1) a tumor antigen repertoire was preserved; (2) membrane-anchored Hsp70s acted as an endogenous TLR4 agonist, and (3) PLGA cores enabled pH-responsive cargo release. Crucially, subcutaneous administration of &#945;M-Exos exhibited enhanced lymph node targeting with a 2.7-fold efficiency compared to the control Exos, which was attributed to the abundant expression of Hsp70s, facilitating dual-modal DC activation (<xref rid="fig9" ref-type="fig">Fig. 9</xref>B(b)). The modular design allowed scalable production of vaccines that retained a native exosome topology and diverse tumor neoantigens, leading to effective inhibition of B16F10-OVA and 4T1 tumor growth. This cellular biofactory strategy revolutionizes precision nanovaccinology by leveraging intrinsic biosynthetic pathways for clinically deployable cancer immunotherapy [<xref rid="bib203" ref-type="bibr">203</xref>].</p><p id="p0315">Inspired from the characteristics of exosomes from immune cells and tumor cells, the concept of chimeric exosomes is proposed. Macrophages were treated with the tumor cell nuclei to obtain hybrid cells, and LPS was added to stimulate the macrophage-based hybrid cells to enhance the expression of costimulatory molecules (<xref rid="fig9" ref-type="fig">Fig. 9</xref>C(a)). Chimeric exosomes (aMT-Exos) were obtained from the cell culture supernatant via gradient centrifugation and ultracentrifugation. They contained tumor cell components including EpCAM on 4T1 cell membranes and TRP1 on B16&#160;cell membranes, and immune stimulatory molecules including CD86, MHC &#8544;, and MHC &#8545; (<xref rid="fig9" ref-type="fig">Fig. 9</xref>C(b-c)). aMT-Exos exhibited a marked level of accumulation in lymph nodes and tumor sites due to its nano-sized property and homogenic targetability. APCs populations (macrophages and DCs) in aMT-Exos-treated lymph nodes showed a 3-fold elevation compared to the PBS control, and they subsequently migrated to T cell-rich paracortical regions to drive T cell priming (<xref rid="fig9" ref-type="fig">Fig. 9</xref>C(d)). Besides, aMT-Exos promoted polarization towards M1 macrophages and elevated the ratio of CD4<sup>+</sup> or CD8<sup>+</sup> T cells/Treg cells to reshape an immunosuppressive microenvironment. Excellent universality of the chimeric exosomes has been demonstrated in E.G7 lymphoma tumor cells, 4T1-breast cancer cells, and B16 melanoma cells, and they have significantly inhibited primary tumors, displayed potent anti-metastatic effects, and distinctly prevented tumor recurrence after surgery [<xref rid="bib204" ref-type="bibr">204</xref>].</p></sec><sec id="sec3.4.3"><label>3.4.3</label><title>OMVs-derived biomimetic nanoparticles</title><p id="p0320">OMVs bleb from the outer membrane of Gram-negative bacteria, and they are spherical lipid bilayer nanovesicles with a size of around 50&#8211;250&#160;nm [<xref rid="bib205" ref-type="bibr">205</xref>]. The components of OMVs, including bacteria-specific antigens, diverse PAMPs like LPS, enzymes, membrane proteins, DNA and RNA, are similar to those of their parent bacteria [<xref rid="bib206" ref-type="bibr">206</xref>]. Due to these natural characteristics, OMVs have shown great potential in constructing tumor vaccine nanoplatforms [<xref rid="bib207" ref-type="bibr">207</xref>]. OMVs-based nanovaccines have the following advantages: (1) OMVs can be engulfed by DCs and drained to lymph nodes due to their nano-size; (2) myeloid cells can recognize these PAMPs on OMVs to trigger innate immunity, and OMVs can also activate T cells and B cells to mediate adaptive immunity, thus, it could act as a self-adjuvant in a nanovaccine; and (3) OMVs can be functionalized by chemical modification and genetic engineering to display antigens/epitopes for personalized vaccination.</p><p id="p0325">OMVs decorated with maleimide groups on their surfaces can be an antigen catcher via stable thioether bonds, which can effectively capture tumor antigens from tumor cells after ICD to establish <italic toggle="yes">in situ</italic> vaccination. For example, OMVs were incubated with Mal-PEG<sub>4</sub>-NHS under room temperature for 2&#160;h, and maleimide-modified OMVs (Mal-OMVs) were obtained after treatment with N-ethylmaleimide to consume free thiol groups (<xref rid="fig10" ref-type="fig">Fig. 10</xref>A(a-b)) [<xref rid="bib208" ref-type="bibr">208</xref>]. The antigen capture percentage of Mal-OMVs (21.1&#160;%) was two folds higher than that of OMVs without any modification (11.3&#160;%) (<xref rid="fig10" ref-type="fig">Fig. 10</xref>A(c)). To reverse an immunosuppressive immune microenvironment, 1-methyl-tryptophan (1-MT), an IDO inhibitor, was encapsulated into Mal-OMVs to construct 1-MT@Mal-OMVs. After combination with photothermal therapy, 1-MT@Mal-OMVs effectively captured the released antigens and the captured antigens were then delivered to DCs. After DCs engulfed OMVs and their captured antigens, the levels of co-stimulatory molecules including CD86 and CD80 were elevated, leading to an increase in the antigen presentation molecules (MHC class &#8545;). The <italic toggle="yes">in vivo</italic> antigen delivery results revealed that Mal-OMVs effectively delivered antigens into draining lymph nodes for T cell activation. Treatment with 1-MT@Mal-OMVs significantly reduced the proportion of immunosuppressive CD3<sup>+</sup>CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs and increased the percentage of immunoactivated IFN-&#947;-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells at the tumor site, which resulted in pronounced inhibition of primary tumor growth, delayed progression of distant tumors, and an extended survival rate of 54&#160;% for CT26-bearing mice for over 42 days [<xref rid="bib208" ref-type="bibr">208</xref>]. Patel et al. also showed that Mal-OMVs in synergy with radiotherapy could induce <italic toggle="yes">in situ</italic> vaccination against B78 melanoma and NXS2 neuroblastoma. They constructed a multifunctional nano-drug delivery system (BNP). The PC7A/CpG polyplex was the core of BNP and Mal-OMVs were its outer layer. In this nanosystem, radiotherapy mediated tumor antigen release and the outer membrane of BNP captured the antigens. The PC7A/CpG polyplex in the core acted as a potent adjuvant to strengthen antigen presentation, which facilitated CD4<sup>+</sup>/CD8<sup>+</sup> T cell infiltration and mediated strong long-term immune memory [<xref rid="bib209" ref-type="bibr">209</xref>].<fig id="fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>OMVs-based tumor nanovaccines. A. Maleimide (Mal)-modified OMVs as an antigen capturer to form <italic toggle="yes">in situ</italic> vaccines. (a) Illustration of preparation of an OMVs-based 1-MT@OMV-Mal nanovaccine. Functionalization of OMVs was achieved through covalent conjugation of maleimide-Mal-PEG<sub>4</sub>-NHS to primary amine residues, and 1-MT as an IDO inhibitor was subsequently encapsulated via electroporation. (b&#8211;c) ICD of tumor cells was induced after photothermal therapy (PTT), and the released neoantigens were captured by 1-MT@OMV-Mal to form <italic toggle="yes">in situ</italic> vaccines. Reproduced with permission [<xref rid="bib208" ref-type="bibr">208</xref>]. Copyright 2022, Wiley-VCH. B. An OMVs-based nanovaccine (Nano Vac) platform for displaying tumor antigens was modified with anti PD-L1 antibodies through the SpyCatcher/SpyTag technology. Reproduced with permission [<xref rid="bib214" ref-type="bibr">214</xref>]. Copyright 2025, Wiley-VCH. C. OMVs as tumor vaccines produced <italic toggle="yes">in situ</italic> by genetically engineered <italic toggle="yes">E. Coli</italic> for tumor treatment. (a&#8211;b) <italic toggle="yes">E. Coli</italic> was genetically engineered with a specific tumor antigen, the released OMVs containing expressed tumor antigens crossed the intestinal epithelial barriers, and DCs engulfed these OMVs to induce immune responses. (c) The engineered <italic toggle="yes">E. Coli</italic> effectively inhibited MC-38 tumor growth after oral administration. (d&#8211;e) The oral vaccine mediated the production of potent central memory T cells to prevent lung metastatic in a B16F10 melanoma model. Reproduced with permission [<xref rid="bib215" ref-type="bibr">215</xref>]. Copyright 2022, Springer Nature.</p></caption><alt-text id="alttext0060">Fig. 10</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr10.jpg"/></fig></p><p id="p0330">Genetic engineering of Gram-negative bacteria could help tuning the surface components of OMVs and this approach has been actively explored to build a vaccine platform. The technology of &#8220;Plug and Display&#8221; based on genetic engineering has been applied in personalized nanovaccine construction [<xref rid="bib210" ref-type="bibr">210</xref>]. This modular platform utilizes a covalently conjugated peptide pair (e.g., SpyTag/SpyCatcher), which is genetically fused to the ClyA scaffold protein expressed on the surface of OMVs. This system enables site-specific antigen display on OMV surfaces through spontaneous isopeptide bond formation between the peptide pair and target antigens, thereby allowing modular and scalable loading of diverse TAAs for tailored vaccine development [<xref rid="bib211" ref-type="bibr">211</xref>]. Cheng et al. employed recombinant DNA technology to express SpyCatcher (SpC) and SnoopCatcher (SnC) as a fusion protein with ClyA on the surface of OMVs, and SpyTag (SpT) or SnoopTag (SnT)-labeled antigens were bound to SpC or SnC on the OMVs. The antigen epitope, tyrosinase-related protein 2 (TRP2), was displayed on the OMVs, and the OMVs-based vaccine facilitated CD8<sup>+</sup> T cells infiltration into the lung to eliminate B16F10 melanoma metastasis. It is worth noting that they also found that two antigens could be loaded onto the OMVs via the catcher-decorated method, and the resulting OMVs-based vaccine induced strong anti-tumor immune responses [<xref rid="bib212" ref-type="bibr">212</xref>]. Similarly, in an OMVs-based nanovaccine (Nano Vac) platform, a covalent protein ligation system was implemented by utilizing SpyCatcher/SpyTag technology for rapid antigen modularization. Genetic fusion of SpyCatcher002 to ClyA, an OMV-anchored pore-forming protein, enabled site-specific surface functionalization through spontaneous isopeptide bond formation with SpyTag002-conjugated tumor antigens. Immunization with NanoVac facilitated DC maturation and antigen presentation to mediate antigen-specific T cell immune responses. NanoVac displayed a potent anti-tumor effect in subcutaneous B16F10 tumor and hepatic carcinoma models [<xref rid="bib213" ref-type="bibr">213</xref>]. An advanced OMVs-based nanovaccine platform with an antigen presentation signal enhancer (APSE) was developed through synergistic integration of SpyCatcher/SpyTag-mediated antigen display and Fc-selective antibody conjugation (<xref rid="fig10" ref-type="fig">Fig. 10</xref>B). The SpyCatcher/SpyTag bioconjugation system allowed covalent, site-specific anchoring of heterologous antigens onto OMVs via spontaneous isopeptide bond formation. In parallel, ClyA-engineered single-chain variable fragment binding proteins (ClyA-SPAb) facilitated orientation-controlled immobilization of PD-L1-blocking antibodies through Fc domain recognition, preserving paratope integrity for dual checkpoint inhibition by suppressing PD-L1/PD-1 interactions. The OMVs-based nanovaccine displayed potent antitumor efficacy, which was evidenced with effective tumor growth inhibition in a Pa02-OVA pancreatic adenocarcinoma model, a suppression rate of 65.8&#160;% in MC38 colorectal carcinoma-bearing mice, and concurrent reduction in the lung metastasis formation in a B16F10-OVA tumor model [<xref rid="bib214" ref-type="bibr">214</xref>].</p><p id="p0335">Furthermore, OMVs after genetic engineering modification can be applied as an ideal nanocarrier for mRNA to construct mRNA-based vaccines. For example, OMVs were decorated with L7Ae, an RNA-binding protein, and listeriolysin O, a lysosomal escape protein to produce OMVs-LL. L7Ae could specifically bind to box C/D-labeled mRNA to achieve effective loading of mRNA. After OMVs-LL was uptaken by DCs, listeriolysin O could form pores on endosomal membranes in an acidic environment to promote mRNA release into the cytoplasm. The OMVs-based mRNA vaccine displayed a potent anti-tumor efficacy in both pulmonary metastatic melanoma with a survival rate of 42.8&#160;% of mice for 40 days and subcutaneous colon cancer with a tumor inhibition rate of 93.6&#160;%. Compared with traditional mRNA vaccines formulated from lipid nanoparticles, OMV-LL induced a higher ratio of IFN-&#947;<sup>+</sup>CD8<sup>+</sup> T cells in the spleen to significantly prevent MC38 colon cancer progression [<xref rid="bib216" ref-type="bibr">216</xref>].</p><p id="p0340">It has been a common practice to administrate vaccines by intramuscular injection or subcutaneous injection. Intestine, the largest immune organ, has 70&#160;% of immune cells in the body system, thus oral administration of vaccines may be one promising administration route [<xref rid="bib217" ref-type="bibr">217</xref>]. An orally administrated bacterial robot vaccine exhibited its potential in eliciting robust anti-tumor immune responses (<xref rid="fig10" ref-type="fig">Fig. 10</xref>C). First, tumor antigens and the Fc fragment of a mouse IgG were fused to the surface protein ClyA via genetic engineering of <italic toggle="yes">E. Coli</italic> and arabinose was employed as an inducible promoter to control the secretion of antigen-displayed OMVs (<xref rid="fig10" ref-type="fig">Fig. 10</xref>C(a-b)). The released OMVs could penetrate through intestinal epithelial barriers, and the Fc fragment was recognized by DCs, thus activating antigen-specific T cells, achieving a notable anti-tumor effect in a subcutaneous MC38 colon cancer model (<xref rid="fig10" ref-type="fig">Fig. 10</xref>C(c)), and inducing long-term memory immune responses against rechallenges in a melanoma model (<xref rid="fig10" ref-type="fig">Fig. 10</xref>C(d-e)) [<xref rid="bib215" ref-type="bibr">215</xref>].</p></sec></sec><sec id="sec3.5"><label>3.5</label><title>Hydrogels</title><p id="p0345">Hydrogels with a three-dimensional (3D) cross-linked network, one of the most attractive drug delivery systems, have been applied in biomedicine delivery [<xref rid="bib218" ref-type="bibr">218</xref>]. Hydrogels with a porous structure exhibit an outstanding loading capacity, and small molecule drugs, biomacromolecules, and cells can be encapsulated into hydrogels [<xref rid="bib219" ref-type="bibr">219</xref>]. Hydrogels delivered at a tumor site can sustainedly and controllably release the loaded cargos to induce the depot effect, which is crucial for vaccine delivery [<xref rid="bib220" ref-type="bibr">220</xref>]. Hydrogels are formed through cross-linking of chemical synthetic polymers or natural polysaccharides. Based on these advantages of hydrogels, they have been applied for delivery of tumor antigens, adjuvants, cytokines and other immunomodulators for tumor immunotherapy [<xref rid="bib221" ref-type="bibr">221</xref>].</p><sec id="sec3.5.1"><label>3.5.1</label><title>Natural polysaccharides-based hydrogels</title><p id="p0350">Natural polysaccharides with excellent biocompatibility, such as sodium alginate, chitosan, and hyaluronic acid, have been employed to prepare hydrogels under a mild condition. Sodium alginate is the most widely used water-soluble polysaccharide. The negatively charged carboxyl group on the side chain of sodium alginate crosslinks with polyvalent cations including Ca<sup>2+</sup> and Mg<sup>2+</sup> to facilitate &#8220;sol-gel&#8221; transformation [<xref rid="bib222" ref-type="bibr">222</xref>]. After injection of sodium alginate into a biological tissue, it often crosslinks with calcium ions under a physiological condition to form hydrogels. Ke et al. designed a sodium alginate-based hydrogel vaccine by encapsulating bifunctional fusion membrane nanoparticles from <italic toggle="yes">Mycobacterium phlei</italic> (M.ph) membrane extracts, tumor cell membranes, and GM-CSF into the hydrogel. M.ph membranes stimulated DC maturation and tumor cell membranes provided tumor antigens. The fusion membrane nanoparticles (FM NPs) were prepared by sequential extrusion through 100&#160;nm polycarbonate membranes using a mini-extruder apparatus. Subsequently, FM NPs and GM-CSF were co-encapsulated within a porous hydrogel matrix with an interconnected pore ranging from 20 to 50&#160;&#956;m. The release rates of FM NPs and GM-CSF were different due to their distinct sizes and electrostatic interactions. Specifically, 50&#160;% of GM-CSF was released within one week to recruit DCs into the hydrogel, while 82.17&#160;% of FM NPs were retained within the hydrogel to activate the recruited DCs to process the tumor antigens in these cells. Treatment with the bifunctional fusion membrane-based hydrogel resulted in a survival rate of 66.67&#160;% in 4T1-bearing mice for up to 60 days, and potent immune responses were observed in lymph nodes, the spleen, and the tumor. The hydrogel exhibited excellent biocompatibility with low systemic inflammation and great biodegradability with complete degradation after 105 days [<xref rid="bib223" ref-type="bibr">223</xref>]. Another similar sodium alginate-based functionalized hydrogel was reported by Nie et al<italic toggle="yes">.</italic>[224]. They constructed a functionalized hydrogel through three process steps: first, tumor cell membranes and OMVs were coextruded through a polycarbonate membrane to obtain the fusion membranes (HCMs); next, to modify HCMs with mannose to obtain MHCMs, HCMs were incubated with DSPE-PEG-mannose to allow insertion of the DSPE moiety into the bilayer of the cell membrane; finally, NaIO<sub>4</sub> oxidized sodium alginate with an aldehyde group which reacted with the amino group on membrane proteins through Schiff base reaction to form O-MHCMs as a gelator. After subcutaneous injection of the mixture of E64, an irreversible cysteine protease inhibitor, and the O-MHCMs solution, O-MHCMs cross-linked with Ca<sup>2+</sup> under a physiological condition at a Ca<sup>2+</sup> concentration of 1.8&#160;&#215;&#160;10<sup>&#8722;3</sup>&#160;M to form a hydrogel. E64 was encapsulated inside the hydrogel micropores. The hydrogel realized controlled release of MHCMs, which improved the DC uptake efficiency due to mannose modification and promoted DC maturation due to adjuvanticity of OMVs and immunogenicity of tumor cell membranes. The released E64 suppressed tumor antigen degradation in lysosomes, thus adequate antigens were presented to T cells. With single vaccination, the functionalized hydrogel induced potent T cell activation to prevent 4T1 breast tumor recurrence [<xref rid="bib224" ref-type="bibr">224</xref>].</p><p id="p0355">To improve structural stability of sodium alginate-based hydrogels, a chitosan-modified sodium alginate hydrogel was reported for oral immunization. The intriguing programmable oral bacterial hydrogel as a nanovaccine was prepared via the following steps (<xref rid="fig11" ref-type="fig">Fig. 11</xref>A): (1) <italic toggle="yes">E. Coli</italic> was genetically engineered to express AH1-A5, a segment of the envelope protein MuLV GP70 on the bacterial surface; and (2) the engineered <italic toggle="yes">E. Coli</italic> was encapsulated in the chitosan-modified sodium alginate hydrogel, which protected the bacterium with high activity in the gastrointestinal transit environment. After oral administration of the hydrogel, it adhered onto the gastrointestinal surface and the nanovaccine was periodically released in a controlled manner. DCs in mesenteric lymph nodes effectively internalized the released nanovaccine to induce effective CD8<sup>+</sup> T cell responses, resulting in an inhibition rate of 75&#160;% in CT26-bearing mice [<xref rid="bib225" ref-type="bibr">225</xref>].<fig id="fig11" position="float" orientation="portrait"><label>Fig. 11</label><caption><p>Hydrogels for tumor vaccine delivery. A. A chitosan-modified sodium alginate hydrogel-based <italic toggle="yes">in situ</italic> nanovaccine. Engineered <italic toggle="yes">E. coli</italic> was encapsulated into the chitosan-modified sodium alginate hydrogel. Tumor nanovaccines were released under spatiotemporal control of a synthetic biological synchronous lysis circuit to induce anti-tumor immune responses. Reproduced with permission [<xref rid="bib225" ref-type="bibr">225</xref>]. Copyright 2023, Elsevier. B. A thermo-sensitive polymeric hydrogel-based nanovaccine. Dual PLGA-b-PEG-b-PLGA copolymers at a range of PLGA/PEG ratios were mixed with R837, CaCl<sub>2</sub> and CaCO<sub>3</sub> in water, and the mixture underwent sol-gel transition at a body temperature. The overloaded Ca ions induced ICD to release tumor antigens, and the sustained release of R834 promoted DC maturation to mediate immune responses Reproduced with permission [<xref rid="bib228" ref-type="bibr">228</xref>]. Copyright 2022, Wiley-VCH. C. A bioinspired supramolecular hydrogel-based nanovaccine. Three synthetic epitope-conjugated peptides spontaneously formed a hydrogel matrix characterized by a porous, three-dimensional architecture with an interconnected polymeric network. This multivalent peptide-based hydrogel vaccine displayed efficient antigen presentation to DCs and elicited a broad spectrum of CD8<sup>+</sup> T cell responses. Reproduced with permission [<xref rid="bib229" ref-type="bibr">229</xref>]. Copyright 2023, Elsevier.</p></caption><alt-text id="alttext0065">Fig. 11</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr11.jpg"/></fig></p><p id="p0360">Hyaluronic acid is a natural biopolymer material with excellent water solubility and biocompatibility [<xref rid="bib226" ref-type="bibr">226</xref>]. A hyaluronan-based hydrogel was developed to deliver mRNA. mRNA and R848 as an adjuvant were loaded in LNPs through electrostatic interactions and hydrophobic interactions, respectively. LNPs mixed with hyaluronan at a ratio of 4:1 to form a dynamic hyaluronan hydrogel. The hydrogel was excellent in stabilizing mRNA LNPs through mitigating their hydrolysis and aggregation/fusion. It is noteworthy that the hyaluronan-based dynamic hydrogel could maintain stability after storage at room temperature for a minimum of 14 days. Long-term release of mRNA in LNPs for up to 20 days effectively promoted DC maturation, activated IFN-&#947;<sup>+</sup>CD8<sup>+</sup> T cell responses, and enhanced cytokines secretion to inhibit melanoma growth. Remarkably, the intensity of immune responses was not weakened after injection of the hydrogel stored under room temperature for at least 2 weeks [<xref rid="bib227" ref-type="bibr">227</xref>].</p></sec><sec id="sec3.5.2"><label>3.5.2</label><title>Polymer-based hydrogels</title><p id="p0365">Polymer-based hydrogels with stimuli-responsive characteristic have been employed for vaccine delivery. Thermosensitive hydrogels exhibit sol-gel transition at a volume phase transition temperature (VPTT): a polymeric solution below the VPTT is transformed into a gel when the temperature exceeds the VPTT [<xref rid="bib230" ref-type="bibr">230</xref>]. The sol-gel transition can be achieved under a physiological condition. Triblock copolymers of poly(d,l-lactide-co-glycolide)-poly(ethylene glycol)-poly(d,l-lactide-co-glycolide) (PLGA-PEG-PLGA) are thermosensitive and they self-assemble into micelles. The thermosensitive property of PLGA-PEG-PLGA arises from the PEG segment, which forms a thin corona around the crew-cut micelle structure [<xref rid="bib231" ref-type="bibr">231</xref>]. Cao et al. constructed a PLGA-PEF-PLGA copolymer-based hydrogel to deliver an inorganic calcium salt and organic R837 and prepared a therapeutic-prophylactic vaccine (<xref rid="fig11" ref-type="fig">Fig. 11</xref>B). A solution of PLGA-PEF-PLGA copolymers at two different molecular weights were mixed with CaCl<sub>2</sub>, CaCO<sub>3</sub>, and R837 to form a thermosensitive hydrogel due to the formation of a percolated network. The sol-gel transition temperature (T<sub>gel</sub>) was about 29&#160;&#176;C, and gel transition occurred when the <italic toggle="yes">in vivo</italic> temperature was higher than T<sub>gel</sub>. Burst-released Ca<sup>2+</sup> induced ICD of tumor cells to promote CRT exposure and sustainedly released R848 strengthened immune responses. The hydrogel as a therapeutic-prophylactic vaccine effectively prevented recurrence and metastasis in a postoperative orthotopic breast mice model [<xref rid="bib228" ref-type="bibr">228</xref>]. Copolymers of poly (d, l-lactide)-poly (ethylene glycol)-poly (d, l-lactide) (PDLLA-PEG-PDLLA, PLEL) with similar thermosensitive characteristics were also used for hydrogel preparation. A biodegradable thermosensitive PLEL hydrogel vaccine was composed of the tumor cell lysate, GM-CSF, and CpG. The PLEL hydrogel displayed sol-gel transition under a physiological condition, and the antigen and the immunomodulator were sustainedly released from hydrogels. 90.79&#160;% of GM-CSF and 97.28&#160;% of CpG were released within 7 days, while 60&#160;% of the antigen was released on day 10. Administration of the hydrogel vaccine resulted in 3-fold mature DCs compared with the saline group and enhanced secretion of cytokines including IFN-&#947; and IL-6, leading to effective inhibition of B16F10 and CT26 tumor growth [<xref rid="bib232" ref-type="bibr">232</xref>].</p><p id="p0370">Polymers can form hydrogels not only through physical cross-linking but also chemical reaction with crosslinkers. Poly (vinyl alcohol) (PVA) with the diols moiety can complex with two phenylboronic acid molecules in the presence of N1-(4-boronobenzyl)-N3-(4-boronophenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diaminium (TSPBA), a ROS-labile crosslinker, to form hydrogels [<xref rid="bib233" ref-type="bibr">233</xref>]. For example, a ROS-responsive hydrogel platform, termed as (ACCO&#160;+&#160;CpG) @gel, was developed through crosslinking between PVA and TSPBA. Autologous tumor cells underwent oncolysis after treatment with an oncolytic peptide LTX-315. These ICD-induced tumor cells as the source of TAAs, designated as ACOO, and CpG as an immunoadjuvant were encapsulated into the hydrogel. (ACCO&#160;+&#160;CpG) @gel displayed controlled biodegradation and sustained release of ACCO and CpG over 7 days. More strikingly, it exhibited potent anti-tumor effects in B16F10 melanoma, CT26 colon carcinoma, and LLC-1 Lewis lung carcinoma models [<xref rid="bib234" ref-type="bibr">234</xref>]. Another similar hydrogel was developed from crosslinking of phenylboronic acid ester-modified PEI and mannose. PEI was functionalized with 2-formylphenylboronic acid via Schiff base conjugation between the primary amine groups and the aromatic aldehyde moieties, yielding phenylboronic acid-grafted PEI, denoted as PF. Polyribocytidylic acid as a TLR3 adjuvant and mitoxantrone hydrochloride-treated tumor cells were mixed with the PF solution, and mannose was added to yield the hydrogel, termed as Angel-Vax. Three-dimensional reconstructed images revealed that the hydrogel had a continuous network of porous structures, and the pre-treated tumor cells were embedded within the network. The Angel-Vax platform enhanced activation and maturation of APCs, including DCs and macrophages, and elicited robust tumor-specific immunity, thereby functioning as a preventive and therapeutic vaccine in B16F10 murine melanoma model [<xref rid="bib235" ref-type="bibr">235</xref>].</p></sec><sec id="sec3.5.3"><label>3.5.3</label><title>Bioinspired-based hydrogels</title><p id="p0375">Bioinspired hydrogels have demonstrated significant potential in tumor vaccine delivery. Huang et al. reported a blood plasma-derived natural hydrogel, inspired by the observation that blood stasis in the subcutaneous tissue can spontaneously recruit macrophages and other immune cells. Plasma can chelate with Ca<sup>2+</sup> to trigger the agglutination reaction through the formation of insoluble fibrin. The plasma solution loaded with OVA as an antigen and Mn<sup>2+</sup> as an adjuvant can be transformed into a hydrogel within 10&#160;min after subcutaneous injection of Ca<sup>2+</sup>. <italic toggle="yes">In vivo</italic> DC recruitment results demonstrated that the plasma hydrogel exhibited persistent capacity to recruit DCs, while the free OVA group showed a moderate level of recruitment of DCs within 24&#160;h. Released Mn<sup>2+</sup> activated the STING pathway to potentiate and prolong immune responses. By activation of both innate and adaptive immunity, the plasma hydrogel pronouncedly delayed B16F10-OVA tumor progression [<xref rid="bib236" ref-type="bibr">236</xref>]. Furthermore, a bioinspired self-assembled peptide-based hydrogel was constructed. Three tumor-associated antigenic epitopes: glycoprotein 100<sub>209-217</sub> (gp100<sub>209-217</sub>), tyrosinase<sub>369-377</sub> (Tyr<sub>369-377</sub>), and the melanoma antigen recognized by T cells 1<sub>26-35</sub> (MART-1<sub>26-35</sub>), were individually conjugated to a lysine-rich carrier peptide (FEFEFKFK, F peptide) through covalent linkage, generating three epitope-functionalized peptide constructs: F-gp100<sub>209-217</sub>, F-Tyr<sub>369-377</sub>, and F-MART-1<sub>26-35</sub>, respectively (<xref rid="fig11" ref-type="fig">Fig. 11</xref>C). The trivalent peptide vaccine was constructed through spontaneous self-assembly of F-gp100<sub>209-217</sub>, F-Tyr<sub>369-377</sub>, and F-MART-1<sub>26-35</sub> at 20&#160;mg/mL for each conjugate in an aqueous medium into a supramolecular hydrogel with a 3D nanofibrous architecture via synergistic electrostatic and &#960;-&#960; stacking interactions. Immunization with the hydrogel vaccine facilitated antigen presentation to T cells, promoted secretion of IFN-&#947;, and elicited a broad spectrum of antitumor CD8<sup>+</sup> T cell responses, eventually suppressing tumor growth in B16F10-bearing mice [<xref rid="bib229" ref-type="bibr">229</xref>].</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Clinical trials and clinical translation challenges</title><p id="p0380">Inspired by promising therapeutic and preventive effects of tumor vaccines, a great many of tumor vaccines including DNA vaccines, mRNA vaccines, peptide-based vaccines, and cell-based vaccines are currently in clinical trials at different phases. A comprehensive analysis of cancer vaccine clinical trials conducted over the past ten years is systematically presented in <xref rid="tbl3" ref-type="table">Table 3</xref>, and key milestones and future trends in the field can be observed from the table.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Cancer vaccine clinical trials conducted over the past decade.</p></caption><alt-text id="alttext0085">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Tumor vaccine types</th><th colspan="1" rowspan="1">Antigens or adjuvants of tumor vaccine</th><th colspan="1" rowspan="1">Administration route</th><th colspan="1" rowspan="1">Combinatorial treatment</th><th colspan="1" rowspan="1">Indications</th><th colspan="1" rowspan="1">Phase stage</th><th colspan="1" rowspan="1">NCT number</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold><italic toggle="yes">DNA vaccines</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">CEA DNA vaccine</td><td align="left" colspan="1" rowspan="1">tetwtCEA DNA plasmid encoding wild type human CEA fused to a tetanus toxoid T helper epitope and GM-CSF as adjuvant</td><td align="left" colspan="1" rowspan="1">Intradermal injection (ID) by electroporation device, Derma Vax (Cyto Pulse Sciences)</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Colorectal cancer</td><td align="left" colspan="1" rowspan="1">Phase 1 and 2, completed in 2016</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01064375" id="intref0015">NCT01064375</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GX-188E</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Intramuscular injection (IM) using the electroporator</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Cervical intraepithelial neoplasia</td><td align="left" colspan="1" rowspan="1">Phase 2, completed in 2016</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02139267" id="intref0020">NCT02139267</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GX-188E</td><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="1" rowspan="1">IM by electroporation</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Cervical intraepithelial neoplasia (Type 16 and/or 18 Positive)</td><td align="left" colspan="1" rowspan="1">Phase 2, completed in 2018</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02596243" id="intref0025">NCT02596243</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="1" rowspan="1">Plasmid DNA encoding human prostate-specific membrane antigen</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Kidney cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, completed in 2018</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00096629" id="intref0030">NCT00096629</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VGX-3100</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">IM via CELLECTRA&#8482; 5PSP</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion</td><td align="left" colspan="1" rowspan="1">Phase 3, REVEAL 1, completed in 2021</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03185013" id="intref0035">NCT03185013</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">VGX-3100</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">IM via CELLECTRA&#8482; 5PSP</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Cervical dysplasia, cervical high grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesions</td><td align="left" colspan="1" rowspan="1">Phase 3, REVEAL 2 trial, completed in 2022</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03721978" id="intref0040">NCT03721978</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">HPV DNA vaccine</td><td align="left" colspan="1" rowspan="1">pNGVL4aCRTE6E7L2 plasmid DNA</td><td align="left" colspan="1" rowspan="1">IM with TriGrid&#8482; electroporation</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Human papillomavirus type 16; cervical intraepithelial neoplasia Grade II;<break/>cervical intraepithelial neoplasia, Grade III</td><td align="left" colspan="1" rowspan="1">Phase I, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04131413" id="intref0045">NCT04131413</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">pTVG-HP DNA vaccine</td><td align="left" colspan="1" rowspan="1">pTVG-HP is a plasmid DNA, produced in <italic toggle="yes">E. coli</italic>, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Castration-resistant prostate cancer; metastatic cancer;<break/>prostate cancer</td><td align="left" colspan="1" rowspan="1">Phase II, active</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04090528" id="intref0050">NCT04090528</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoepitope-based personalized DNA vaccine</td><td align="left" colspan="1" rowspan="1">Personalized neoantigen DNA vaccine</td><td align="left" colspan="1" rowspan="1">IM using an integrated electroporation device</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Pediatric recurrent brain tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, not yet recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03988283" id="intref0055">NCT03988283</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">AST-301</td><td align="left" colspan="1" rowspan="1">pNGVL3-hICD plasmid DNA with recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Gastric cancer patients with HER2 expression (including HER2 expression at a low or high level)</td><td align="left" colspan="1" rowspan="1">Phase 2, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05771584" id="intref0060">NCT05771584</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DNA vaccine</td><td align="left" colspan="1" rowspan="1">DNA-polyethylenimine conjugate (IM) and attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine (oral administration)</td><td align="left" colspan="1" rowspan="1">IM and oral administration</td><td align="left" colspan="1" rowspan="1">Cyclophosphamid, lenalidomide</td><td align="left" colspan="1" rowspan="1">Relapsed neuroblastoma</td><td align="left" colspan="1" rowspan="1">Early phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04049864" id="intref0065">NCT04049864</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Mammaglobin-A DNA vaccine</td><td align="left" colspan="1" rowspan="1">Mammaglobin-A plasmid DNA purified from bacteria</td><td align="left" colspan="1" rowspan="1">Injection by TriGrid electroporation device</td><td align="left" colspan="1" rowspan="1">Neoadjuvant endocrine therapy</td><td align="left" colspan="1" rowspan="1">Breast cancer; breast carcinoma;<break/>malignant neoplasm of breast</td><td align="left" colspan="1" rowspan="1">Phase 1, active</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02204098" id="intref0070">NCT02204098</ext-link></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold><italic toggle="yes">mRNA vaccines</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA-2752</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Durvalumab</td><td align="left" colspan="1" rowspan="1">Dose Escalation: relapsed/refractory solid tumor malignancies or lymphoma<break/>Dose Expansion: triple negative breast cancer, HNSCC, non-hodgkins, urothelial cancer, immune checkpoint refractory melanoma, and NSCLC lymphoma</td><td align="left" colspan="1" rowspan="1">Phase 1, active, not recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03739931" id="intref0075">NCT03739931</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA vaccine</td><td align="left" colspan="1" rowspan="1">EBV mRNA</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">EBV-positive advanced malignant tumors</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05714748" id="intref0080">NCT05714748</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen mRNA vaccine</td><td align="left" colspan="1" rowspan="1">Choose appropriate patients with advanced solid cancers;<break/>Perform biopsy to get fresh sample for DNA/RNA-seqencings and bioinformatics analysis;<break/>Produce high quality mRNA vaccine</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06195384" id="intref0085">NCT06195384</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen mRNA vaccine</td><td align="left" colspan="1" rowspan="1">SW1115C3</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05198752" id="intref0090">NCT05198752</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen mRNA vaccine</td><td align="left" colspan="1" rowspan="1">SJ-Neo006</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Camrelizumab, Gemcitabine&#160;+&#160;Abraxane</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Early Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06326736" id="intref0095">NCT06326736</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized mRNA vaccine</td><td align="left" colspan="1" rowspan="1">iNeo-Vac-R01</td><td align="left" colspan="1" rowspan="1">Hypodermic injection</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Digestive system neoplasms</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06019702" id="intref0100">NCT06019702</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA vaccine</td><td align="left" colspan="1" rowspan="1">BI 1361849</td><td align="left" colspan="1" rowspan="1">ID by PharmaJet Tropis&#174; device</td><td align="left" colspan="1" rowspan="1">Durvalumab or tremelimumab</td><td align="left" colspan="1" rowspan="1">Non-small Cell lung cancer (NSCLC), metastatic NSCLC</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03164772" id="intref0105">NCT03164772</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized mRNA tumor vaccine</td><td align="left" colspan="1" rowspan="1">mRNA-0217/S001 vaccine encoding personalized tumor neoantigens</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Advanced pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Early Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05916261" id="intref0110">NCT05916261</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized tumor vaccines</td><td align="left" colspan="1" rowspan="1">mRNA-0217/S001 vaccine encoding personalized tumor neoantigens</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Advanced solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05916248" id="intref0115">NCT05916248</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">RNA tumor vaccine</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">IM</td><td align="left" colspan="1" rowspan="1">Navuliumab</td><td align="left" colspan="1" rowspan="1">Advanced solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05202561" id="intref0120">NCT05202561</ext-link></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold><italic toggle="yes">Peptides based tumor vaccines</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Peptide vaccines</td><td align="left" colspan="1" rowspan="1">Adjuvant PEP-3-KLH conjugate vaccine</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sargramostim/Temozolomide</td><td align="left" colspan="1" rowspan="1">Malignant neoplasms of brain</td><td align="left" colspan="1" rowspan="1">Phase 2, completed, 2016</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00643097" id="intref0125">NCT00643097</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen cancer vaccine</td><td align="left" colspan="1" rowspan="1">Neoantigen peptides and poly-ICLC as the adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Phase 1, completed, 2018</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01970358" id="intref0130">NCT01970358</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized genomic vaccine</td><td align="left" colspan="1" rowspan="1">Personalized genomic vaccine 001 (PGV001) based on a patient's own tumor sequence and Poly-ICLC as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Lenalidomide</td><td align="left" colspan="1" rowspan="1">Solid tumors</td><td align="left" colspan="1" rowspan="1">Phase 1, completed, 2020</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02721043" id="intref0135">NCT02721043</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen-based vaccine</td><td align="left" colspan="1" rowspan="1">PGV001, Poly-ICLC as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Atezolizumab</td><td align="left" colspan="1" rowspan="1">Urothelial/bladder cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, completed,2021</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03359239" id="intref0140">NCT03359239</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen cancer vaccine</td><td align="left" colspan="1" rowspan="1">iNeo-Vac-P01neoantigen peptides and GM-CSF as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Pancreatic cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, completed,2021</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03645148" id="intref0145">NCT03645148</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">Synthetic Multiple antigenic glycopeptide displaying a Tri Tn glycotop (MAG-Tn3) and AS15 adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Breast neoplasms</td><td align="left" colspan="1" rowspan="1">Phase 1, completed, 2021</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02364492" id="intref0150">NCT02364492</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DSP-7888 vaccine</td><td align="left" colspan="1" rowspan="1">WT1 peptides</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Bevacizumab</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">Phase 3, completed, 2021</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03149003" id="intref0155">NCT03149003</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen Peptides vaccine</td><td align="left" colspan="1" rowspan="1">Neoantigen peptides and montanide ISA-51 VG as adjuvant</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Neoplasms</td><td align="left" colspan="1" rowspan="1">Early Phase 1, completed, 2022</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04509167" id="intref0160">NCT04509167</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen cancer vaccine</td><td align="left" colspan="1" rowspan="1">GRT-C901 and GRT-R902</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Nivolumab and ipilimumab</td><td align="left" colspan="1" rowspan="1">NSCLC, colorectal cancer; gastroesophageal adenocarcinoma;<break/>urothelial, carcinoma</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, completed, 2022</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03639714" id="intref0165">NCT03639714</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized multi-peptide vaccines</td><td align="left" colspan="1" rowspan="1">PGV001 and Poly-ICLC as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">CDX-301 (soluble recombinant human protein to work on stem cell)</td><td align="left" colspan="1" rowspan="1">Prostate cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, active, not recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05010200" id="intref0170">NCT05010200</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Synthetic long peptide vaccine</td><td align="left" colspan="1" rowspan="1">Synthetic long peptides which are 25&#8211;30 amino acids and Poly-ICLC as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, enrolling by invitation</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05741242" id="intref0175">NCT05741242</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen Peptides vaccine</td><td align="left" colspan="1" rowspan="1">Individualized neoantigen peptides</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Neoplasms</td><td align="left" colspan="1" rowspan="1">Early Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05475106" id="intref0180">NCT05475106</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">SurVaxM</td><td align="left" colspan="1" rowspan="1">SVN53-67/M57-KLH peptide and incomplete Freunds adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Temozolomide</td><td align="left" colspan="1" rowspan="1">Digestive system neuroendocrine neoplasm; lung neuroendocrine neoplasm; malignant solid neoplasm; pancreatic neuroendocrine neoplasm</td><td align="left" colspan="1" rowspan="1">Phase 2, not yet recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06202066" id="intref0185">NCT06202066</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen cancer vaccine</td><td align="left" colspan="1" rowspan="1">iNeo-Vac-P01neoantigen peptides and GM-CSF as adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Advanced malignant solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03662815" id="intref0190">NCT03662815</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized cancer vaccine</td><td align="left" colspan="1" rowspan="1">Tumour antigen peptides identified and separated from each patient and autologous activated monocytes with autologous tumor derived heat shock protein 70 as adjuvant</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection (SC)</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05059821" id="intref0195">NCT05059821</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen vaccine</td><td align="left" colspan="1" rowspan="1">Several distinct peptides and poly-ICLC as the adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Pancreatic tumor</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03558945" id="intref0200">NCT03558945</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen polypeptide vaccine</td><td align="left" colspan="1" rowspan="1">Neoantigen polypeptide</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06195293" id="intref0205">NCT06195293</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">YB-01 cancer vaccine</td><td align="left" colspan="1" rowspan="1">A recombinant fusion protein of MUC1 with aluminium adjuvant and CpG182 adjuvant</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05986981" id="intref0210">NCT05986981</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized neoantigen cancer vaccine</td><td align="left" colspan="1" rowspan="1">Peptide, rhGM-CSF, and imiquimod 5&#160;% topical cream</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Toripalimab</td><td align="left" colspan="1" rowspan="1">Melanoma (Skin)</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04072900" id="intref0215">NCT04072900</ext-link></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold><italic toggle="yes">Cell-based vaccines</italic></bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Cancer stem cells vaccine</td><td align="left" colspan="1" rowspan="1">Cancer stem cells loaded DC</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Hepatocellular cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, completed, 2015</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02089919" id="intref0220">NCT02089919</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">GeniusVac-Mel4</td><td align="left" colspan="1" rowspan="1">The irradiated allogeneic plasmacytoid dendritic cell (pDC) line loaded with 4 melanoma peptides derived from Melan-A, gp100, Tyrosinase or Mage-A3</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Phase 1, completed, 2017</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01863108" id="intref0225">NCT01863108</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DC vaccine</td><td align="left" colspan="1" rowspan="1">Myeloid DC (mDC) to induce/enhance of tumor-specific T cells, pDC to induce of an IFN signature. DC was loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator&#174; which covers the complete antigen</td><td align="left" colspan="1" rowspan="1">Intranodal injection</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Prostatic neoplasms</td><td align="left" colspan="1" rowspan="1">Phase 2, completed, 2019</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02692976" id="intref0230">NCT02692976</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Personalized cellular vaccine</td><td align="left" colspan="1" rowspan="1">mRNA tumor antigen pulsed DCs</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Brain cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, completed, 2019</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02808416" id="intref0235">NCT02808416</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;DC1 vaccine</td><td align="left" colspan="1" rowspan="1">Patients' autologous alpha-DC1s loaded with autologous tumor material</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Celecoxib, Interferon Alfa-2b</td><td align="left" colspan="1" rowspan="1">Malignant neoplasm of pancreas metastatic to peritoneal surface, malignant peritoneal mesothelioma,<break/>peritoneal carcinomatosis</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, completed, 2019</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02151448" id="intref0240">NCT02151448</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Mix vaccine</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Metastasis from malignant tumor of kidney (Disorder)</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, completed, 2019</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03357289" id="intref0245">NCT03357289</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">TLPLDC vaccine</td><td align="left" colspan="1" rowspan="1">Vaccines were prepared by producing TL through freeze/thaw cycling and then loaded into pre-prepared YCWP. The TL-loaded YCWP will be introduced to the DC for phagocytosis thus creating the TLPLDC vaccine which will be frozen in single dose vials</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Melanoma</td><td align="left" colspan="1" rowspan="1">Phase 2, completed, 2022</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT02301611" id="intref0250">NCT02301611</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DCVax-L vaccine</td><td align="left" colspan="1" rowspan="1">Autologous DCs pulsed with tumor lysate antigen</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">Nivolumab</td><td align="left" colspan="1" rowspan="1">Giant cell glioblastoma,<break/>Gliosarcoma,<break/>Oligodendroglioma, recurrent glioblastoma, small cell glioblastoma</td><td align="left" colspan="1" rowspan="1">Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03014804" id="intref0255">NCT03014804</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DCVax&#174;-L</td><td align="left" colspan="1" rowspan="1">DCs isolated from white blood cells are educated by patient's own tumor lysate</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Glioblastoma multiforme, glioblastoma,<break/>grade IV astrocytoma,<break/>glioma, brain cancer,</td><td align="left" colspan="1" rowspan="1">Phase 3</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT00045968" id="intref0260">NCT00045968</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DC-based vaccine</td><td align="left" colspan="1" rowspan="1">NY-ESO-1 TCR transgenic peripheral blood mononuclear cell (PBMC), NY-ESO-1 (157&#8211;165) peptide pulsed DC</td><td align="left" colspan="1" rowspan="1">Intravenous injection and ID</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide, and IL-12</td><td align="left" colspan="1" rowspan="1">Malignant neoplasm</td><td align="left" colspan="1" rowspan="1">Phase 2, active, not recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT01697527" id="intref0265">NCT01697527</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DC vaccine</td><td align="left" colspan="1" rowspan="1">Autologous mature DC-loaded with HPV 16/18 E6/E7</td><td align="left" colspan="1" rowspan="1">Injected into the adjacent lymph-node</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Cervical intraepithelial neoplasia</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03870113" id="intref0270">NCT03870113</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Dendritic and glioma cells fusion vaccine</td><td align="left" colspan="1" rowspan="1">Vaccine is derived from the participants DCs and tumor cells.</td><td align="left" colspan="1" rowspan="1">ID close to a cervical lymph node</td><td align="left" colspan="1" rowspan="1">IL-12, and Temozolomide</td><td align="left" colspan="1" rowspan="1">Glioblastoma</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04388033" id="intref0275">NCT04388033</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">TSA-DC vaccine</td><td align="left" colspan="1" rowspan="1">Tumor Specific antigen-loaded DC</td><td align="left" colspan="1" rowspan="1">SC</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide</td><td colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Not Applicable, 2019</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03185429" id="intref0280">NCT03185429</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">DC vaccine</td><td align="left" colspan="1" rowspan="1">MIDRIX4-LUNG DC</td><td align="left" colspan="1" rowspan="1">Intravenous infusions or ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Non-small cell lung cancer metastatic</td><td align="left" colspan="1" rowspan="1">Phase 1</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04082182" id="intref0285">NCT04082182</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen derived DC vaccine</td><td align="left" colspan="1" rowspan="1">Tumor lysate or carcinoembryonic antigen (CEA) loaded DCs</td><td align="left" colspan="1" rowspan="1">Injected into inguinal area</td><td align="left" colspan="1" rowspan="1">Lenvatinib and Nivolumab</td><td align="left" colspan="1" rowspan="1">Refractory tumor, solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05767684" id="intref0290">NCT05767684</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Autologous tumour vaccine (ATV)</td><td align="left" colspan="1" rowspan="1">ATV is manufactured as a tumour lysate extract which is stored frozen, and then formulated with Advax adjuvant on day of administration</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Solid tumor</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT05807035" id="intref0295">NCT05807035</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">Autologous TLPO Vaccine</td><td align="left" colspan="1" rowspan="1">Tumor lysates from freeze-thaw cycling were loaded into pre-prepared yeast-cell wall particles (YCWP)</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Tumor</td><td align="left" colspan="1" rowspan="1">Phase 2, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06175221" id="intref0300">NCT06175221</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">NV-001</td><td align="left" colspan="1" rowspan="1">Hybrid-membrane (tumor cell membrane and adjuvant membrane)</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Malignant neoplasm</td><td align="left" colspan="1" rowspan="1">Phase 1, recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06051760" id="intref0305">NCT06051760</ext-link></td></tr><tr><td align="left" colspan="1" rowspan="1">ACIT-1 vaccine</td><td align="left" colspan="1" rowspan="1">Cell suspension</td><td align="left" colspan="1" rowspan="1">ID</td><td align="left" colspan="1" rowspan="1">/</td><td align="left" colspan="1" rowspan="1">Cancer</td><td align="left" colspan="1" rowspan="1">Phase 1, Phase 2, active, not recruiting</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT03096093" id="intref0310">NCT03096093</ext-link></td></tr></tbody></table></table-wrap></p><p id="p0385">A COVID-19 DNA vaccine, ZycoV-D, has been recently approved in India, and it is the first DNA vaccine authorized for clinical use [<xref rid="bib237" ref-type="bibr">237</xref>]. DNA vaccines for tumor treatment have been intended for Cervical Intraepithelial Neoplasia. VGX-3100, a DNA vaccine containing plasmids designed to express the E6 and E7 oncoproteins of HPV types 16 and 18, has been successfully through its phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03185013">NCT03185013</ext-link>) in 2021, and it has shown efficacy in treating high-grade cervical dysplasia. DNA vaccines could be a potentially groundbreaking therapeutic modality for treating cancer, and VGX-3100 may become one of the first DNA vaccines approved for HPV-related precancerous lesions. Poor immunogenicity of DNA vaccines is the main obstacles for their progression into clinical application. DNA vaccines based on chimeric antigens and multi-epitope antigens has been demonstrated to improve their immunogenicity [<xref rid="bib238" ref-type="bibr">238</xref>]. Chimeric antigen-encoding DNA vaccines can express both heterologous proteins to evade immune tolerance and homologous proteins to stimulate specific immune responses. Multi-epitope antigen-encoding DNA vaccines can express multiple antigens to induce a wide spectrum of antigen specific CD8<sup>+</sup> T cell responses to overcome the tumor heterogeneity.</p><p id="p0390">Two mRNA vaccines, Moderna's Spikevax and Pfizer's BNT162b2, have been approved by FDA for COVID-19. With the characteristics of rapid production and effective translation, mRNA vaccines could be a potential platform for personalized cancer vaccine development [<xref rid="bib239" ref-type="bibr">239</xref>]. Moderna's lipid-based mRNA vaccine mRNA-2752, in which mRNAs encoding OX40 ligand (OX40L), IL-23, and IL-36&#947; are co-encapsulated in lipid nanoparticles, is under Phase I evaluation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link>). The vaccine is combined with a PD-L1 inhibitor durvalumab for advanced solid tumors or lymphomas. Despite numerous advantages of mRNA vaccines, there are several outstanding challenges. mRNA is susceptible to degradation by various nucleases and encapsulation of mRNA within a nanocarrier can significantly reduce its degradation rate. LNPs, known for their high safety and controlled design, facilitate efficient delivery of mRNA, and they are the most widely used nanomaterials for the construction of mRNA tumor vaccines [<xref rid="bib240" ref-type="bibr">240</xref>]. The LNP stability in the mRNA-1273 vaccine (Moderna) was achieved via lyophilization optimization and ionizable lipid engineering, and the stability was instrumental for scalable manufacturing and eliciting robust immunogenicity during Phase III trials. Conversely, failures in early-stage RNA nanotherapies (e.g., siRNA-LNPs for solid tumors) are attributed to nanoparticle aggregation, endosomal entrapment, and dysregulated protein corona formation. Furthermore, rational modification of the backbone of mRNA can enhance its stability and improve its translation efficiency [<xref rid="bib241" ref-type="bibr">241</xref>]. The 5&#8242; cap, a pivotal component of mRNA, is responsible for recruiting eukaryotic translation initiation factor 4E (EIF4E) to initiate the translation process. The CleanCap&#8482; technology enables efficient co-transcriptional capping, improving mRNA integrity during synthesis.</p><p id="p0395">Peptide vaccines are another promising candidate for tumor vaccine development in clinical research [<xref rid="bib242" ref-type="bibr">242</xref>]. MUC1 is excessively expressed in a variety of forms on adenomatous polyps and colorectal cancer, and it could be a potential target for constructing peptides-based vaccines [<xref rid="bib243" ref-type="bibr">243</xref>]. In a phase II trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00773097">NCT00773097</ext-link>), MUC1 peptides were co-administered with Poly-ICLC as an adjuvant in patients with advanced colorectal adenoma. DSP-7888 containing peptides derived from the Wilms&#8217; tumor 1 (WT1) protein with immunomodulating, and antineoplastic activities is combined with bevacizumab for recurrent or progressive glioblastoma (Phase III, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03149003">NCT03149003</ext-link>). Next-generation sequencing (NGS) technologies have been extensively employed for precise antigen selection and therapeutic protocol optimization, thus facilitating the development of personalized vaccines. An NGS-based peptide vaccine combined with Montanide ISA-51 VG as an adjuvant is administered via intradermal injection and this vaccine is still in the Early Phase 1 period (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04509167">NCT04509167</ext-link>). Personalized genomic vaccine 001 (PGV001) is a peptide-based vaccine specifically tailored to the tumor sequence of a patient with advanced non-hematologic malignancies, and PGV001 is combined with the Poly-ICLC adjuvant to enhance immune responses (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02721043">NCT02721043</ext-link>). To develop the peptide vaccine PGV001, RNA and DNA of the tumor from the patient were first sequenced, and the OpenVax computational pipeline was utilized to identify peptides and predict their binding affinity to MHC class I. 13 patients were enrolled in the phase I trial. <italic toggle="yes">Ex vivo</italic> ELISPOT analysis of patient blood samples revealed remarkable induction of CD4<sup>+</sup>/CD8<sup>+</sup> T cell responses after administration of ten doses of the PGV001 peptide vaccine [<xref rid="bib244" ref-type="bibr">244</xref>]. Furthermore, PGV001, a multipeptide personalized neoantigen vaccine, was combined with Poly-ICLC as an adjuvant and atezolizumab, an anti PD-1 antibody, for urothelial/bladder cancer treatment (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03359239">NCT03359239</ext-link>). In the Phase I trial, 12 patients with urothelial/bladder cancer were stratified into non-metastatic and metastatic cohorts. Among the non-metastatic subgroup (n&#160;=&#160;4), no recurrence was observed, and 2/5 metastatic patients achieved an objective response [<xref rid="bib245" ref-type="bibr">245</xref>]. It has been reported that it takes 18&#8211;19.9 weeks to prepare personalized neoantigen peptide vaccines [<xref rid="bib246" ref-type="bibr">246</xref>], and high cost may impede clinical translation of peptides-based vaccines. Novel and efficient sequencing technologies, artificial intelligence (AI) and machine-learning (ML)-aided neoantigen prediction algorithms, and facile peptides synthetic technologies may accelerate the development process and reduce the cost associated with peptide vaccines.</p><p id="p0400">Cell-based vaccines could be another promising candidate for next generation tumor immunotherapy. They have been extensively clinically studied with distinct anti-tumor effects [<xref rid="bib247" ref-type="bibr">247</xref>]. Cell-based vaccines that are undergoing clinical trials are predominantly DC-based vaccines and tumor cell-based vaccines. Inspired by Provenge (sipuleucel-T), an FDA approved DC vaccine for metastatic castration-resistant prostate cancer, a few DC vaccines are currently undergoing different phases of clinical trials, and they have demonstrated encouraging results. DCs sourced from monocytes are pulsed with a tumor antigen or mRNA encoding the antigen and injected into patients to induce antigen-specific CD4<sup>+</sup>/CD8<sup>+</sup> T cell responses. For example, autologous DCs pulsed with the tumor lysate antigen, termed as DCVax-L, were combined with nivolumab for patients with glioblastoma (phase &#8545;, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03014804">NCT03014804</ext-link>). The anti-tumor efficacy of DCVax-L vaccine for newly diagnosed Glioblastoma (nGBM) patients who have received the standard of care including radiation and temozolomide therapy was assessed in a phase III study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00045968">NCT00045968</ext-link>). A total of 331 patients were enrolled in the trial and the overall survival rate of nGBM patients was pronouncedly prolonged compared to the external control patients [<xref rid="bib248" ref-type="bibr">248</xref>]. The DC vaccine pulsed with tumor antigen mRNA was explored to treat advanced cancer patients with brain metastases (phase I, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02808416">NCT02808416</ext-link>).</p><p id="p0405">Tumor cell-derived vaccines, specifically those containing the tumor lysate, are popular due to the rich antigenic information content on tumor cells. In a phase &#8545; study on the tumor lysate particle only (TLPO) vaccine for solid tumor malignancies (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06175221">NCT06175221</ext-link>), 250&#8211;500&#160;&#956;g of a tumor tissue was used to prepare the tumor lysate (TL) and TL was loaded into yeast-cell wall microparticles with a diameter of 1&#8211;5 &#956;m for DC phagocytosis and antigen processing. Besides, tumor cell membranes can also be used to construct vaccines. NV-001, a novel tumor vaccine developed through the hybridization of tumor cell membranes with adjuvant-containing membranes. It could elicit potent anti-tumor immune responses against malignant neoplasms, the vaccine is currently under evaluation in a phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06051760">NCT06051760</ext-link>). The cell-based tumor vaccines necessitate the isolation and <italic toggle="yes">ex vivo</italic> modification of patient-derived cells (e.g., DCs and tumor cells), resulting in a time-consuming process and substantial financial costs, thereby hindering their scalability. And more attention needs to be focused on critical parameters such as cell viability, antigen-loading efficiency, and immunostimulatory capacity, due to potential heterogeneity across production batches, which compromises the therapeutic reproducibility of cell-based vaccines.</p></sec><sec id="sec5"><label>5</label><title>Conclusions and perspectives</title><p id="p0410">Tumor vaccines could open a new avenue for tumor prevention and treatment. In this review, we summarized antigens and adjuvants that have been discovered and applied for tumor vaccine and surveyed biomaterial nanoplatforms for efficient delivery of antigens and adjuvants. We elaborated design principles and application examples of these nanoplatforms including LNPs, polymeric nanoparticles, inorganic nanoparticles, biomimetic nanoparticles, and hydrogels for co-delivery of antigens and adjuvants to targeted tissues to induce antigen-specific immune responses. Clinical trial results of DNA vaccines, mRNA vaccines, peptide vaccines, and cell-based vaccines have confirmed these vaccines could significantly extend the patient survival rate, suggesting that patients with advanced cancer could be benefit from rapid advances in the development of tumor vaccines.</p><p id="p0415">The development of nanotherapeutics, mandated by FDA guidelines, requires a multidisciplinary framework that rigorously integrates physicochemical characterization, preclinical safety assessments, good manufacturing practice (GMP)-compliant manufacturing controls, and clinical validation to ensure therapeutic efficacy and patient safety, which underpin the advancing field of tumor vaccines. Despite encouraging results in preclinical and clinical studies on tumor vaccines, the following areas remained to be addressed (<xref rid="fig12" ref-type="fig">Fig. 12</xref>).<list list-type="simple" id="olist0025"><list-item id="o0055"><label>(1)</label><p id="p0420">Antigen predication: Antigens selection is an essential process in designing cancer vaccines. Clinical screening of tumor neoantigens to identify immunogenic targets for personalized immunotherapy could be efficient through multidisciplinary collaboration through systematical integration of genomic profiling, computational immunology, and functional validation. Tumor-normal paired whole-exome sequencing (WES) and RNA sequencing (RNA-seq) are initially performed to detect somatic mutations (e.g., nonsynonymous single-nucleotide variants, indels) and fusion events, while high-resolution HLA genotyping defines patient-specific MHC class I/II alleles to guide epitope restriction. Bioinformatics pipelines can filter mutations for tumor specificity by excluding germline variants via public databases like dbSNP and prioritize those with functional relevance using annotation tools such as ANNOVAR. Predicted neoantigens are subsequently evaluated through a multi-tiered computational framework: the MHC binding affinity is quantified using algorithms like NetMHCpan 4.0 or MHCflurry; the proteasomal processing efficiency is modeled via NetChop 3.0, and the TCR-pMHC interaction probabilities are estimated via machine learning platforms such as pMTnet or PRIME 2.0 [<xref rid="bib249" ref-type="bibr">249</xref>,<xref rid="bib250" ref-type="bibr">250</xref>]. Neoantigens are primarily derived from two distinct origins: (i) non-synonymous somatic mutations in malignant cells and (ii) viral oncoproteins expressed during persistent infection. The mutational landscape of cancer genomes is predominantly shaped by four classes of genomic alterations: single nucleotide variants (SNVs), small insertions/deletions, chromosomal rearrangements generating from fusion transcripts, and alternative splicing aberrations. Mitochondrial genome mutations are an emerging fifth category of mutations in tumors. The antigen predictors often identify the neoantigens from SNVs, and numerous neoantigens in other categories remain to be characterized or discovered [<xref rid="bib251" ref-type="bibr">251</xref>,<xref rid="bib252" ref-type="bibr">252</xref>]. Furthermore, while mainstream computer simulation models are primarily oriented towards predicting the binding affinity between neoantigens and MHC molecules, other crucial factors such as antigen cleavage in proteasomes and peptide transportation are often neglected. Therefore, comprehensive predictors that take essential factors for tumor antigen predictions into consideration should be constructed.</p></list-item><list-item id="o0060"><label>(2)</label><p id="p0425">Development of safety and efficient adjuvants: The clinical translation of these therapies remains hindered by a critical bottleneck: the scarcity of safe, efficient, and adaptable adjuvants. Current clinical trials predominantly rely on Poly-ICLC as the primary adjuvant, indicating that the stark paucity of alternatives and novel adjuvants remain to be discovered for tumor vaccines. The cGAS-STING agonist could be a promising candidate for adjuvants in clinical applications [<xref rid="bib253" ref-type="bibr">253</xref>]. Synergizes computational prediction, biochemical validation, and translational optimization may be an admissible approach to discovery of high-efficacy STING agonists. Initial screening employs molecular docking against STING structures (e.g., PDB:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="https://www.rcsb.org/structure/4LOH" id="intref0010">4LOH</ext-link>) and machine learning models to prioritize compounds with high CDN-pocket affinity and optimal ADMET (A: absorption; D: distribution; M: metabolism; E: excretion; T: toxicity) profiles. Subsequently, biochemical and cell-based high-throughput screening (HTS) employs STING-dependent luciferase reporter assays in engineered HEK293T or THP-1&#160;cells, fluorescence polarization competition assays with labeled CDN, and phenotypic cytokine profiling in primary immune cells to quantify interferon pathway activation and ligand binding kinetics. Functional validation progresses to <italic toggle="yes">in vitro</italic> co-culture systems assessing T cell priming and tumor cytotoxicity, followed by <italic toggle="yes">in vivo</italic> testing in syngeneic tumor models. Clinical translation requires cross-species reactivity validation, formulation stability, and toxicity screening using humanized organoids.</p></list-item><list-item id="o0065"><label>(3)</label><p id="p0430">Modulation of the immunosuppressive tumor microenvironment: The solid tumor microenvironment has a detrimental effect on the efficacy of tumor vaccines. Tumor-associated macrophages (TAMs, CD206<sup>+</sup>) and Tregs (Foxp3<sup>+</sup>CTLA-4<sup>+</sup>) can secrete cytokines, such as IL-10 and transforming growth factor-&#946; (TGF-&#946;), to impair DC-mediated antigen presentation [<xref rid="bib254" ref-type="bibr">254</xref>,<xref rid="bib255" ref-type="bibr">255</xref>]. The impairment of antigen presentation induced by TSAs or TAAs in tumor vaccines results in a low efficiency in activating CD8<sup>+</sup>/CD4<sup>+</sup> T cells. Myeloid-derived suppressor cells (MDSCs, CD11b<sup>+</sup>Gr1<sup>+</sup>) can deplete microenvironmental arginine through arginase-1 (Arg1), thereby inhibiting the mTOR pathway in T cells and inducing functional anergy [<xref rid="bib256" ref-type="bibr">[256]</xref>, <xref rid="bib257" ref-type="bibr">[257]</xref>, <xref rid="bib258" ref-type="bibr">[258]</xref>]. Neutrophils exhibit context-dependent effects in tumor progression, and they orchestrate stage-specific modulation of the tumor microenvironment. N1-polarization induces ROS/TNF-&#945;-mediated early apoptosis, while N2-polarization drives MMP-9/VEGF-dependent angiogenesis and immunosuppression via TGF-&#946;/STAT3 signaling [<xref rid="bib259" ref-type="bibr">259</xref>]. Cancer-associated fibroblasts (CAFs), the most abundant stromal cells within the tumor microenvironment, contribute to physical barriers through CXCL12 secretion and extracellular matrix component synthesis to obstruct T cell infiltration [<xref rid="bib260" ref-type="bibr">260</xref>]. Non-cellular constituents, particularly the extracellular matrix (ECM), regulate tumor progression via mechanobiological remodeling [<xref rid="bib261" ref-type="bibr">261</xref>]. The ECM-comprising collagen, fibronectin, elastin, and laminin-forms a fibrotic barrier to block CTL infiltration while driving metastasis through integrin/FAK mechanotransduction and structural heterogeneity-mediated apoptotic resistance [<xref rid="bib262" ref-type="bibr">262</xref>,<xref rid="bib263" ref-type="bibr">263</xref>]. Consequently, deciphering the multidimensional immunosuppressive network within the tumor microenvironment and developing precisely targeted combination therapies are pivotal strategies for optimizing the efficacy of cancer vaccines.</p></list-item><list-item id="o0070"><label>(4)</label><p id="p0435">A balance in complicated nanoplatform design and clinical translation. Challenges of translating multifunctional nanovaccines into clinical trials could be relieved by carefully balancing between structural sophistication and manufacturing feasibility. Multifunctional integration (e.g., co-delivery of antigen/adjuvant with immune checkpoint modulators) in tumor nanovaccines requires a multi-stage GMP-compliant manufacturing process. The manufacture process complexity inevitably leads to 1) an exponential cost escalation, 2) chromatographic purification challenges of removing impurities, and 3) batch-batch variations [<xref rid="bib264" ref-type="bibr">264</xref>,<xref rid="bib265" ref-type="bibr">265</xref>]. Manufacturing scalability of lipid-based systems, exemplified by the Moderna's clinically validated mRNA-1273 platform, has been demonstrated through precise microfluidic synthesis and lyophilization stabilization, while persistent GMP hurdles including lipid purity thresholds and cold chain logistics should be surmounted. By contrast, inorganic carriers like MSNs exhibit superior thermal resilience and ambient storage stability, but they are produced from energy-intensive solvothermal synthesis and the product may contain cytotoxic leaching residues. Emerging approaches, such as modular nanoparticle architectures and AI-driven Quality by Design (QbD) platforms, could be employed to minimize batch-to-batch variations [<xref rid="bib266" ref-type="bibr">266</xref>]. This paradigm-shifting approach enables systematic deconvolution of the structural complexity-clinical translatability matrix, thus predictive algorithms could be established to balance the immunological multifunctionality with the pharmaceutical manufacturability in next-generation cancer vaccine development.</p></list-item></list><fig id="fig12" position="float" orientation="portrait"><label>Fig. 12</label><caption><p>To propel the clinical translation of bionanomaterial-engineered tumor vaccines by leveraging their advantages, the following strategic dimensions merit prioritized investigation: (1) Broadening the spectrum of tumor antigens prediction through next-generation epitope mapping algorithms integrating neoantigen prediction (NetMHCpan 4.2) and immunopeptidome validation. (2) Development of safe and efficient adjuvants through AI-enhanced construction of target-specific agonist libraries and multi-tiered immunological validation platforms <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>. (3) Alleviation of immunosuppressive microenvironment through reducing the population of myeloid-derived suppressor cells (MDSCs), M2-tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and Tregs and increasing the ratio of DCs, M1-TAMs, CD4<sup>+</sup>/8<sup>+</sup> T cells; (4) Optimization of biomaterial-based nanoplatforms and clinical translation. To striking a balance between functional sophistication of nano-delivery platforms and their manufacturability for clinical-scale production under GMP compliance.</p></caption><alt-text id="alttext0070">Fig. 12</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr12.jpg"/></fig></p><p id="p0440">Rapid advances in tumor immunotherapy, coupled with breakthroughs in RNA sequencing (RNA-Seq), AI/ML-driven neoantigen prediction, nanomaterial synthesis, analytical characterization, and tumor microenvironment profiling, have driven a paradigm shift of cancer vaccine development toward personalized immunotherapy. By leveraging patient-specific genetic and immunogenic signatures, personalized tumor vaccines enable precise activation of tumor-reactive T cells while mitigating immune tolerance, underscoring a transformative framework in precision oncology. These tumor vaccines are dynamically optimized to align with the evolving genomic and immunological landscapes of individual patients, thereby converting transient therapeutic responses into sustained clinical remissions. Collectively, tumor vaccines tailored to individual cancer patients could be developed with enhanced efficacy and biosafety profiles.</p></sec><sec id="sec6"><title>CRediT authorship contribution statement</title><p id="p0445"><bold>Zhilin Li:</bold> Writing &#8211; original draft, Visualization, Funding acquisition, Formal analysis, Data curation, Conceptualization. <bold>Hongbin Zhang:</bold> Supervision. <bold>Qiyong Gong:</bold> Supervision. <bold>Kui Luo:</bold> Writing &#8211; review &amp; editing, Supervision, Funding acquisition.</p></sec><sec id="sec7"><title>Ethics approval and consent to participate</title><p id="p0450">The manuscript is a review article. The authors declare no experimentation on human or animals were designed.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0455">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>M.C.</given-names></name></person-group><article-title>Advances and prospects of biomarkers for immune checkpoint inhibitors</article-title><source>Cell Rep. Med.</source><volume>5</volume><issue>7</issue><year>2024</year><object-id pub-id-type="publisher-id">101621</object-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2024.101621</pub-id><pub-id pub-id-type="pmcid">PMC11293349</pub-id><pub-id pub-id-type="pmid">38906149</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ti</surname><given-names>H.</given-names></name></person-group><article-title>Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy</article-title><source>Asian J. Pharm. Sci.</source><volume>19</volume><issue>2</issue><year>2024</year><object-id pub-id-type="publisher-id">100902</object-id><pub-id pub-id-type="doi">10.1016/j.ajps.2024.100902</pub-id><pub-id pub-id-type="pmcid">PMC11002556</pub-id><pub-id pub-id-type="pmid">38595331</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>June</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M.J.</given-names></name></person-group><article-title>Delivery technologies for cancer immunotherapy</article-title><source>Nat. Rev. Drug Discov.</source><volume>18</volume><issue>3</issue><year>2019</year><fpage>175</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/s41573-018-0006-z</pub-id><pub-id pub-id-type="pmid">30622344</pub-id><pub-id pub-id-type="pmcid">PMC6410566</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Deckers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anbergen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hokke</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>de Dreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schrijver</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Toner</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Beldman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Spangler</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>de Greef</surname><given-names>T.F.A.</given-names></name><name name-style="western"><surname>Grisoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>van der Meel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>Merkx</surname><given-names>M.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>W.J.M.</given-names></name></person-group><article-title>Engineering cytokine therapeutics</article-title><source>Nat. Rev. Bioeng.</source><volume>1</volume><issue>4</issue><year>2023</year><fpage>286</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/s44222-023-00030-y</pub-id><pub-id pub-id-type="pmid">37064653</pub-id><pub-id pub-id-type="pmcid">PMC9933837</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>2</issue><year>2024</year><fpage>854</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.08.014</pub-id><pub-id pub-id-type="pmid">38322330</pub-id><pub-id pub-id-type="pmcid">PMC10840399</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Nano drug delivery systems for advanced immune checkpoint blockade therapy</article-title><source>Theranostics</source><volume>15</volume><issue>11</issue><year>2025</year><fpage>5440</fpage><lpage>5480</lpage><pub-id pub-id-type="doi">10.7150/thno.112475</pub-id><pub-id pub-id-type="pmid">40303342</pub-id><pub-id pub-id-type="pmcid">PMC12036873</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name></person-group><article-title>Therapeutic cancer vaccines: advancements, challenges, and prospects</article-title><source>Signal Transduct. Target. Ther.</source><volume>8</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">450</object-id><pub-id pub-id-type="doi">10.1038/s41392-023-01674-3</pub-id><pub-id pub-id-type="pmcid">PMC10716479</pub-id><pub-id pub-id-type="pmid">38086815</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Brandenburg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brossart</surname><given-names>P.</given-names></name></person-group><article-title>Next-generation cancer vaccines and emerging immunotherapy combinations</article-title><source>Trends Cancer</source><volume>10</volume><issue>8</issue><year>2024</year><fpage>749</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2024.06.003</pub-id><pub-id pub-id-type="pmid">39048489</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name></person-group><article-title>Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection</article-title><source>Nat. Biomed. Eng.</source><volume>9</volume><issue>2</issue><year>2025</year><fpage>201</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/s41551-025-01343-6</pub-id><pub-id pub-id-type="pmid">39948171</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Linderman</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>DeRidder</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sanjurjo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Foote</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kirtane</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G.</given-names></name></person-group><article-title>Enhancing immunotherapy with tumour-responsive nanomaterials</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2025</year><fpage>262</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/s41571-025-01000-6</pub-id><pub-id pub-id-type="pmid">40050505</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Engineering customized nanovaccines for enhanced cancer immunotherapy</article-title><source>Bioact. Mater.</source><volume>36</volume><year>2024</year><fpage>330</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2024.02.028</pub-id><pub-id pub-id-type="pmid">38496036</pub-id><pub-id pub-id-type="pmcid">PMC10940734</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Stimuli-activatable nanomedicine meets cancer theranostics</article-title><source>Theranostics</source><volume>13</volume><issue>15</issue><year>2023</year><fpage>5386</fpage><lpage>5417</lpage><pub-id pub-id-type="doi">10.7150/thno.87854</pub-id><pub-id pub-id-type="pmid">37908735</pub-id><pub-id pub-id-type="pmcid">PMC10614691</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><volume>13</volume><issue>2</issue><year>2021</year><object-id pub-id-type="publisher-id">e1670</object-id><pub-id pub-id-type="doi">10.1002/wnan.1670</pub-id><pub-id pub-id-type="pmid">32949116</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Functional gadolinium-based nanoscale systems for cancer theranostics</article-title><source>J. Control. Release</source><volume>329</volume><year>2021</year><fpage>482</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.08.064</pub-id><pub-id pub-id-type="pmid">32898594</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Biomarker-driven molecular imaging probes in radiotherapy</article-title><source>Theranostics</source><volume>14</volume><issue>10</issue><year>2024</year><fpage>4127</fpage><lpage>4146</lpage><pub-id pub-id-type="doi">10.7150/thno.97768</pub-id><pub-id pub-id-type="pmid">38994026</pub-id><pub-id pub-id-type="pmcid">PMC11234278</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Ruzzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Riccardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tarone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Semprini</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bolli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barutello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Quaglino</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lollini</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>F.</given-names></name></person-group><article-title>Cancer vaccines: target antigens, vaccine platforms and preclinical models</article-title><source>Mol. Aspects Med.</source><volume>101</volume><year>2025</year><object-id pub-id-type="publisher-id">101324</object-id><pub-id pub-id-type="doi">10.1016/j.mam.2024.101324</pub-id><pub-id pub-id-type="pmid">39631227</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>A recent perspective on designing tumor vaccines for tumor immunology</article-title><source>Int. Immunopharmacol</source><volume>142</volume><issue>Pt A</issue><year>2024</year><object-id pub-id-type="publisher-id">113090</object-id><pub-id pub-id-type="doi">10.1016/j.intimp.2024.113090</pub-id><pub-id pub-id-type="pmid">39244900</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Svensson-Arvelund</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lubitz</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Brody</surname><given-names>J.D.</given-names></name></person-group><article-title>Cancer vaccines: the next immunotherapy frontier</article-title><source>Nat. Cancer</source><volume>3</volume><issue>8</issue><year>2022</year><fpage>911</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00418-6</pub-id><pub-id pub-id-type="pmid">35999309</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Katsikis</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Schliehe</surname><given-names>C.</given-names></name></person-group><article-title>Challenges in developing personalized neoantigen cancer vaccines</article-title><source>Nat. Rev. Immunol.</source><volume>24</volume><issue>3</issue><year>2024</year><fpage>213</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00937-y</pub-id><pub-id pub-id-type="pmid">37783860</pub-id><pub-id pub-id-type="pmcid">PMC12001822</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Pagliari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dema</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanchez-Martinez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montalvo Zurbia-Flores</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rollier</surname><given-names>C.S.</given-names></name></person-group><article-title>DNA vaccines: history, molecular mechanisms and future perspectives</article-title><source>J. Mol. Biol.</source><volume>435</volume><issue>23</issue><year>2023</year><object-id pub-id-type="publisher-id">168297</object-id><pub-id pub-id-type="doi">10.1016/j.jmb.2023.168297</pub-id><pub-id pub-id-type="pmid">37797831</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Shariati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khezrpour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shariati</surname><given-names>F.</given-names></name><name name-style="western"><surname>Afkhami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yarahmadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alavimanesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamrani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Modarressi</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Khani</surname><given-names>P.</given-names></name></person-group><article-title>DNA vaccines as promising immuno-therapeutics against cancer: a new insight</article-title><source>Front. Immunol.</source><volume>15</volume><year>2024</year><object-id pub-id-type="publisher-id">1498431</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1498431</pub-id><pub-id pub-id-type="pmcid">PMC11769820</pub-id><pub-id pub-id-type="pmid">39872522</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Guasp</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reiche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>V.P.</given-names></name></person-group><article-title>RNA vaccines for cancer: principles to practice</article-title><source>Cancer Cell</source><volume>42</volume><issue>7</issue><year>2024</year><fpage>1163</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.05.005</pub-id><pub-id pub-id-type="pmid">38848720</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>Advanced nano-based strategies for mRNA tumor vaccine</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>1</issue><year>2024</year><fpage>170</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.07.025</pub-id><pub-id pub-id-type="pmid">38239240</pub-id><pub-id pub-id-type="pmcid">PMC10792970</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Sayour</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Boczkowski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.K.</given-names></name></person-group><article-title>Cancer mRNA vaccines: clinical advances and future opportunities</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>21</volume><issue>7</issue><year>2024</year><fpage>489</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/s41571-024-00902-1</pub-id><pub-id pub-id-type="pmid">38760500</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Che</surname><given-names>X.</given-names></name></person-group><article-title>Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective</article-title><source>Vaccines (Basel)</source><volume>12</volume><issue>8</issue><year>2024</year><object-id pub-id-type="publisher-id">950</object-id><pub-id pub-id-type="doi">10.3390/vaccines12080950</pub-id><pub-id pub-id-type="pmcid">PMC11359700</pub-id><pub-id pub-id-type="pmid">39204073</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>D'Aniello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Bene</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mottola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazzarella</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutolo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Campagna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Di Maro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Messere</surname><given-names>A.</given-names></name></person-group><article-title>The bright side of chemistry: exploring synthetic peptide-based anticancer vaccines</article-title><source>J. Pept. Sci.</source><volume>30</volume><issue>8</issue><year>2024</year><object-id pub-id-type="publisher-id">e3596</object-id><pub-id pub-id-type="doi">10.1002/psc.3596</pub-id><pub-id pub-id-type="pmid">38571326</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.M.</given-names></name></person-group><article-title>Chemical strategies to boost cancer vaccines</article-title><source>Chem. Rev.</source><volume>120</volume><issue>20</issue><year>2020</year><fpage>11420</fpage><lpage>11478</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00833</pub-id><pub-id pub-id-type="pmid">32914967</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Sotirov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>I.</given-names></name></person-group><article-title>Tumor-derived antigenic peptides as potential cancer vaccines</article-title><source>Int. J. Mol. Sci.</source><volume>25</volume><issue>9</issue><year>2024</year><object-id pub-id-type="publisher-id">4934</object-id><pub-id pub-id-type="doi">10.3390/ijms25094934</pub-id><pub-id pub-id-type="pmcid">PMC11084719</pub-id><pub-id pub-id-type="pmid">38732150</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Nanovaccines with cell-derived components for cancer immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><volume>182</volume><year>2022</year><object-id pub-id-type="publisher-id">114107</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.114107</pub-id><pub-id pub-id-type="pmid">34995678</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells</article-title><source>Adv. Mater.</source><volume>33</volume><issue>43</issue><year>2021</year><object-id pub-id-type="publisher-id">e2104849</object-id><pub-id pub-id-type="doi">10.1002/adma.202104849</pub-id><pub-id pub-id-type="pmid">34536044</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name></person-group><article-title>A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>2</issue><year>2023</year><fpage>804</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.09.017</pub-id><pub-id pub-id-type="pmid">36873172</pub-id><pub-id pub-id-type="pmcid">PMC9979264</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Huynh</surname><given-names>T.M.H.</given-names></name><name name-style="western"><surname>Luc</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.H.</given-names></name></person-group><article-title>Programmed lung metastasis immunotherapy via cascade&#8208;responsive cell membrane&#8208;mimetic copolymer&#8208;wrapped Nanoraspberry&#8208;Mediated Elesclomol&#8208;Copper delivery</article-title><source>Adv. Funct. Mater.</source><volume>34</volume><issue>34</issue><year>2024</year><object-id pub-id-type="publisher-id">2401806</object-id><pub-id pub-id-type="doi">10.1002/adfm.202401806</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Yalamandala</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>T.M.H.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.H.</given-names></name></person-group><article-title>A self-cascade penetrating brain tumor immunotherapy mediated by near-infrared II cell membrane-disrupting nanoflakes via detained dendritic cells</article-title><source>ACS Nano</source><volume>18</volume><issue>28</issue><year>2024</year><fpage>18712</fpage><lpage>18728</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c06183</pub-id><pub-id pub-id-type="pmid">38952208</pub-id><pub-id pub-id-type="pmcid">PMC11256899</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor-associated macrophages</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>8</issue><year>2023</year><fpage>3471</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.003</pub-id><pub-id pub-id-type="pmid">37655313</pub-id><pub-id pub-id-type="pmcid">PMC10465875</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>2</issue><year>2024</year><fpage>765</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.10.006</pub-id><pub-id pub-id-type="pmid">38322349</pub-id><pub-id pub-id-type="pmcid">PMC10840428</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name></person-group><article-title>Self-sufficient nanoparticles with dual-enzyme activity trigger radical storms and activate cascade-amplified antitumor immunologic responses</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>2</issue><year>2024</year><fpage>821</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.10.003</pub-id><pub-id pub-id-type="pmid">38322329</pub-id><pub-id pub-id-type="pmcid">PMC10840429</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.H.</given-names></name></person-group><article-title>Reprogramming dysfunctional dendritic cells by a versatile catalytic dual oxide antigen-captured nanosponge for remotely enhancing lung metastasis immunotherapy</article-title><source>ACS Nano</source><volume>19</volume><issue>2</issue><year>2025</year><fpage>2117</fpage><lpage>2135</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c09525</pub-id><pub-id pub-id-type="pmid">39739571</pub-id><pub-id pub-id-type="pmcid">PMC11760334</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>8</issue><year>2024</year><fpage>3680</fpage><lpage>3696</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.03.010</pub-id><pub-id pub-id-type="pmid">39220877</pub-id><pub-id pub-id-type="pmcid">PMC11365400</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency</article-title><source>Adv. Sci.</source><volume>9</volume><issue>22</issue><year>2022</year><object-id pub-id-type="publisher-id">e2201734</object-id><pub-id pub-id-type="doi">10.1002/advs.202201734</pub-id><pub-id pub-id-type="pmcid">PMC9353475</pub-id><pub-id pub-id-type="pmid">35652198</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>In situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>9</issue><year>2024</year><fpage>4102</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.06.003</pub-id><pub-id pub-id-type="pmid">39309485</pub-id><pub-id pub-id-type="pmcid">PMC11413692</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Powles</surname><given-names>T.</given-names></name><name name-style="western"><surname>Turley</surname><given-names>S.J.</given-names></name></person-group><article-title>The cancer-immunity cycle: indication, genotype, and immunotype</article-title><source>Immunity</source><volume>56</volume><issue>10</issue><year>2023</year><fpage>2188</fpage><lpage>2205</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.09.011</pub-id><pub-id pub-id-type="pmid">37820582</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Naskar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sriraman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>K.</given-names></name></person-group><article-title>Tumor antigen presentation and the associated signal transduction during carcinogenesis</article-title><source>Pathol. Res. Pract.</source><volume>261</volume><year>2024</year><object-id pub-id-type="publisher-id">155485</object-id><pub-id pub-id-type="doi">10.1016/j.prp.2024.155485</pub-id><pub-id pub-id-type="pmid">39088877</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Halima</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T.A.</given-names></name></person-group><article-title>Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>20</volume><issue>9</issue><year>2023</year><fpage>604</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00789-4</pub-id><pub-id pub-id-type="pmid">37328642</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>MacNabb</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>J.</given-names></name></person-group><article-title>MHC cross-dressing in antigen presentation</article-title><source>Adv. Immunol.</source><volume>159</volume><year>2023</year><fpage>115</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2023.07.001</pub-id><pub-id pub-id-type="pmid">37996206</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Luri-Rey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teijeira</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Wculek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>de Andrea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lopez-Janeiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Ruiz</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Heras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aggelakopoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berraondo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name></person-group><article-title>Cross-priming in cancer immunology and immunotherapy</article-title><source>Nat. Rev. Cancer</source><volume>25</volume><issue>4</issue><year>2025</year><fpage>249</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41568-024-00785-5</pub-id><pub-id pub-id-type="pmid">39881005</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Moussion</surname><given-names>C.</given-names></name><name name-style="western"><surname>Delamarre</surname><given-names>L.</given-names></name></person-group><article-title>Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy</article-title><source>Semin. Immunol.</source><volume>71</volume><year>2024</year><object-id pub-id-type="publisher-id">101848</object-id><pub-id pub-id-type="doi">10.1016/j.smim.2023.101848</pub-id><pub-id pub-id-type="pmid">38035643</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Giles</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Globig</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kaech</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name></person-group><article-title>CD8(+) T cells in the cancer-immunity cycle</article-title><source>Immunity</source><volume>56</volume><issue>10</issue><year>2023</year><fpage>2231</fpage><lpage>2253</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2023.09.005</pub-id><pub-id pub-id-type="pmid">37820583</pub-id><pub-id pub-id-type="pmcid">PMC11237652</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Kyrysyuk</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wucherpfennig</surname><given-names>K.W.</given-names></name></person-group><article-title>Designing cancer immunotherapies that engage T cells and NK cells</article-title><source>Annu. Rev. Immunol.</source><volume>41</volume><year>2023</year><fpage>17</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101921-044122</pub-id><pub-id pub-id-type="pmid">36446137</pub-id><pub-id pub-id-type="pmcid">PMC10159905</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>C.P.</given-names></name></person-group><article-title>Vaccine adjuvants: tailoring innate recognition to send the right message</article-title><source>Immunity</source><volume>57</volume><issue>4</issue><year>2024</year><fpage>772</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.015</pub-id><pub-id pub-id-type="pmid">38599170</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Boucetta</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>A.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Next-generation aluminum adjuvants: immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>11</issue><year>2024</year><fpage>4665</fpage><lpage>4682</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.09.012</pub-id><pub-id pub-id-type="pmid">39664431</pub-id><pub-id pub-id-type="pmcid">PMC11628803</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patarroyo</surname><given-names>M.A.</given-names></name></person-group><article-title>Adjuvants approved for human use: what do we know and what do we need to know for designing good adjuvants?</article-title><source>Eur. J. Pharmacol.</source><volume>945</volume><year>2023</year><object-id pub-id-type="publisher-id">175632</object-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175632</pub-id><pub-id pub-id-type="pmid">36863555</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Man</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>B.J.</given-names></name></person-group><article-title>Context-dependent functions of pattern recognition receptors in cancer</article-title><source>Nat. Rev. Cancer</source><volume>22</volume><issue>7</issue><year>2022</year><fpage>397</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1038/s41568-022-00462-5</pub-id><pub-id pub-id-type="pmid">35355007</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Pasare</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>G.M.</given-names></name></person-group><article-title>Control of adaptive immunity by pattern recognition receptors</article-title><source>Immunity</source><volume>57</volume><issue>4</issue><year>2024</year><fpage>632</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.014</pub-id><pub-id pub-id-type="pmid">38599163</pub-id><pub-id pub-id-type="pmcid">PMC11037560</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Toll-like receptors in health and disease</article-title><source>MedComm</source><volume>5</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">e549</object-id><pub-id pub-id-type="doi">10.1002/mco2.549</pub-id><pub-id pub-id-type="pmcid">PMC11057423</pub-id><pub-id pub-id-type="pmid">38685971</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikegawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ori</surname><given-names>D.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Decoding toll-like receptors: recent insights and perspectives in innate immunity</article-title><source>Immunity</source><volume>57</volume><issue>4</issue><year>2024</year><fpage>649</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.03.004</pub-id><pub-id pub-id-type="pmid">38599164</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>E.</given-names></name><name name-style="western"><surname>McNeel</surname><given-names>D.G.</given-names></name></person-group><article-title>Toll-like receptor agonists as cancer vaccine adjuvants</article-title><source>Hum. Vaccin. Immunother.</source><volume>20</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">2297453</object-id><pub-id pub-id-type="doi">10.1080/21645515.2023.2297453</pub-id><pub-id pub-id-type="pmcid">PMC10760790</pub-id><pub-id pub-id-type="pmid">38155525</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burtner</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Criswell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coventry</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tran-Pearson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>King</surname><given-names>N.P.</given-names></name></person-group><article-title>De novo design of protein minibinder agonists of TLR3</article-title><source>Nat. Commun.</source><volume>16</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">1234</object-id><pub-id pub-id-type="doi">10.1038/s41467-025-56369-w</pub-id><pub-id pub-id-type="pmcid">PMC11785957</pub-id><pub-id pub-id-type="pmid">39890776</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Bryant</surname><given-names>C.E.</given-names></name></person-group><article-title>Rethinking toll-like receptor signalling</article-title><source>Curr. Opin. Immunol.</source><volume>91</volume><year>2024</year><object-id pub-id-type="publisher-id">102460</object-id><pub-id pub-id-type="doi">10.1016/j.coi.2024.102460</pub-id><pub-id pub-id-type="pmid">39288726</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Brimble</surname><given-names>M.A.</given-names></name></person-group><article-title>TLR2 agonists and their structure-activity relationships</article-title><source>Org. Biomol. Chem.</source><volume>18</volume><issue>27</issue><year>2020</year><fpage>5073</fpage><lpage>5094</lpage><pub-id pub-id-type="doi">10.1039/d0ob00942c</pub-id><pub-id pub-id-type="pmid">32582902</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Nishizaki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Adashek</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Toll-like receptor 3: a double-edged sword</article-title><source>Biomark. Res.</source><volume>13</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">32</object-id><pub-id pub-id-type="doi">10.1186/s40364-025-00739-5</pub-id><pub-id pub-id-type="pmcid">PMC11849352</pub-id><pub-id pub-id-type="pmid">39988665</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Heine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zamyatina</surname><given-names>A.</given-names></name></person-group><article-title>Therapeutic targeting of TLR4 for inflammation, infection, and cancer: a perspective for disaccharide lipid A mimetics</article-title><source>Pharmaceuticals</source><volume>16</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">23</object-id><pub-id pub-id-type="doi">10.3390/ph16010023</pub-id><pub-id pub-id-type="pmcid">PMC9864529</pub-id><pub-id pub-id-type="pmid">36678520</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Afzal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murtaza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.T.</given-names></name></person-group><article-title>Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation</article-title><source>Mol. Biol. Rep.</source><volume>52</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">104</object-id><pub-id pub-id-type="doi">10.1007/s11033-024-10146-y</pub-id><pub-id pub-id-type="pmcid">PMC11706886</pub-id><pub-id pub-id-type="pmid">39775323</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Le&#347;niak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipniarska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Majka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kopyt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lejman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zawitkowska</surname><given-names>J.</given-names></name></person-group><article-title>The role of TRL7/8 agonists in cancer therapy, with special emphasis on hematologic malignancies</article-title><source>Vaccines (Basel)</source><volume>11</volume><issue>2</issue><year>2023</year><object-id pub-id-type="publisher-id">277</object-id><pub-id pub-id-type="doi">10.3390/vaccines11020277</pub-id><pub-id pub-id-type="pmcid">PMC9967151</pub-id><pub-id pub-id-type="pmid">36851155</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name></person-group><article-title>Molecule engineering strategy of toll-like receptor 7/8 agonists designed for potentiating immune stimuli activation</article-title><source>Chem. Comm.</source><volume>60</volume><issue>42</issue><year>2024</year><fpage>5474</fpage><lpage>5485</lpage><pub-id pub-id-type="doi">10.1039/d4cc00792a</pub-id><pub-id pub-id-type="pmid">38712400</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Dongye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity</article-title><source>Br. J. Cancer</source><volume>127</volume><issue>9</issue><year>2022</year><fpage>1584</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01876-6</pub-id><pub-id pub-id-type="pmid">35902641</pub-id><pub-id pub-id-type="pmcid">PMC9333350</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Kayraklioglu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Horuluoglu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><article-title>CpG oligonucleotides as vaccine adjuvants</article-title><source>Methods Mol. Biol.</source><volume>2197</volume><year>2021</year><fpage>51</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0872-2_4</pub-id><pub-id pub-id-type="pmid">32827132</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Samson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ablasser</surname><given-names>A.</given-names></name></person-group><article-title>The cGAS-STING pathway and cancer</article-title><source>Nat. Cancer</source><volume>3</volume><issue>12</issue><year>2022</year><fpage>1452</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00468-w</pub-id><pub-id pub-id-type="pmid">36510011</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Nanoparticle-mediated STING activation for cancer immunotherapy</article-title><source>Adv. Healthc. Mater.</source><volume>12</volume><issue>19</issue><year>2023</year><object-id pub-id-type="publisher-id">e2300260</object-id><pub-id pub-id-type="doi">10.1002/adhm.202300260</pub-id><pub-id pub-id-type="pmid">36905358</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name></person-group><article-title>Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy</article-title><source>J. Control. Release</source><volume>381</volume><year>2025</year><object-id pub-id-type="publisher-id">113560</object-id><pub-id pub-id-type="doi">10.1016/j.jconrel.2025.02.056</pub-id><pub-id pub-id-type="pmid">40023225</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>H.U.</given-names></name><name name-style="western"><surname>Terzi&#263;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kocic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poli&#263;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>STING in cancer immunoediting: modeling tumor-immune dynamics throughout cancer development</article-title><source>Cancer Lett.</source><volume>612</volume><year>2025</year><object-id pub-id-type="publisher-id">217410</object-id><pub-id pub-id-type="doi">10.1016/j.canlet.2024.217410</pub-id><pub-id pub-id-type="pmid">39826670</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Dvorkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cambier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Volkman</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Stetson</surname><given-names>D.B.</given-names></name></person-group><article-title>New frontiers in the cGAS-STING intracellular DNA-Sensing pathway</article-title><source>Immunity</source><volume>57</volume><issue>4</issue><year>2024</year><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.02.019</pub-id><pub-id pub-id-type="pmid">38599167</pub-id><pub-id pub-id-type="pmcid">PMC11013568</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name></person-group><article-title>cGAS/STING signalling pathway in senescence and oncogenesis</article-title><source>Semin. Cancer Biol.</source><volume>106&#8211;107</volume><year>2024</year><fpage>87</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2024.08.007</pub-id><pub-id pub-id-type="pmcid">PMC11625615</pub-id><pub-id pub-id-type="pmid">39222763</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Van Herck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name></person-group><article-title>Delivery of STING agonists for adjuvanting subunit vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><volume>179</volume><year>2021</year><object-id pub-id-type="publisher-id">114020</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.114020</pub-id><pub-id pub-id-type="pmid">34756942</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marloye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lawler</surname><given-names>S.E.</given-names></name></person-group><article-title>Pharmacological modulation of the STING pathway for cancer immunotherapy</article-title><source>Trends Mol. Med.</source><volume>25</volume><issue>5</issue><year>2019</year><fpage>412</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2019.02.007</pub-id><pub-id pub-id-type="pmid">30885429</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishimasu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kasuya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ishitani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tokunaga</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nureki</surname><given-names>O.</given-names></name></person-group><article-title>Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1</article-title><source>Nat. Commun.</source><volume>9</volume><issue>1</issue><year>2018</year><object-id pub-id-type="publisher-id">4424</object-id><pub-id pub-id-type="doi">10.1038/s41467-018-06922-7</pub-id><pub-id pub-id-type="pmcid">PMC6200793</pub-id><pub-id pub-id-type="pmid">30356045</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Meric-Bernstam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sweis</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Messersmith</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Andtbacka</surname><given-names>R.H.I.</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>McWhirter</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>J.J.</given-names></name></person-group><article-title>Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas</article-title><source>Clin. Cancer Res.</source><volume>28</volume><issue>4</issue><year>2022</year><fpage>677</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-21-1963</pub-id><pub-id pub-id-type="pmid">34716197</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Temizoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hioki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.S.J.</given-names></name><name name-style="western"><surname>Surucu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sag</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kumanogoh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gursel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuroda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Coban</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation</article-title><source>Front. Immunol.</source><volume>15</volume><year>2024</year><object-id pub-id-type="publisher-id">1353336</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1353336</pub-id><pub-id pub-id-type="pmcid">PMC10963404</pub-id><pub-id pub-id-type="pmid">38533502</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Conlon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burdette</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rathinam</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name></person-group><article-title>Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid</article-title><source>J. Immunol.</source><volume>190</volume><issue>10</issue><year>2013</year><fpage>5216</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300097</pub-id><pub-id pub-id-type="pmid">23585680</pub-id><pub-id pub-id-type="pmcid">PMC3647383</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Ramanjulu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pesiridis</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Concha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singhaus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Muelbaier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mehlmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leister</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graybill</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Charnley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nevins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Behnia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Kasparcova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nurse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Puhl</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hopson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Guss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bantscheff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reilly</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Gough</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Marquis</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Smothers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>J.</given-names></name></person-group><article-title>Design of amidobenzimidazole STING receptor agonists with systemic activity</article-title><source>Nature</source><volume>564</volume><issue>7736</issue><year>2018</year><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0705-y</pub-id><pub-id pub-id-type="pmid">30405246</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>5</issue><year>2024</year><fpage>2194</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.02.006</pub-id><pub-id pub-id-type="pmid">38799622</pub-id><pub-id pub-id-type="pmcid">PMC11121173</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vartabedian</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gamo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vernier</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kissai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Benish</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Pe&#241;a</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hampton</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Young</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Wolan</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Petrassi</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Teijaro</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lairson</surname><given-names>L.L.</given-names></name></person-group><article-title>Antitumor activity of a systemic STING-Activating non-nucleotide cGAMP mimetic</article-title><source>Science</source><volume>369</volume><issue>6506</issue><year>2020</year><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1126/science.abb4255</pub-id><pub-id pub-id-type="pmid">32820126</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Piesvaux</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Presland</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Cumming</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Trotter</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Buevich</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cemerski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dandliker</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haidle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kariv</surname><given-names>I.</given-names></name><name name-style="western"><surname>Knemeyer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kopinja</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Laskey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lesburg</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Long</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minnihan</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Otte</surname><given-names>R.</given-names></name><name name-style="western"><surname>Price</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rakhilina</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sauvagnat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tyagarajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wyss</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Addona</surname><given-names>G.H.</given-names></name></person-group><article-title>An orally available non-nucleotide STING agonist with antitumor activity</article-title><source>Science</source><volume>369</volume><issue>6506</issue><year>2020</year><object-id pub-id-type="publisher-id">eaba6098</object-id><pub-id pub-id-type="doi">10.1126/science.aba6098</pub-id><pub-id pub-id-type="pmid">32820094</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name></person-group><article-title>Cytosolic DNA sensing by cGAS: regulation, function, and human diseases</article-title><source>Signal Transduct. Target. Ther.</source><volume>6</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">170</object-id><pub-id pub-id-type="doi">10.1038/s41392-021-00554-y</pub-id><pub-id pub-id-type="pmcid">PMC8085147</pub-id><pub-id pub-id-type="pmid">33927185</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name></person-group><article-title>Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses</article-title><source>Immunity</source><volume>48</volume><issue>4</issue><year>2018</year><fpage>675</fpage><lpage>687.e7</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.017</pub-id><pub-id pub-id-type="pmid">29653696</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy</article-title><source>J. Control. Release</source><volume>370</volume><year>2024</year><fpage>354</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.04.042</pub-id><pub-id pub-id-type="pmid">38685387</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name></person-group><article-title>Mn(2+) directly activates cGAS and structural analysis suggests Mn(2+) induces a noncanonical catalytic synthesis of 2'3'-cGAMP</article-title><source>Cell Rep.</source><volume>32</volume><issue>7</issue><year>2020</year><object-id pub-id-type="publisher-id">108053</object-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108053</pub-id><pub-id pub-id-type="pmid">32814054</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy</article-title><source>Biomaterials</source><volume>311</volume><year>2024</year><object-id pub-id-type="publisher-id">122695</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2024.122695</pub-id><pub-id pub-id-type="pmid">38954960</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Riteau</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name></person-group><article-title>Chitosan: an adjuvant with an unanticipated STING</article-title><source>Immunity</source><volume>44</volume><issue>3</issue><year>2016</year><fpage>522</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.03.002</pub-id><pub-id pub-id-type="pmid">26982361</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Wolf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>H.B.T.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S.</given-names></name><name name-style="western"><surname>McEntee</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agger</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hertzog</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bowie</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-Dependent induction of type I interferons</article-title><source>Immunity</source><volume>44</volume><issue>3</issue><year>2016</year><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.004</pub-id><pub-id pub-id-type="pmid">26944200</pub-id><pub-id pub-id-type="pmcid">PMC4852885</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Porembka</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Lea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>A STING-Activating nanovaccine for cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><volume>12</volume><issue>7</issue><year>2017</year><fpage>648</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/nnano.2017.52</pub-id><pub-id pub-id-type="pmid">28436963</pub-id><pub-id pub-id-type="pmcid">PMC5500418</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cholka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Prolonged activation of innate immune pathways by a polyvalent STING agonist</article-title><source>Nat. Biomed. Eng.</source><volume>5</volume><issue>5</issue><year>2021</year><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00675-9</pub-id><pub-id pub-id-type="pmid">33558734</pub-id><pub-id pub-id-type="pmcid">PMC8126516</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yunus</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Mariuzza</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>T.R.</given-names></name></person-group><article-title>In vivo and in vitro potency of polyphosphazene immunoadjuvants with hepatitis C virus antigen and the role of their supramolecular assembly</article-title><source>Mol. Pharm.</source><volume>18</volume><issue>2</issue><year>2021</year><fpage>726</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00487</pub-id><pub-id pub-id-type="pmid">32530637</pub-id><pub-id pub-id-type="pmcid">PMC7755742</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group><article-title>Polyphosphazene immunoadjuvants: historical perspective and recent advances</article-title><source>J. Control. Release</source><volume>329</volume><year>2021</year><fpage>299</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.12.001</pub-id><pub-id pub-id-type="pmid">33285104</pub-id><pub-id pub-id-type="pmcid">PMC7904599</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Demuynck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Engelen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Skirtach</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lentacker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Krysko</surname><given-names>D.V.</given-names></name></person-group><article-title>Nanomedicine to aid immunogenic cell death (ICD)-Based anticancer therapy</article-title><source>Trends Cancer</source><volume>10</volume><issue>6</issue><year>2024</year><fpage>486</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2024.03.003</pub-id><pub-id pub-id-type="pmid">38553361</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Fucikova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spisek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Calreticulin and cancer</article-title><source>Cell Res.</source><volume>31</volume><issue>1</issue><year>2021</year><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0383-9</pub-id><pub-id pub-id-type="pmid">32733014</pub-id><pub-id pub-id-type="pmcid">PMC7853084</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody</article-title><source>Bioac. Mater.</source><volume>21</volume><year>2023</year><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2022.08.028</pub-id><pub-id pub-id-type="pmcid">PMC9478499</pub-id><pub-id pub-id-type="pmid">36157245</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lotze</surname><given-names>M.T.</given-names></name></person-group><article-title>The multifunctional protein HMGB1: 50 years of discovery</article-title><source>Nat. Rev. Immunol.</source><volume>23</volume><issue>12</issue><year>2023</year><fpage>824</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00894-6</pub-id><pub-id pub-id-type="pmid">37322174</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Krysko</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kaczmarek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krysko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Agostinis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P.</given-names></name></person-group><article-title>Immunogenic cell death and DAMPs in cancer therapy</article-title><source>Nat. Rev. Cancer</source><volume>12</volume><issue>12</issue><year>2012</year><fpage>860</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1038/nrc3380</pub-id><pub-id pub-id-type="pmid">23151605</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Amiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molavi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sabetkam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jafari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Montazersaheb</surname><given-names>S.</given-names></name></person-group><article-title>Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds</article-title><source>Cancer Cell Int.</source><volume>23</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">200</object-id><pub-id pub-id-type="doi">10.1186/s12935-023-03058-7</pub-id><pub-id pub-id-type="pmcid">PMC10500939</pub-id><pub-id pub-id-type="pmid">37705051</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Orchestrating cancer therapy: recent advances in nanoplatforms harmonize immunotherapy with multifaceted treatments</article-title><source>Mater. Today Bio</source><volume>30</volume><year>2025</year><object-id pub-id-type="publisher-id">101386</object-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2024.101386</pub-id><pub-id pub-id-type="pmcid">PMC11683241</pub-id><pub-id pub-id-type="pmid">39742149</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3</article-title><source>J. Control. Release</source><volume>363</volume><year>2023</year><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.09.044</pub-id><pub-id pub-id-type="pmid">37748583</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy</article-title><source>J. Control. Release</source><volume>356</volume><year>2023</year><fpage>525</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.03.015</pub-id><pub-id pub-id-type="pmid">36918084</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>GSH-Sensitive polymeric prodrug: synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine</article-title><source>Acta Pharm. Sin. B</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>424</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.05.003</pub-id><pub-id pub-id-type="pmid">35127396</pub-id><pub-id pub-id-type="pmcid">PMC8799999</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment</article-title><source>Acta Pharm. Sin. B</source><volume>11</volume><issue>2</issue><year>2021</year><fpage>544</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2020.07.023</pub-id><pub-id pub-id-type="pmid">33643830</pub-id><pub-id pub-id-type="pmcid">PMC7893117</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis</article-title><source>J. Control. Release</source><volume>318</volume><year>2020</year><fpage>124</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.12.017</pub-id><pub-id pub-id-type="pmid">31838206</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>A nasally administrated reactive oxygen species-responsive carrier-free gene delivery nanosystem for alzheimer's disease combination therapy</article-title><source>J. Control. Release</source><volume>381</volume><year>2025</year><object-id pub-id-type="publisher-id">113604</object-id><pub-id pub-id-type="doi">10.1016/j.jconrel.2025.113604</pub-id><pub-id pub-id-type="pmid">40043915</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>Recent advances in reactive oxygen species (ROS)-Responsive drug delivery systems for photodynamic therapy of cancer</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>12</issue><year>2024</year><fpage>5106</fpage><lpage>5131</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.10.015</pub-id><pub-id pub-id-type="pmid">39807318</pub-id><pub-id pub-id-type="pmcid">PMC11725102</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name></person-group><article-title>Transepithelial transport of nanoparticles in oral drug delivery: from the perspective of surface and holistic property modulation</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>9</issue><year>2024</year><fpage>3876</fpage><lpage>3900</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.06.015</pub-id><pub-id pub-id-type="pmid">39309496</pub-id><pub-id pub-id-type="pmcid">PMC11413706</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name></person-group><article-title>Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation</article-title><source>Acta Pharm. Sin. B</source><volume>15</volume><issue>5</issue><year>2025</year><fpage>2746</fpage><lpage>2763</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2025.03.016</pub-id><pub-id pub-id-type="pmid">40487644</pub-id><pub-id pub-id-type="pmcid">PMC12145006</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name></person-group><article-title>Autophagy-activating aluminum hydroxide nanovaccine for enhanced antigen presentation and anti-tumor immunity</article-title><source>J. Control. Release</source><volume>377</volume><year>2025</year><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.11.018</pub-id><pub-id pub-id-type="pmid">39547420</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects</article-title><source>Exp. Hematol. Oncol.</source><volume>14</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">11</object-id><pub-id pub-id-type="doi">10.1186/s40164-025-00602-1</pub-id><pub-id pub-id-type="pmcid">PMC11786384</pub-id><pub-id pub-id-type="pmid">39891180</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>5</issue><year>2023</year><fpage>2176</fpage><lpage>2187</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.02.009</pub-id><pub-id pub-id-type="pmid">37250156</pub-id><pub-id pub-id-type="pmcid">PMC10213972</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fourniols</surname><given-names>T.</given-names></name><name name-style="western"><surname>Labrak</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name><name name-style="western"><surname>Beloqui</surname><given-names>A.</given-names></name><name name-style="western"><surname>des Rieux</surname><given-names>A.</given-names></name></person-group><article-title>Surface modification of lipid-based nanoparticles</article-title><source>ACS Nano</source><volume>16</volume><issue>5</issue><year>2022</year><fpage>7168</fpage><lpage>7196</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c02347</pub-id><pub-id pub-id-type="pmid">35446546</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name></person-group><article-title>Lipid nanoparticles optimized for targeting and release of nucleic acid</article-title><source>Adv. Mater.</source><volume>36</volume><issue>4</issue><year>2024</year><object-id pub-id-type="publisher-id">e2305300</object-id><pub-id pub-id-type="doi">10.1002/adma.202305300</pub-id><pub-id pub-id-type="pmid">37547955</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><volume>6</volume><issue>12</issue><year>2021</year><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Lipid nanovehicles overcome barriers to systemic RNA delivery: lipid components, fabrication methods, and rational design</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>2</issue><year>2024</year><fpage>579</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.10.012</pub-id><pub-id pub-id-type="pmid">38322344</pub-id><pub-id pub-id-type="pmcid">PMC10840434</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name></person-group><article-title>An mRNA vaccine elicits STING-Dependent antitumor immune responses</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>3</issue><year>2023</year><fpage>1274</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.013</pub-id><pub-id pub-id-type="pmid">36970194</pub-id><pub-id pub-id-type="pmcid">PMC10031366</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>You</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name></person-group><article-title>Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling</article-title><source>Proc. Natl. Acad. Sci. U. S. A. A.</source><volume>118</volume><issue>6</issue><year>2021</year><object-id pub-id-type="publisher-id">e2005191118</object-id><pub-id pub-id-type="doi">10.1073/pnas.2005191118</pub-id><pub-id pub-id-type="pmcid">PMC8017939</pub-id><pub-id pub-id-type="pmid">33547233</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>J&#246;rgensen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wibel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title>Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients</article-title><source>Small</source><volume>19</volume><issue>17</issue><year>2023</year><object-id pub-id-type="publisher-id">e2206968</object-id><pub-id pub-id-type="doi">10.1002/smll.202206968</pub-id><pub-id pub-id-type="pmid">36610004</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group><article-title>Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy</article-title><source>Biomater. Sci.</source><volume>8</volume><issue>4</issue><year>2020</year><fpage>1101</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1039/c9bm01564g</pub-id><pub-id pub-id-type="pmid">31793928</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Delcassian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chahal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sadtler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Doloff</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.G.</given-names></name></person-group><article-title>Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-Mediated immune cell activation</article-title><source>Nat. Biotechnol.</source><volume>37</volume><issue>10</issue><year>2019</year><fpage>1174</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0247-3</pub-id><pub-id pub-id-type="pmid">31570898</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name></person-group><article-title>Spleen-selective co-delivery of mRNA and TLR4 agonist-loaded LNPs for synergistic immunostimulation and Th1 immune responses</article-title><source>J. Control. Release</source><volume>357</volume><year>2023</year><fpage>133</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.03.041</pub-id><pub-id pub-id-type="pmid">36972863</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Luozhong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>McCurdy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilkens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs</article-title><source>Nano Lett.</source><volume>22</volume><issue>20</issue><year>2022</year><fpage>8304</fpage><lpage>8311</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.2c03234</pub-id><pub-id pub-id-type="pmid">36194390</pub-id><pub-id pub-id-type="pmcid">PMC12126148</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Abd Elwakil</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khalifa</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Elshami</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Isono</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elewa</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Harnessing topology and stereochemistry of glycidylamine&#8208;derived lipid nanoparticles for in vivo mRNA delivery to immune cells in spleen and their application for cancer vaccination</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><issue>45</issue><year>2023</year><object-id pub-id-type="publisher-id">2303795</object-id><pub-id pub-id-type="doi">10.1002/adfm.202303795</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name></person-group><article-title>Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>119</volume><issue>34</issue><year>2022</year><object-id pub-id-type="publisher-id">e2207841119</object-id><pub-id pub-id-type="doi">10.1073/pnas.2207841119</pub-id><pub-id pub-id-type="pmcid">PMC9407666</pub-id><pub-id pub-id-type="pmid">35969778</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nayanathara</surname><given-names>U.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Such</surname><given-names>G.K.</given-names></name></person-group><article-title>Polymeric nanoparticles for drug delivery</article-title><source>Chem. Rev.</source><volume>124</volume><issue>9</issue><year>2024</year><fpage>5505</fpage><lpage>5616</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.3c00705</pub-id><pub-id pub-id-type="pmid">38626459</pub-id><pub-id pub-id-type="pmcid">PMC11086401</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Advances and applications of nanoparticles in cancer therapy</article-title><source>MedComm&#8211;Oncol.</source><volume>3</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e67</object-id><pub-id pub-id-type="doi">10.1002/mog2.67</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name></person-group><article-title>Nanomaterials based on functional polymers for sensitizing cancer radiotherapy</article-title><source>Macromol. Rapid Commun.</source><volume>43</volume><issue>18</issue><year>2022</year><object-id pub-id-type="publisher-id">e2200194</object-id><pub-id pub-id-type="doi">10.1002/marc.202200194</pub-id><pub-id pub-id-type="pmid">35578790</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>A branched polymer-based agent for efficient and precise targeting of fibrosis diseases by magnetic resonance imaging</article-title><source>J. Control. Release</source><volume>373</volume><year>2024</year><fpage>905</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.07.072</pub-id><pub-id pub-id-type="pmid">39089506</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name></person-group><article-title>Recent applications of PLGA in drug delivery systems</article-title><source>Polymers</source><volume>16</volume><issue>18</issue><year>2024</year><fpage>2606</fpage><pub-id pub-id-type="doi">10.3390/polym16182606</pub-id><pub-id pub-id-type="pmid">39339068</pub-id><pub-id pub-id-type="pmcid">PMC11435547</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Da Silva</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Camps</surname><given-names>M.G.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name></person-group><article-title>Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines</article-title><source>Biomaterials</source><volume>220</volume><year>2019</year><object-id pub-id-type="publisher-id">119417</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119417</pub-id><pub-id pub-id-type="pmid">31419588</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Modularly programmable nanoparticle vaccine based on polyethyleneimine for personalized cancer immunotherapy</article-title><source>Adv. Sci.</source><volume>8</volume><issue>5</issue><year>2021</year><object-id pub-id-type="publisher-id">2002577</object-id><pub-id pub-id-type="doi">10.1002/advs.202002577</pub-id><pub-id pub-id-type="pmcid">PMC7927624</pub-id><pub-id pub-id-type="pmid">33717838</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy</article-title><source>Bioact. Mater.</source><volume>26</volume><year>2023</year><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2023.02.016</pub-id><pub-id pub-id-type="pmid">36883121</pub-id><pub-id pub-id-type="pmcid">PMC9982230</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Personalized nanovaccine based on STING-activating nanocarrier for robust cancer immunotherapy</article-title><source>ACS Nano</source><volume>19</volume><issue>3</issue><year>2025</year><fpage>3226</fpage><lpage>3239</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c11014</pub-id><pub-id pub-id-type="pmid">39817337</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Baljon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines</article-title><source>Biomaterials</source><volume>182</volume><year>2018</year><fpage>82</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.07.052</pub-id><pub-id pub-id-type="pmid">30107272</pub-id><pub-id pub-id-type="pmcid">PMC6778406</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy</article-title><source>Adv. Sci.</source><volume>9</volume><issue>23</issue><year>2022</year><object-id pub-id-type="publisher-id">e2201895</object-id><pub-id pub-id-type="doi">10.1002/advs.202201895</pub-id><pub-id pub-id-type="pmcid">PMC9376841</pub-id><pub-id pub-id-type="pmid">35712773</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Le</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name></person-group><article-title>Self-degradable poly(&#946;-amino ester)s promote endosomal escape of antigen and agonist</article-title><source>J. Control. Release</source><volume>345</volume><year>2022</year><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.006</pub-id><pub-id pub-id-type="pmid">35259460</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><issue>12</issue><year>2020</year><fpage>1043</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00781-4</pub-id><pub-id pub-id-type="pmid">33139933</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name></person-group><article-title>Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines</article-title><source>Chem. Eng. J.</source><volume>456</volume><year>2023</year><object-id pub-id-type="publisher-id">140930</object-id><pub-id pub-id-type="doi">10.1016/j.cej.2022.140930</pub-id><pub-id pub-id-type="pmcid">PMC9743697</pub-id><pub-id pub-id-type="pmid">36531858</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name></person-group><article-title>Proton-driven transformable nanovaccine for cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><issue>12</issue><year>2020</year><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00782-3</pub-id><pub-id pub-id-type="pmid">33106640</pub-id><pub-id pub-id-type="pmcid">PMC7719078</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Si</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity</article-title><source>Biomaterials</source><volume>284</volume><year>2022</year><object-id pub-id-type="publisher-id">121489</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121489</pub-id><pub-id pub-id-type="pmid">35364489</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Paurevi&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#352;rajer Gajdo&#353;ik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ribi&#263;</surname><given-names>R.</given-names></name></person-group><article-title>Mannose ligands for mannose receptor targeting</article-title><source>Int. J. Mol. Sci.</source><volume>25</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">1370</object-id><pub-id pub-id-type="doi">10.3390/ijms25031370</pub-id><pub-id pub-id-type="pmcid">PMC10855088</pub-id><pub-id pub-id-type="pmid">38338648</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer</article-title><source>Nano Lett.</source><volume>20</volume><issue>6</issue><year>2020</year><fpage>4393</fpage><lpage>4402</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c01140</pub-id><pub-id pub-id-type="pmid">32459969</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peeler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Olshefsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sylvestre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stayton</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Pun</surname><given-names>S.H.</given-names></name></person-group><article-title>Well-defined mannosylated polymer for peptide vaccine delivery with enhanced antitumor immunity</article-title><source>Adv. Healthc. Mater.</source><volume>11</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">e2101651</object-id><pub-id pub-id-type="doi">10.1002/adhm.202101651</pub-id><pub-id pub-id-type="pmcid">PMC9043035</pub-id><pub-id pub-id-type="pmid">34706166</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Pei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name></person-group><article-title>Bioactive inorganic nanomaterials for cancer theranostics</article-title><source>Chem. Soc. Rev.</source><volume>52</volume><issue>6</issue><year>2023</year><fpage>2031</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1039/d2cs00352j</pub-id><pub-id pub-id-type="pmid">36633202</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Umar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baskoutas</surname><given-names>S.</given-names></name></person-group><article-title>Functional inorganic nanomaterials for optical cancer theranostics</article-title><source>Chem. Eng. J.</source><volume>485</volume><year>2024</year><object-id pub-id-type="publisher-id">150067</object-id><pub-id pub-id-type="doi">10.1016/j.cej.2024.150067</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Qie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name></person-group><article-title>Targeted inhibition of lymphovascular invasion formation with CREKA peptide-modified silicasomes to boost chemotherapy in bladder cancer</article-title><source>Nano Lett.</source><volume>24</volume><issue>33</issue><year>2024</year><fpage>10186</fpage><lpage>10195</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.4c02485</pub-id><pub-id pub-id-type="pmid">39136297</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Multifunctional mesoporous silica nanoparticles for biomedical applications</article-title><source>Signal Transduct. Target. Ther.</source><volume>8</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">435</object-id><pub-id pub-id-type="doi">10.1038/s41392-023-01654-7</pub-id><pub-id pub-id-type="pmcid">PMC10667354</pub-id><pub-id pub-id-type="pmid">37996406</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency</article-title><source>Sci. Adv.</source><volume>6</volume><issue>25</issue><year>2020</year><object-id pub-id-type="publisher-id">eaaz4462</object-id><pub-id pub-id-type="doi">10.1126/sciadv.aaz4462</pub-id><pub-id pub-id-type="pmcid">PMC7304990</pub-id><pub-id pub-id-type="pmid">32596445</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>Effects of skeleton structure of mesoporous silica nanoadjuvants on cancer immunotherapy</article-title><source>Small</source><volume>20</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">e2305567</object-id><pub-id pub-id-type="doi">10.1002/smll.202305567</pub-id><pub-id pub-id-type="pmid">37702141</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuwen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>Y.</given-names></name></person-group><article-title>Elastic nanovaccine enhances dendritic cell-mediated tumor immunotherapy</article-title><source>Small</source><volume>18</volume><issue>32</issue><year>2022</year><object-id pub-id-type="publisher-id">e2201108</object-id><pub-id pub-id-type="doi">10.1002/smll.202201108</pub-id><pub-id pub-id-type="pmid">35734820</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Escriche-Navarro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Escudero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucena-S&#225;nchez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sancen&#243;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garc&#237;a-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-M&#225;&#241;ez</surname><given-names>R.</given-names></name></person-group><article-title>Mesoporous silica materials as an emerging tool for cancer immunotherapy</article-title><source>Adv. Sci.</source><volume>9</volume><issue>26</issue><year>2022</year><object-id pub-id-type="publisher-id">e2200756</object-id><pub-id pub-id-type="doi">10.1002/advs.202200756</pub-id><pub-id pub-id-type="pmcid">PMC9475525</pub-id><pub-id pub-id-type="pmid">35866466</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Im</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold</article-title><source>Biomaterials</source><volume>239</volume><year>2020</year><object-id pub-id-type="publisher-id">119859</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119859</pub-id><pub-id pub-id-type="pmid">32070828</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>Hollow mesoporous silica nanoparticles for drug formulation and delivery: opportunities for cancer therapy</article-title><source>Colloids Surf. B Biointerfaces</source><volume>249</volume><year>2025</year><object-id pub-id-type="publisher-id">114534</object-id><pub-id pub-id-type="doi">10.1016/j.colsurfb.2025.114534</pub-id><pub-id pub-id-type="pmid">39874869</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine</article-title><source>ACS Appl. Mater. &amp; Inter.</source><volume>12</volume><issue>31</issue><year>2020</year><fpage>34658</fpage><lpage>34666</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c09484</pub-id><pub-id pub-id-type="pmid">32662625</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name></person-group><article-title>Metal-phenolic network-encapsulated nanovaccine with pH and reduction dual responsiveness for enhanced cancer immunotherapy</article-title><source>Mol. Pharm.</source><volume>17</volume><issue>12</issue><year>2020</year><fpage>4603</fpage><lpage>4615</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00802</pub-id><pub-id pub-id-type="pmid">33175556</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shakya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>F.</given-names></name></person-group><article-title>Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives</article-title><source>J. Nanobiotechnology</source><volume>23</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">157</object-id><pub-id pub-id-type="doi">10.1186/s12951-025-03252-x</pub-id><pub-id pub-id-type="pmcid">PMC11871784</pub-id><pub-id pub-id-type="pmid">40022098</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy</article-title><source>Asian J. Pharm. Sci.</source><volume>20</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">101017</object-id><pub-id pub-id-type="doi">10.1016/j.ajps.2025.101017</pub-id><pub-id pub-id-type="pmcid">PMC11808527</pub-id><pub-id pub-id-type="pmid">39931355</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>X.</given-names></name></person-group><article-title>Metal&#8208;organic&#8208;framework&#8208;based vaccine platforms for enhanced systemic immune and memory response</article-title><source>Adv. Funct. Mater.</source><volume>26</volume><issue>35</issue><year>2016</year><fpage>6454</fpage><lpage>6461</lpage><pub-id pub-id-type="doi">10.1002/adfm.201600650</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Zinc-organometallic framework vaccine controlled-release Zn(2+) regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy</article-title><source>Adv. Sci.</source><volume>10</volume><issue>27</issue><year>2023</year><object-id pub-id-type="publisher-id">e2302967</object-id><pub-id pub-id-type="doi">10.1002/advs.202302967</pub-id><pub-id pub-id-type="pmcid">PMC10520680</pub-id><pub-id pub-id-type="pmid">37439462</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.Y.</given-names></name></person-group><article-title>Application research progress of nanomaterial graphene and its derivative complexes in tumor diagnosis and therapy</article-title><source>Curr. Med. Chem.</source><volume>31</volume><issue>39</issue><year>2024</year><fpage>6436</fpage><lpage>6459</lpage><pub-id pub-id-type="doi">10.2174/0109298673251648231106112354</pub-id><pub-id pub-id-type="pmid">38299292</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name></person-group><article-title>A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy</article-title><source>Chin. Chem. Lett.</source><volume>33</volume><issue>8</issue><year>2022</year><fpage>4089</fpage><lpage>4095</lpage><pub-id pub-id-type="doi">10.1016/j.cclet.2022.01.071</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Efficient lymph node-targeted delivery of personalized cancer vaccines with reactive oxygen species-inducing reduced graphene oxide nanosheets</article-title><source>ACS Nano</source><volume>14</volume><issue>10</issue><year>2020</year><fpage>13268</fpage><lpage>13278</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c05062</pub-id><pub-id pub-id-type="pmid">32902245</pub-id><pub-id pub-id-type="pmcid">PMC7606610</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>X.</given-names></name></person-group><article-title>Construction of ph-sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy</article-title><source>Small</source><volume>19</volume><issue>37</issue><year>2023</year><object-id pub-id-type="publisher-id">e2301420</object-id><pub-id pub-id-type="doi">10.1002/smll.202301420</pub-id><pub-id pub-id-type="pmid">37154213</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Unlocking the potential of amorphous calcium carbonate: a star ascending in the realm of biomedical application</article-title><source>Acta Pharm. Sin. B</source><volume>14</volume><issue>2</issue><year>2024</year><fpage>602</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.08.027</pub-id><pub-id pub-id-type="pmid">38322345</pub-id><pub-id pub-id-type="pmcid">PMC10840486</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Lybaert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Nuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Rycke</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Wever</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chon</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Esser-Kahn</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>De Geest</surname><given-names>B.G.</given-names></name></person-group><article-title>Cancer cell lysate entrapment in CaCO<sub>3</sub> engineered with polymeric TLR-agonists: immune-modulating microparticles in view of personalized antitumor vaccination</article-title><source>Chem. Mater.</source><volume>29</volume><issue>10</issue><year>2017</year><fpage>4209</fpage><lpage>4217</lpage><pub-id pub-id-type="doi">10.1021/acs.chemmater.6b05062</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Engineering of stimuli-responsive self-assembled biomimetic nanoparticles</article-title><source>Adv. Drug Deliv. Rev.</source><volume>179</volume><year>2021</year><object-id pub-id-type="publisher-id">114006</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.114006</pub-id><pub-id pub-id-type="pmid">34655662</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Samanta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haldar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pamecha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gajbhiye</surname><given-names>V.</given-names></name></person-group><article-title>Cell membrane-camouflaged nanocarriers: a cutting-edge biomimetic technology to develop cancer immunotherapy</article-title><source>Int. J. Pharm.</source><volume>672</volume><year>2025</year><object-id pub-id-type="publisher-id">125336</object-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2025.125336</pub-id><pub-id pub-id-type="pmid">39947362</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Targeting drugs to tumours using cell membrane-coated nanoparticles</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>20</volume><issue>1</issue><year>2023</year><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00699-x</pub-id><pub-id pub-id-type="pmid">36307534</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aryal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>108</volume><issue>27</issue><year>2011</year><fpage>10980</fpage><lpage>10985</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106634108</pub-id><pub-id pub-id-type="pmid">21690347</pub-id><pub-id pub-id-type="pmcid">PMC3131364</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>6</issue><year>2023</year><fpage>2464</fpage><lpage>2482</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.03.004</pub-id><pub-id pub-id-type="pmid">37425034</pub-id><pub-id pub-id-type="pmcid">PMC10326251</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name></person-group><article-title>Cell membrane coated-nanoparticles for cancer immunotherapy</article-title><source>Acta Pharm. Sin. B</source><volume>12</volume><issue>8</issue><year>2022</year><fpage>3233</fpage><lpage>3254</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.023</pub-id><pub-id pub-id-type="pmid">35967284</pub-id><pub-id pub-id-type="pmcid">PMC9366230</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Tumor-antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma</article-title><source>ACS Nano</source><volume>17</volume><issue>3</issue><year>2023</year><fpage>2341</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c09033</pub-id><pub-id pub-id-type="pmid">36688797</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name></person-group><article-title>pH-Responsive biomimetic polymeric micelles as lymph node-targeting vaccines for enhanced antitumor immune responses</article-title><source>Biomacromolecules</source><volume>21</volume><issue>7</issue><year>2020</year><fpage>2818</fpage><lpage>2828</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.0c00518</pub-id><pub-id pub-id-type="pmid">32496052</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name></person-group><article-title>PEI-Modified macrophage cell membrane-coated PLGA nanoparticles encapsulating dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses</article-title><source>Int. J. Biol. Macromol.</source><volume>165</volume><issue>Pt A</issue><year>2020</year><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.09.187</pub-id><pub-id pub-id-type="pmid">32979446</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martikainen</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>K&#229;rlund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pulkkinen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ruhanen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roponen</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#228;kel&#228;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lehto</surname><given-names>V.P.</given-names></name></person-group><article-title>Systematic design of cell membrane coating to improve tumor targeting of nanoparticles</article-title><source>Nat. Commun.</source><volume>13</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">6181</object-id><pub-id pub-id-type="doi">10.1038/s41467-022-33889-3</pub-id><pub-id pub-id-type="pmcid">PMC9580449</pub-id><pub-id pub-id-type="pmid">36261418</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name></person-group><article-title>Personalized nanovaccine coated with Calcinetin-Expressed cancer cell membrane antigen for cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><issue>19</issue><year>2021</year><fpage>8418</fpage><lpage>8425</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.1c03004</pub-id><pub-id pub-id-type="pmid">34546061</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Takayama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kusamori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>M.</given-names></name></person-group><article-title>Click chemistry as a tool for cell engineering and drug delivery</article-title><source>Molecules</source><volume>24</volume><issue>1</issue><year>2019</year><object-id pub-id-type="publisher-id">172</object-id><pub-id pub-id-type="doi">10.3390/molecules24010172</pub-id><pub-id pub-id-type="pmcid">PMC6337375</pub-id><pub-id pub-id-type="pmid">30621193</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>R.C.</given-names></name></person-group><article-title>Recent progress and perspectives on cell surface modification</article-title><source>Chem. Asian J.</source><volume>16</volume><issue>21</issue><year>2021</year><fpage>3250</fpage><lpage>3258</lpage><pub-id pub-id-type="doi">10.1002/asia.202100852</pub-id><pub-id pub-id-type="pmid">34427996</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><issue>5</issue><year>2021</year><fpage>2094</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c04783</pub-id><pub-id pub-id-type="pmid">33622034</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Engineered cell membrane-camouflaged nanomaterials for biomedical applications</article-title><source>Nanomaterials</source><volume>14</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">413</object-id><pub-id pub-id-type="doi">10.3390/nano14050413</pub-id><pub-id pub-id-type="pmcid">PMC10935217</pub-id><pub-id pub-id-type="pmid">38470744</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma</article-title><source>ACS Nano</source><volume>9</volume><issue>7</issue><year>2015</year><fpage>6918</fpage><lpage>6933</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b01042</pub-id><pub-id pub-id-type="pmid">26153897</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Equipping cancer cell membrane vesicles with functional DNA as a targeted vaccine for cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><issue>22</issue><year>2021</year><fpage>9410</fpage><lpage>9418</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.1c02582</pub-id><pub-id pub-id-type="pmid">34730968</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><volume>16</volume><issue>11</issue><year>2021</year><fpage>1271</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1038/s41565-021-00972-7</pub-id><pub-id pub-id-type="pmid">34580467</pub-id></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chekuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity</article-title><source>Adv. Mater.</source><volume>32</volume><issue>30</issue><year>2020</year><object-id pub-id-type="publisher-id">e2001808</object-id><pub-id pub-id-type="doi">10.1002/adma.202001808</pub-id><pub-id pub-id-type="pmcid">PMC7669572</pub-id><pub-id pub-id-type="pmid">32538494</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>Tumor cell nanovaccines based on genetically engineered antibody-anchored membrane</article-title><source>Adv. Mater.</source><volume>35</volume><issue>13</issue><year>2023</year><object-id pub-id-type="publisher-id">e2208923</object-id><pub-id pub-id-type="doi">10.1002/adma.202208923</pub-id><pub-id pub-id-type="pmid">36715052</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><object-id pub-id-type="publisher-id">4909</object-id><pub-id pub-id-type="doi">10.1038/s41467-020-18626-y</pub-id><pub-id pub-id-type="pmcid">PMC7527506</pub-id><pub-id pub-id-type="pmid">32999291</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.W.</given-names></name></person-group><article-title>Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy</article-title><source>Acta Biomater.</source><volume>112</volume><year>2020</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.05.028</pub-id><pub-id pub-id-type="pmid">32470527</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Hybrid cell membrane&#8208;coated nanoparticles for biomedical applications</article-title><source>Small Struct.</source><volume>5</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">2300473</object-id><pub-id pub-id-type="doi">10.1002/sstr.202300473</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Development of a dendritic cell/tumor cell fusion cell membrane nano-vaccine for the treatment of ovarian cancer</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">828263</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.828263</pub-id><pub-id pub-id-type="pmcid">PMC8893350</pub-id><pub-id pub-id-type="pmid">35251013</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>M.</given-names></name></person-group><article-title>Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications</article-title><source>J. Control. Release</source><volume>365</volume><year>2024</year><fpage>1089</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.11.057</pub-id><pub-id pub-id-type="pmid">38065416</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Exosomes as carriers to stimulate an anti-cancer immune response in immunotherapy and as predictive markers</article-title><source>Biochem. Pharmacol.</source><volume>232</volume><year>2025</year><object-id pub-id-type="publisher-id">116699</object-id><pub-id pub-id-type="doi">10.1016/j.bcp.2024.116699</pub-id><pub-id pub-id-type="pmid">39647605</pub-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Enhancing drug penetration in solid tumors via nanomedicine: evaluation models, strategies and perspectives</article-title><source>Bioact. Mater.</source><volume>32</volume><year>2024</year><fpage>445</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2023.10.017</pub-id><pub-id pub-id-type="pmid">37965242</pub-id><pub-id pub-id-type="pmcid">PMC10641097</pub-id></element-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brocchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.R.</given-names></name></person-group><article-title>Extracellular vesicle-embedded materials</article-title><source>J. Control. Release</source><volume>361</volume><year>2023</year><fpage>280</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.07.059</pub-id><pub-id pub-id-type="pmid">37536545</pub-id></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Dendritic cell-derived exosomes in cancer immunotherapy</article-title><source>Pharmaceutics</source><volume>15</volume><issue>8</issue><year>2023</year><object-id pub-id-type="publisher-id">2070</object-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15082070</pub-id><pub-id pub-id-type="pmcid">PMC10457773</pub-id><pub-id pub-id-type="pmid">37631284</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>Q.S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A.</given-names></name></person-group><article-title>DC-Derived exosomes for cancer immunotherapy</article-title><source>Cancers</source><volume>13</volume><issue>15</issue><year>2021</year><object-id pub-id-type="publisher-id">3667</object-id><pub-id pub-id-type="doi">10.3390/cancers13153667</pub-id><pub-id pub-id-type="pmcid">PMC8345209</pub-id><pub-id pub-id-type="pmid">34359569</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Damo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Simeoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name></person-group><article-title>TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma</article-title><source>Sci. Rep.</source><volume>5</volume><year>2015</year><object-id pub-id-type="publisher-id">17622</object-id><pub-id pub-id-type="doi">10.1038/srep17622</pub-id><pub-id pub-id-type="pmcid">PMC4668567</pub-id><pub-id pub-id-type="pmid">26631690</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name></person-group><article-title>Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies</article-title><source>J. Control. Release</source><volume>353</volume><year>2023</year><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.053</pub-id><pub-id pub-id-type="pmid">36470333</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name></person-group><article-title>Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects</article-title><source>Signal Transduct. Target. Ther.</source><volume>7</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">74</object-id><pub-id pub-id-type="doi">10.1038/s41392-022-00894-3</pub-id><pub-id pub-id-type="pmcid">PMC8924195</pub-id><pub-id pub-id-type="pmid">35292619</pub-id></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Che</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment</article-title><source>iScience</source><volume>25</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">103639</object-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.103639</pub-id><pub-id pub-id-type="pmcid">PMC8724970</pub-id><pub-id pub-id-type="pmid">35024580</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>New roles of tumor-derived exosomes in tumor microenvironment</article-title><source>Chin. J. Cancer Res.</source><volume>36</volume><issue>2</issue><year>2024</year><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.21147/j.issn.1000-9604.2024.02.05</pub-id><pub-id pub-id-type="pmid">38751437</pub-id><pub-id pub-id-type="pmcid">PMC11090792</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer</article-title><source>Mol. Cancer</source><volume>21</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">45</object-id><pub-id pub-id-type="doi">10.1186/s12943-022-01515-x</pub-id><pub-id pub-id-type="pmcid">PMC8831689</pub-id><pub-id pub-id-type="pmid">35148751</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>You</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Biologically self-assembled tumor cell-derived cancer nanovaccines as an all-in-one platform for cancer immunotherapy</article-title><source>ACS Nano</source><volume>18</volume><issue>8</issue><year>2024</year><fpage>6702</fpage><lpage>6717</lpage><pub-id pub-id-type="doi">10.1021/acsnano.4c01050</pub-id><pub-id pub-id-type="pmid">38359389</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name></person-group><article-title>Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment</article-title><source>Sci. Transl. Med.</source><volume>13</volume><issue>615</issue><year>2021</year><object-id pub-id-type="publisher-id">eabb6981</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abb6981</pub-id><pub-id pub-id-type="pmid">34644149</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name></person-group><article-title>Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><volume>186</volume><year>2022</year><object-id pub-id-type="publisher-id">114321</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2022.114321</pub-id><pub-id pub-id-type="pmid">35533789</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name></person-group><article-title>Bacterial outer membrane vesicles in tumor prevention and treatment: advancements in research and application</article-title><source>J. Mater. Chem. B</source><volume>13</volume><issue>12</issue><year>2025</year><fpage>3786</fpage><lpage>3805</lpage><pub-id pub-id-type="doi">10.1039/d4tb01899k</pub-id><pub-id pub-id-type="pmid">40019469</pub-id></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Bacterial outer membrane vesicles as a platform for biomedical applications: an update</article-title><source>J. Control. Release</source><volume>323</volume><year>2020</year><fpage>253</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.04.031</pub-id><pub-id pub-id-type="pmid">32333919</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Antigen capture and immune modulation by bacterial outer membrane vesicles as in situ vaccine for cancer immunotherapy post-photothermal therapy</article-title><source>Small</source><volume>18</volume><issue>14</issue><year>2022</year><object-id pub-id-type="publisher-id">e2107461</object-id><pub-id pub-id-type="doi">10.1002/smll.202107461</pub-id><pub-id pub-id-type="pmid">35152555</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Jaquish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zangl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>I.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sriramaneni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>Z.S.</given-names></name></person-group><article-title>Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles</article-title><source>Adv. Mater.</source><volume>31</volume><issue>43</issue><year>2019</year><object-id pub-id-type="publisher-id">e1902626</object-id><pub-id pub-id-type="doi">10.1002/adma.201902626</pub-id><pub-id pub-id-type="pmcid">PMC6810793</pub-id><pub-id pub-id-type="pmid">31523868</pub-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group><article-title>Nanocarriers based on bacterial membrane materials for cancer vaccine delivery</article-title><source>Nat. Protoc.</source><volume>17</volume><issue>10</issue><year>2022</year><fpage>2240</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00713-7</pub-id><pub-id pub-id-type="pmid">35879454</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Bruun</surname><given-names>T.U.J.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M.</given-names></name></person-group><article-title>Engineering a rugged nanoscaffold to enhance plug-and-display vaccination</article-title><source>ACS Nano</source><volume>12</volume><issue>9</issue><year>2018</year><fpage>8855</fpage><lpage>8866</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b02805</pub-id><pub-id pub-id-type="pmid">30028591</pub-id><pub-id pub-id-type="pmcid">PMC6158681</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group><article-title>Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology</article-title><source>Nat. Commun.</source><volume>12</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">2041</object-id><pub-id pub-id-type="doi">10.1038/s41467-021-22308-8</pub-id><pub-id pub-id-type="pmcid">PMC8024398</pub-id><pub-id pub-id-type="pmid">33824314</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis</article-title><source>ACS Nano</source><volume>17</volume><issue>1</issue><year>2023</year><fpage>437</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c08880</pub-id><pub-id pub-id-type="pmid">36534945</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K.</given-names></name></person-group><article-title>An OMV-based nanovaccine as antigen presentation signal enhancer for cancer immunotherapy</article-title><source>Adv. Mater.</source><volume>37</volume><issue>8</issue><year>2025</year><object-id pub-id-type="publisher-id">e2413392</object-id><pub-id pub-id-type="doi">10.1002/adma.202413392</pub-id><pub-id pub-id-type="pmid">39811977</pub-id></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group><article-title>Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria</article-title><source>Nat. Biomed. Eng.</source><volume>6</volume><issue>7</issue><year>2022</year><fpage>898</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1038/s41551-022-00886-2</pub-id><pub-id pub-id-type="pmid">35501399</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group><article-title>Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine</article-title><source>Adv. Mater.</source><volume>34</volume><issue>20</issue><year>2022</year><object-id pub-id-type="publisher-id">e2109984</object-id><pub-id pub-id-type="doi">10.1002/adma.202109984</pub-id><pub-id pub-id-type="pmid">35315546</pub-id></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Gambirasi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Safa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vruzhaj</surname><given-names>I.</given-names></name><name name-style="western"><surname>Giacomin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Toffoli</surname><given-names>G.</given-names></name></person-group><article-title>Oral administration of cancer vaccines: challenges and future perspectives</article-title><source>Vaccines (Basel)</source><volume>12</volume><issue>1</issue><year>2023</year><object-id pub-id-type="publisher-id">26</object-id><pub-id pub-id-type="doi">10.3390/vaccines12010026</pub-id><pub-id pub-id-type="pmcid">PMC10821404</pub-id><pub-id pub-id-type="pmid">38250839</pub-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name></person-group><article-title>Advances in hydrogel-based drug delivery systems</article-title><source>Gels</source><volume>10</volume><issue>4</issue><year>2024</year><object-id pub-id-type="publisher-id">262</object-id><pub-id pub-id-type="doi">10.3390/gels10040262</pub-id><pub-id pub-id-type="pmcid">PMC11048949</pub-id><pub-id pub-id-type="pmid">38667681</pub-id></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name></person-group><article-title>Smart hydrogel: a new platform for cancer therapy</article-title><source>Adv. Colloid Interface Sci.</source><volume>340</volume><year>2025</year><object-id pub-id-type="publisher-id">103470</object-id><pub-id pub-id-type="doi">10.1016/j.cis.2025.103470</pub-id><pub-id pub-id-type="pmid">40086017</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Hameed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Faheem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paiva-Santos</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Jamshaid</surname><given-names>M.</given-names></name></person-group><article-title>A comprehensive review of hydrogel-based drug delivery systems: classification, properties, recent trends, and applications</article-title><source>AAPS PharmSciTech</source><volume>25</volume><issue>4</issue><year>2024</year><object-id pub-id-type="publisher-id">64</object-id><pub-id pub-id-type="doi">10.1208/s12249-024-02786-x</pub-id><pub-id pub-id-type="pmid">38514495</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="journal" id="sref221"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>N.A.</given-names></name></person-group><article-title>Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy</article-title><source>Sci. Adv.</source><volume>8</volume><issue>47</issue><year>2022</year><object-id pub-id-type="publisher-id">eadc8738</object-id><pub-id pub-id-type="doi">10.1126/sciadv.adc8738</pub-id><pub-id pub-id-type="pmcid">PMC9699680</pub-id><pub-id pub-id-type="pmid">36427310</pub-id></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>A review of sodium alginate-based hydrogels: structure, mechanisms, applications, and perspectives</article-title><source>Int. J. Biol. Macromol.</source><volume>292</volume><year>2025</year><object-id pub-id-type="publisher-id">139151</object-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.139151</pub-id><pub-id pub-id-type="pmid">39725117</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Bifunctional fusion membrane&#8208;based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells</article-title><source>Adv. Funct. Mater.</source><volume>32</volume><issue>29</issue><year>2022</year><object-id pub-id-type="publisher-id">2201306</object-id><pub-id pub-id-type="doi">10.1002/adfm.202201306</pub-id></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>Y.</given-names></name></person-group><article-title>A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel</article-title><source>Acta Biomater.</source><volume>169</volume><year>2023</year><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.08.010</pub-id><pub-id pub-id-type="pmid">37574158</pub-id></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy</article-title><source>Biomaterials</source><volume>299</volume><year>2023</year><object-id pub-id-type="publisher-id">122147</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122147</pub-id><pub-id pub-id-type="pmid">37182418</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Tailoring hyaluronic acid hydrogels for biomedical applications</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><issue>49</issue><year>2023</year><fpage>2306554</fpage><pub-id pub-id-type="doi">10.1002/adfm.202306554</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Stabilizing RNA nanovaccines with transformable hyaluronan dynamic hydrogel for durable cancer immunotherapy</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><issue>3</issue><year>2023</year><object-id pub-id-type="publisher-id">2204636</object-id><pub-id pub-id-type="doi">10.1002/adfm.202204636</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name></person-group><article-title>Unified therapeutic&#8208;prophylactic vaccine demonstrated with a postoperative filler gel to prevent tumor recurrence and metastasis</article-title><source>Adv. Funct. Mater.</source><volume>32</volume><issue>40</issue><year>2022</year><object-id pub-id-type="publisher-id">2206084</object-id><pub-id pub-id-type="doi">10.1002/adfm.202206084</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy</article-title><source>Acta Biomater.</source><volume>158</volume><year>2023</year><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2022.12.070</pub-id><pub-id pub-id-type="pmid">36632876</pub-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name></person-group><article-title>Recent advances on thermosensitive hydrogels-mediated precision therapy</article-title><source>Asian J. Pharm. Sci.</source><volume>19</volume><issue>3</issue><year>2024</year><object-id pub-id-type="publisher-id">100911</object-id><pub-id pub-id-type="doi">10.1016/j.ajps.2024.100911</pub-id><pub-id pub-id-type="pmcid">PMC11214189</pub-id><pub-id pub-id-type="pmid">38948400</pub-id></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Thang</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Cuong</surname><given-names>D.X.</given-names></name></person-group><article-title>Polymer-based hydrogels applied in drug delivery: an overview</article-title><source>Gels</source><volume>9</volume><issue>7</issue><year>2023</year><object-id pub-id-type="publisher-id">523</object-id><pub-id pub-id-type="doi">10.3390/gels9070523</pub-id><pub-id pub-id-type="pmcid">PMC10379988</pub-id><pub-id pub-id-type="pmid">37504402</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>A biodegradable thermosensitive hydrogel vaccine for cancer immunotherapy</article-title><source>Appl. Mater. Today</source><volume>19</volume><year>2020</year><object-id pub-id-type="publisher-id">100608</object-id><pub-id pub-id-type="doi">10.1016/j.apmt.2020.100608</pub-id></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Caranasos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>J.</given-names></name></person-group><article-title>Injection of ROS&#8208;responsive hydrogel loaded with basic fibroblast growth factor into the pericardial cavity for heart repair</article-title><source>Adv. Funct. Mater.</source><volume>31</volume><issue>15</issue><year>2021</year><object-id pub-id-type="publisher-id">2004377</object-id><pub-id pub-id-type="doi">10.1002/adfm.202004377</pub-id></element-citation></ref><ref id="bib234"><label>234</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors</article-title><source>J. Control. Release</source><volume>351</volume><year>2022</year><fpage>231</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.027</pub-id><pub-id pub-id-type="pmid">36122899</pub-id></element-citation></ref><ref id="bib235"><label>235</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>You</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name></person-group><article-title>Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination</article-title><source>Biomaterials</source><volume>301</volume><year>2023</year><object-id pub-id-type="publisher-id">122218</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2023.122218</pub-id><pub-id pub-id-type="pmid">37393695</pub-id></element-citation></ref><ref id="bib236"><label>236</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>Natural blood plasma-based hydrogels as tumor vaccines delivery systems to enhance biomimetic recruitment of antigen presenting cells for tumor immunotherapy</article-title><source>Mater. Today Bio</source><volume>17</volume><year>2022</year><object-id pub-id-type="publisher-id">100497</object-id><pub-id pub-id-type="doi">10.1016/j.mtbio.2022.100497</pub-id><pub-id pub-id-type="pmcid">PMC9677221</pub-id><pub-id pub-id-type="pmid">36420056</pub-id></element-citation></ref><ref id="bib237"><label>237</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Baghban</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghasemian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahmoodi</surname><given-names>S.</given-names></name></person-group><article-title>Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)</article-title><source>Arch. Microbiol.</source><volume>205</volume><issue>4</issue><year>2023</year><object-id pub-id-type="publisher-id">150</object-id><pub-id pub-id-type="doi">10.1007/s00203-023-03480-5</pub-id><pub-id pub-id-type="pmcid">PMC10062302</pub-id><pub-id pub-id-type="pmid">36995507</pub-id></element-citation></ref><ref id="bib238"><label>238</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeyn</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>New insights for the development of efficient DNA vaccines</article-title><source>Microb. Biotechnol.</source><volume>17</volume><issue>11</issue><year>2024</year><object-id pub-id-type="publisher-id">e70053</object-id><pub-id pub-id-type="doi">10.1111/1751-7915.70053</pub-id><pub-id pub-id-type="pmcid">PMC11565620</pub-id><pub-id pub-id-type="pmid">39545748</pub-id></element-citation></ref><ref id="bib239"><label>239</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name></person-group><article-title>Recent progress in mRNA cancer vaccines</article-title><source>Hum. Vaccin. Immunother.</source><volume>20</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">2307187</object-id><pub-id pub-id-type="doi">10.1080/21645515.2024.2307187</pub-id><pub-id pub-id-type="pmcid">PMC10826636</pub-id><pub-id pub-id-type="pmid">38282471</pub-id></element-citation></ref><ref id="bib240"><label>240</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Estap&#233; Senti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a Del Valle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schiffelers</surname><given-names>R.M.</given-names></name></person-group><article-title>mRNA delivery systems for cancer immunotherapy: lipid nanoparticles and beyond</article-title><source>Adv. Drug Deliv. Rev.</source><volume>206</volume><year>2024</year><object-id pub-id-type="publisher-id">115190</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2024.115190</pub-id><pub-id pub-id-type="pmid">38307296</pub-id></element-citation></ref><ref id="bib241"><label>241</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>She</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>mRNA vaccine in cancer therapy: current advance and future outlook</article-title><source>Clin. Transl. Med.</source><volume>13</volume><issue>8</issue><year>2023</year><object-id pub-id-type="publisher-id">e1384</object-id><pub-id pub-id-type="doi">10.1002/ctm2.1384</pub-id><pub-id pub-id-type="pmcid">PMC10447885</pub-id><pub-id pub-id-type="pmid">37612832</pub-id></element-citation></ref><ref id="bib242"><label>242</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name></person-group><article-title>Old concepts, new tricks: how peptide vaccines are reshaping cancer immunotherapy?</article-title><source>Int. J. Biol. Macromol.</source><volume>279</volume><issue>Pt 4</issue><year>2024</year><object-id pub-id-type="publisher-id">135541</object-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2024.135541</pub-id><pub-id pub-id-type="pmid">39270889</pub-id></element-citation></ref><ref id="bib243"><label>243</label><element-citation publication-type="journal" id="sref243"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name></person-group><article-title>Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy</article-title><source>J. Cancer</source><volume>15</volume><issue>1</issue><year>2024</year><fpage>54</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.7150/jca.88261</pub-id><pub-id pub-id-type="pmid">38164273</pub-id><pub-id pub-id-type="pmcid">PMC10751670</pub-id></element-citation></ref><ref id="bib244"><label>244</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>Thomas Marron</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Rubinsteyn</surname><given-names>Alex</given-names></name><name name-style="western"><surname>Finnigan</surname><given-names>John</given-names></name><name name-style="western"><surname>Blazquez</surname><given-names>Ana</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>Mansi</given-names></name><name name-style="western"><surname>Meseck</surname><given-names>Marcia</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>Timothy</given-names></name><name name-style="western"><surname>Delbeau</surname><given-names>Daniela</given-names></name><name name-style="western"><surname>Galsky</surname><given-names>Matthew</given-names></name><name name-style="western"><surname>Doroshow</surname><given-names>Deborah</given-names></name><name name-style="western"><surname>Miles</surname><given-names>Brett</given-names></name><name name-style="western"><surname>Misiukiewicz</surname><given-names>Krysztof</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>Irie</given-names></name><name name-style="western"><surname>Tiersten</surname><given-names>Amy</given-names></name><name name-style="western"><surname>Parekh</surname><given-names>Samir</given-names></name><name name-style="western"><surname>Posner</surname><given-names>Marshall</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>Andrea</given-names></name><name name-style="western"><surname>Mandeli</surname><given-names>John</given-names></name><name name-style="western"><surname>Hammerbacher</surname><given-names>Jeffrey</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>Michael</given-names></name><name name-style="western"><surname>Brody</surname><given-names>Rachel</given-names></name><name name-style="western"><surname>Gnjatic</surname><given-names>Sacha</given-names></name><name name-style="western"><surname>Schadt</surname><given-names>Eric</given-names></name><name name-style="western"><surname>Friedlander</surname><given-names>Philip</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>Nina</given-names></name></person-group><article-title>289PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting</article-title><source>J. Immunother. Cancer</source><volume>8</volume><issue>3</issue><year>2020</year><fpage>A1</fpage><lpage>A559</lpage><pub-id pub-id-type="doi">10.1136/jitc-2020-SITC2020.0289</pub-id></element-citation></ref><ref id="bib245"><label>245</label><element-citation publication-type="journal" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>Jonathan Forrest Anker</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kodysh</surname><given-names>Julia</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>Timothy</given-names></name><name name-style="western"><surname>Meseck</surname><given-names>Marcia</given-names></name><name name-style="western"><surname>Hapanowicz</surname><given-names>Olivia</given-names></name><name name-style="western"><surname>Niglio</surname><given-names>Scot Anthony</given-names></name><name name-style="western"><surname>Shah</surname><given-names>Hardik R.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>Yayoi</given-names></name><name name-style="western"><surname>Brody</surname><given-names>Rachel</given-names></name><name name-style="western"><surname>Rubinsteyn</surname><given-names>Alex</given-names></name><name name-style="western"><surname>Sebra</surname><given-names>Robert P.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>Nina</given-names></name><name name-style="western"><surname>Galsky</surname><given-names>Matt D.</given-names></name></person-group><article-title>Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer</article-title><source>J. Clin. Oncol.</source><volume>42</volume><year>2024</year><object-id pub-id-type="publisher-id">597</object-id><pub-id pub-id-type="doi">10.1200/JCO.2024.42.4_suppl.597</pub-id></element-citation></ref><ref id="bib246"><label>246</label><element-citation publication-type="journal" id="sref246"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bozym</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luoma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Olive</surname><given-names>O.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Eisenhaure</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gjini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Javeri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nellaiappan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Daley</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Harden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lennon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodig</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Aster</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Getz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wucherpfennig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neuberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lander</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Hacohen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.J.</given-names></name></person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title><source>Nature</source><volume>547</volume><issue>7662</issue><year>2017</year><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="pmid">28678778</pub-id><pub-id pub-id-type="pmcid">PMC5577644</pub-id></element-citation></ref><ref id="bib247"><label>247</label><element-citation publication-type="journal" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alcover</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Decar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smolinsky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Valdera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vreeland</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Priore</surname><given-names>G.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stojadinovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.</given-names></name></person-group><article-title>Utility of cell-based vaccines as cancer therapy: systematic review and meta-analysis</article-title><source>Hum. Vaccin. Immunother.</source><volume>20</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">2323256</object-id><pub-id pub-id-type="doi">10.1080/21645515.2024.2323256</pub-id><pub-id pub-id-type="pmcid">PMC10984131</pub-id><pub-id pub-id-type="pmid">38544385</pub-id></element-citation></ref><ref id="bib248"><label>248</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Liau</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ashkan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campian</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Trusheim</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Ansstas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cobbs</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Heth</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Salacz</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>D'Andre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aiken</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Moshel</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Pillainayagam</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goldlust</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Bota</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Elinzano</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grewal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lillehei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mikkelsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Walbert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ewend</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Khagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lovick</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Portnow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>L.</given-names></name><name name-style="western"><surname>Loudon</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Avigan</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Geoffroy</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Giglio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gligich</surname><given-names>O.</given-names></name><name name-style="western"><surname>Krex</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lindhorst</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lutzky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meisel</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Nadji-Ohl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanchin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Dunbar</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Etame</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piccioni</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Baskin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lacroix</surname><given-names>M.</given-names></name><name name-style="western"><surname>May</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>New</surname><given-names>P.Z.</given-names></name><name name-style="western"><surname>Pluard</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Toms</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>V.</given-names></name><name name-style="western"><surname>Peak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villano</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Battiste</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Mulholland</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Pearlman</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Petrecca</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schulder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Boynton</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>M.L.</given-names></name></person-group><article-title>Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial</article-title><source>JAMA Oncol.</source><volume>9</volume><issue>1</issue><year>2023</year><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.5370</pub-id><pub-id pub-id-type="pmid">36394838</pub-id><pub-id pub-id-type="pmcid">PMC9673026</pub-id></element-citation></ref><ref id="bib249"><label>249</label><element-citation publication-type="journal" id="sref249"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schr&#246;rs</surname><given-names>B.</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M.</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name></person-group><article-title>Identification of neoantigens for individualized therapeutic cancer vaccines</article-title><source>Nat. Rev. Drug Discov.</source><volume>21</volume><issue>4</issue><year>2022</year><fpage>261</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00387-y</pub-id><pub-id pub-id-type="pmid">35105974</pub-id><pub-id pub-id-type="pmcid">PMC7612664</pub-id></element-citation></ref><ref id="bib250"><label>250</label><element-citation publication-type="journal" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>S.I.</given-names></name></person-group><article-title>Identification of neoantigens in cancer cells as targets for immunotherapy</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><issue>5</issue><year>2022</year><object-id pub-id-type="publisher-id">2594</object-id><pub-id pub-id-type="doi">10.3390/ijms23052594</pub-id><pub-id pub-id-type="pmcid">PMC8910406</pub-id><pub-id pub-id-type="pmid">35269735</pub-id></element-citation></ref><ref id="bib251"><label>251</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Advancing nanotechnology for neoantigen-based cancer theranostics</article-title><source>Chem. Soc. Rev.</source><volume>53</volume><issue>7</issue><year>2024</year><fpage>3224</fpage><lpage>3252</lpage><pub-id pub-id-type="doi">10.1039/d3cs00162h</pub-id><pub-id pub-id-type="pmid">38379286</pub-id></element-citation></ref><ref id="bib252"><label>252</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Metformin-based nanomedicines for reprogramming tumor immune microenvironment</article-title><source>Theranostics</source><volume>15</volume><issue>3</issue><year>2025</year><object-id pub-id-type="publisher-id">993</object-id><pub-id pub-id-type="doi">10.7150/thno.104872</pub-id><pub-id pub-id-type="pmcid">PMC11700864</pub-id><pub-id pub-id-type="pmid">39776799</pub-id></element-citation></ref><ref id="bib253"><label>253</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name></person-group><article-title>cGAS-STING pathway agonists are promising vaccine adjuvants</article-title><source>Med. Res. Rev.</source><volume>44</volume><issue>4</issue><year>2024</year><fpage>1768</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1002/med.22016</pub-id><pub-id pub-id-type="pmid">38323921</pub-id></element-citation></ref><ref id="bib254"><label>254</label><element-citation publication-type="journal" id="sref254"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective</article-title><source>EBioMedicine</source><volume>107</volume><year>2024</year><object-id pub-id-type="publisher-id">105301</object-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105301</pub-id><pub-id pub-id-type="pmcid">PMC11388279</pub-id><pub-id pub-id-type="pmid">39178747</pub-id></element-citation></ref><ref id="bib255"><label>255</label><element-citation publication-type="journal" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy</article-title><source>Acta Pharm. Sin. B</source><volume>12</volume><issue>12</issue><year>2022</year><fpage>4327</fpage><lpage>4347</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.001</pub-id><pub-id pub-id-type="pmid">36561994</pub-id><pub-id pub-id-type="pmcid">PMC9764075</pub-id></element-citation></ref><ref id="bib256"><label>256</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Lasser</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ozbay Kurt</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Arkhypov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Utikal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Umansky</surname><given-names>V.</given-names></name></person-group><article-title>Myeloid-derived suppressor cells in cancer and cancer therapy</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>21</volume><issue>2</issue><year>2024</year><fpage>147</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00846-y</pub-id><pub-id pub-id-type="pmid">38191922</pub-id></element-citation></ref><ref id="bib257"><label>257</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Nong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name></person-group><article-title>Tumor immunotherapy: mechanisms and clinical applications</article-title><source>MedComm&#8211;Oncol</source><volume>1</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">e8</object-id><pub-id pub-id-type="doi">10.1002/mog2.8</pub-id></element-citation></ref><ref id="bib258"><label>258</label><element-citation publication-type="journal" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>B.</given-names></name></person-group><article-title>Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy</article-title><source>J. Control. Release</source><volume>381</volume><year>2025</year><object-id pub-id-type="publisher-id">113603</object-id><pub-id pub-id-type="doi">10.1016/j.jconrel.2025.113603</pub-id><pub-id pub-id-type="pmid">40049520</pub-id></element-citation></ref><ref id="bib259"><label>259</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nepovimova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sivak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heger</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Valko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kuca</surname><given-names>K.</given-names></name></person-group><article-title>Neutrophils in cancer immunotherapy: friends or foes?</article-title><source>Mol. Cancer</source><volume>23</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">107</object-id><pub-id pub-id-type="doi">10.1186/s12943-024-02004-z</pub-id><pub-id pub-id-type="pmcid">PMC11102125</pub-id><pub-id pub-id-type="pmid">38760815</pub-id></element-citation></ref><ref id="bib260"><label>260</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Tsoumakidou</surname><given-names>M.</given-names></name></person-group><article-title>The advent of immune stimulating CAFs in cancer</article-title><source>Nat. Rev. Cancer</source><volume>23</volume><issue>4</issue><year>2023</year><fpage>258</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41568-023-00549-7</pub-id><pub-id pub-id-type="pmid">36807417</pub-id></element-citation></ref><ref id="bib261"><label>261</label><element-citation publication-type="journal" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J.</given-names></name></person-group><article-title>Stimuli-responsive polymer-dasatinib prodrug to reprogram cancer-associated fibroblasts for boosted immunotherapy</article-title><source>J. Control. Release</source><volume>381</volume><year>2025</year><object-id pub-id-type="publisher-id">113606</object-id><pub-id pub-id-type="doi">10.1016/j.jconrel.2025.113606</pub-id><pub-id pub-id-type="pmid">40054628</pub-id></element-citation></ref><ref id="bib262"><label>262</label><element-citation publication-type="journal" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>Sleeboom</surname><given-names>J.J.F.</given-names></name><name name-style="western"><surname>van Tienderen</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Schenke-Layland</surname><given-names>K.</given-names></name><name name-style="western"><surname>van der Laan</surname><given-names>L.J.W.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Verstegen</surname><given-names>M.M.A.</given-names></name></person-group><article-title>The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets</article-title><source>Sci. Transl. Med.</source><volume>16</volume><issue>728</issue><year>2024</year><object-id pub-id-type="publisher-id">eadg3840</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.adg3840</pub-id><pub-id pub-id-type="pmid">38170791</pub-id></element-citation></ref><ref id="bib263"><label>263</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y.</given-names></name></person-group><article-title>Targets of tumor microenvironment for potential drug development</article-title><source>MedComm&#8211;Oncol</source><volume>3</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e68</object-id><pub-id pub-id-type="doi">10.1002/mog2.68</pub-id></element-citation></ref><ref id="bib264"><label>264</label><element-citation publication-type="journal" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>T.Y.</given-names></name></person-group><article-title>Recent advances in the bench-to-bedside translation of cancer nanomedicines</article-title><source>Acta Pharm. Sin. B</source><volume>15</volume><issue>1</issue><year>2025</year><fpage>97</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.12.007</pub-id><pub-id pub-id-type="pmid">40041906</pub-id><pub-id pub-id-type="pmcid">PMC11873642</pub-id></element-citation></ref><ref id="bib265"><label>265</label><element-citation publication-type="journal" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>P.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bradbury</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kavallaris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peracchia</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Popat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prestidge</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rijcken</surname><given-names>C.J.F.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thorn</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>H.A.</given-names></name></person-group><article-title>A translational framework to DELIVER nanomedicines to the clinic</article-title><source>Nat. Nanotechnol.</source><volume>19</volume><issue>11</issue><year>2024</year><fpage>1597</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1038/s41565-024-01754-7</pub-id><pub-id pub-id-type="pmid">39242807</pub-id></element-citation></ref><ref id="bib266"><label>266</label><element-citation publication-type="journal" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K.</given-names></name></person-group><article-title>Artificial intelligence aids in development of nanomedicines for cancer management</article-title><source>Semin. Cancer Biol.</source><volume>89</volume><year>2023</year><fpage>61</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2023.01.005</pub-id><pub-id pub-id-type="pmid">36682438</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0460">This work was supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs1">32401125</award-id>, <award-id award-type="grant" rid="gs1">32271445</award-id>), <funding-source id="gs7">Yunnan Fundamental Research Project</funding-source> (<award-id award-type="grant" rid="gs7">202501CF070064</award-id>), Scientific Research Fund of <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100007846</institution-id><institution>Yunnan Provincial Department of Education</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs2">2024J0008</award-id>), <funding-source id="gs8">Ling-Jun and Yun-Ling Scholars of Yunnan Province</funding-source> (<award-id award-type="grant" rid="gs8">202005AB160003</award-id>), <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004829</institution-id><institution>Department of Science and Technology of Sichuan Province</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs3">2024NSFJQ0050</award-id>), the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012166</institution-id><institution>National Key Research and Development Program of China</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs4">2023YFB3810004</award-id>).</p></ack><fn-group><fn id="d36e1813"><p id="ntpara0010">Peer review under the responsibility of editorial board of Bioactive Materials.</p></fn></fn-group></back></article></pmc-articleset>